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Multiple myeloma (MM) is a largely incurable haematological malignancy characterised 
by the aberrant proliferation of malignant plasma cells (PCs) in the bone marrow (BM). 
Next generation sequencing (NGS) studies have shown that MM patients display complex 
mutational landscapes involving intraclonal genetic heterogeneity. While intraclonal 
heterogeneity is now an established feature of MM, the genomic changes and tumour 
evolution associated with the transformation from the asymptomatic disease stages of 
Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smouldering 
Multiple Myeloma (SMM) to MM remains unknown.  
 
This thesis presents a unique assessment of the genomic architecture and subclonal 
evolution associated with the natural history of disease transformation, with the analyses of 
a rare cohort of paired BM samples from patients when first diagnosed with MGUS or 
SMM, who later went on to develop MM (n = 10). Whole exome sequencing (WES) and 
bioinformatic analyses identified that clonal heterogeneity was present at the asymptomatic 
MGUS/SMM stages of disease, with a changing spectrum of acquired mutations associated 
with transition to MM. Subclonality was observed at MGUS/SMM, with the presence of 
between 5 to 11 subclones. The progression to MM was characterised by a prevailing 
model of subclonal evolution defined by clonal stability, where the transformed PC 
subclones of MM were already present at the MGUS/SMM stage. 
 
RNA sequencing (RNAseq) revealed that the patterns of expressed genes at 
MGUS/SMM to MM were found to be relatively homogeneous. Moreover, RNAseq 
revealed that mutant genes identified by WES were generally not expressed, expressed at 
low levels, with most genes showing wild-type expression. Analysis of the methylome was 
carried out using whole genome bisulphite sequencing (WGBS). Significant 
hypomethylation was observed in PCs recovered at all disease stages (MGUS, SMM and 
MM) compared to normal PCs. Interestingly, the degree of hypomethylation observed at 
MGUS was maintained with progression to SMM and MM stages.  
 
In addition, the phenomenon of RNA editing in SP140, a recurrently mutated gene 
in human MM patients, was investigated in the 5TGM1 MM PC line. A high impact C>T 
(ie. U) RNA editing change was identified in exon 2 of Sp140, resulting in an early STOP 
 vi 
codon, which was hypothesised to result in the formation of truncated Sp140 protein that 
may contribute to MM pathogenesis. In mouse cell lines, Sp140 RNA editing was not 
restricted to the 5TGM1 cell line, but editing was not observed in any human MM PC 
lines. CRISPR-Cas9 mediated mutation of the mouse Apobec1 and Apobec3 genes, 
showed that neither of these cytidine deaminases were responsible for this RNA editing 
phenomenon.  
 
These studies show that MGUS/SMM patients, that progress in a short time frame, 
appear to be sufficiently genetically complex to be on the threshold of transformation to 
MM. Furthermore, the intrinsic genomic complexity of MM is present at the asymptomatic 
stages of disease (MGUS and SMM), suggesting that extrinsic factors from the tumour 
microenvironment play an important role in mediating progression. Indeed, these studies 
suggest that early intervention at MGUS/SMM may be possible to prevent progression and 
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1.1 Biology of Multiple Myeloma  
Multiple Myeloma (MM) is a haematological malignancy resulting from the uncontrolled 
proliferation of malignant plasma cells (PCs) within the bone marrow (BM). MM is an 
age-dependent malignancy and the second most common haematological cancer (Singhal 
and Mehta 2006). Despite advances in therapy, MM remains a largely incurable disease 
with a median survival of 6 years. Notably, MM accounts for 20% of all deaths from 
haematological cancers and 2.1% of deaths from all cancers (NCI 2014, Zweegman, et al 
2014). Strategies such as chemotherapy with combinations of newly developed drugs and 
autologous stem cell transplantation (ASCT) are used to manage the disease following 
diagnosis (Palumbo and Anderson 2011). Over the last ten years, an increase in the 
spectrum of available treatment options has seen a two-fold increase in patient survival 
(Palumbo and Anderson 2011).  
 
The initiating oncogenic events that lead to the development of MM are thought to 
originate with the establishment of a founder precursor PC clone within the germinal 
centre of a peripheral lymphoid organ (Morgan, et al 2012). Healthy PCs are derived from 
B lymphocytes, which undergo rearrangement of their immunoglobulin (Ig) genes within 
the BM to generate precursor cells which express functional B cell receptors (surface 
immunoglobulins) (Shapiro-Shelef and Calame 2005). Following this, immature B cells 
migrate from the BM to the germinal centre of a peripheral lymphoid organ where they 
undergo affinity maturation in response to antigen exposure, specific for the B cell 
receptor. Somatic hypermutation (SHM) initiates point mutations in the hypervariable 
regions of the immunoglobulin heavy chain locus (IGH), resulting in the generation of 
highly specific Ig (Klein, et al 1998). Furthermore, class switch recombination (CSR) 
initiates antibody class switching, through deletional recombination of the Ig locus switch 
region, producing functional Ig of different isotype (Stavnezer 1996). Both molecular 
mechanisms of SHM and CSR are initiated by the expression of the enzyme activation-
induced cytidine deaminase (AID), which generates double stranded DNA breaks in the Ig 
loci (Morgan, et al 2012).  Maturation of B cells in the germinal centre leads to the 
development of memory B cells and plasmablasts, which are rapidly produced and short-
lived effector cells of the early antibody response (Nutt, et al 2015). Terminal 
differentiation of plasmablasts leads to the development of long-lived antibody producing 
PCs. The PCs subsequently migrate to the bone marrow and/or lymph nodes and are 
involved in the body’s immune response, producing Ig which serve to specifically bind to 
and destroy foreign antigens present in the body (Shapiro-Shelef and Calame 2005). 
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In MM however, the neoplastic PC clone, having sustained primary and potentially 
secondary mutations, migrates to the BM, where it expands in number and produces 
abundant, intact clonal Ig, known as Monoclonal (or “M”) protein or paraprotein (Wang 
and Young 2001). Abnormal PCs can also migrate to, and settle at other sites within the 
BM, where they expand in number to form myelomatous tumours at multiple sites 
(Ghobrial 2012). The myelomatous tumours disrupt normal homeostatic bone turnover, 
blood cell production and organ function leading to the clinical hallmarks of MM including 
elevated paraprotein in conjunction with suppressed immunoglobulin production and organ 
or tissue impairment. These clinical determinants of MM are known as the CRAB criteria 
(hypercalcaemia, renal insufficiency, anaemia and bone lesions) (Kyle, et al 2011). 
1.2 Development of Multiple Myeloma 
The development of MM is thought to involve a multistage transformational process, as a 
result of the acquisition of multiple genetic mutations that deregulate normal PC activity 
(Fig. 1) (Walker, et al 2014). Common initiating events in PCs include IGH translocations 
and hyperdiploidy, which result in the proliferation of monoclonal PCs, leading to 
development of a pre-cancerous, asymptomatic disease stage known as Monoclonal 
Gammopathy of Undetermined Clinical Significance (MGUS) (Bergsagel, et al 2005). 
MGUS is a slowly proliferative and relatively stable pre-myeloma stage in which 
paraprotein levels in the serum are < 30g/L and BM PC numbers account for < 10% of the 
nucleated cell count within the BM (International Myeloma Working Group 2003, 
Landgren, et al 2009). MGUS affects approximately 3% of the population aged over 50 
years and 5% of people aged over 70 years (Kyle, et al 2006). Each year, MGUS patients 
have a 0.5-1% risk of progressing to MM (Rajkumar, et al 2014). For this reason, MGUS 
patients are currently monitored but remain untreated until their condition progresses to a 
symptomatic disease stage. However the risk of progression is not uniform in all cases, 
influenced by disease biology factors such as the type and concentration of M protein, 
serum free light chain ratio, bone marrow plasmacytosis, proportion of clonal plasma cells 
and presence of immunoparesis (Rajkumar, et al 2014). Risk of progression can be 
stratified by the Mayo Clinic model based on clonal plasma cell burden with M protein 
values and skewed free light-chain ratios (Rajkumar, et al 2005) or the Spanish study 
group multiparametric flow cytometry model (Perez-Persona, et al 2007). For MGUS the 
Mayo Clinic identifies 3 important risk factors of progression: non-IgG isotype, serum M-
protein concentration > 1.5 g/dL and a skewed free light-chain ratio (< 0.26 or > 1.65) 
(Rajkumar, et al 2005). While the Spanish study group assesses the ratio of aberrant PC 
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(aPC) to normal BM PCs, where MGUS risk factors are a aPC/BMPC ratio > 95% and 
DNA aneuploidy (Perez-Persona, et al 2007). MGUS is followed by an intermediate 
asymptomatic Smouldering Multiple Myeloma (SMM) stage, where patients do not show 
evidence of Myeloma Defining Events (MDEs) or amyloidosis (Rajkumar, et al 2014). The 
SMM stage is known to have an annual risk of transition to MM of 10% in the first 5 years 
following diagnosis, 3% in the next 5 years and 1.5% in the subsequent years thereafter 
(Rajkumar 2016). For SMM, the Mayo Clinic identifies risk factors for progression being 
BM PCs > 10%, M-protein concentration > 3 g/dL and a skewed free light-chain ratio (< 
0.125 or > 8) (Dispenzieri, et al 2008). While the Spanish study group identifies risk 
factors of a aPC/BMPC ratio > 95% and immunoparesis (Perez-Persona, et al 2007). The 
transition to MM is accompanied by an increased plasmacytosis with the presence of ≥ 
10% clonal BM PCs or the presence of biopsy-proven bony or extramedullary 
plasmacytomas, and the presence of at least one of the MDEs (Rajkumar, et al 2014). The 
MDEs include evidence of CRAB features or at least one of the biomarkers of malignancy; 
including either the presence of clonal BM PCs percentage ≥ 60% or a serum free light 
chain ratio ≥ 100 or > 1 focal lesion (from MRI studies) (Rajkumar, et al 2014). In the final 
stage of the transformation process, malignant PC clones may gain independence from the 
BM, enter the peripheral circulation, leading to Plasma Cell Leukaemia (PCL), or form 


































Figure 1. The development of MM is a multistage transformational process. Common 
initiating events of IgH translocations and hyperdiploidy during B cell development 
deregulate normal PC behaviour, leading to asymptomatic MGUS. Further mutational load 
leads to the intermediate stage of SMM before final transformation to symptomatic MM. 
MGUS can take > 25 years to progress, with patients having an annual 0.5-1% risk of 
transition to MM. Whereas SMM usually takes < 5 years to progress, with an annual 10% 
risk of progressing to MM in the first 5 years. However, the risk of progression is not 







































































Using karyotyping and molecular cytogenetic techniques MM PCs have been 
classified under three key subtypes; hyperdiploid, non-hyperdiploid or unclassified 
(Fonseca, et al 2009). Hyperdiploid MM cases are characterised by trisomies and account 
for 50-60% of patients with MM (Sawyer, et al 2016). Non-hyperdiploid cases exhibit 
chromosomal translocations of the IgH locus, which are present in 45% of patients with 
MM (Mikhael, et al 2013). Interestingly IgH translocations arise through the normal 
process of B cell development. As previously described, during late B cell development 
AID induced CSR leads to double stranded breaks in the IgH locus, most of which are 
repaired locally. However, error in reassembly can lead to illegitimate recombination of the 
IgH locus with double stranded breaks elsewhere in the genome, resulting in aberrant 
chromosomal translocations of the IgH locus, where partner oncogenes are put into 
proximity of strong IGH enhancers leading to the hallmark event in MM (Gonzalez, et al 
2007, Morgan, et al 2012). The three most common IgH abnormalities include the t(4;14) 
(chromosome bands p16q32), t(11;14) (chromosome bands q13q32) and t(14;16) 
(chromosome bands q32q23) (Fonseca, et al 2009) translocations. Non-hyperdiploid cases 
represent a more aggressive form of MM and are associated with poor prognosis 
(Bergsagel and Chesi 2013). Other cytogenetic abnormalities including monosomies of 
chromosome 14, and unaltered chromosome structure, are also present at a lower 
frequency of MM patients (Mikhael, et al 2013, Rajkumar 2016). Further studies have 
identified that this may represent a novel hyperhaploid subtype of high risk MM disease 
(Sawyer, et al 2016).  Risk type of active MM can be stratified based on the specific 
genetic lesions harboured by a patient into high risk (t(14;16), t(14;20) and del 17p), 
intermediate risk (t(4;14, gain 1q, hypodiploidy and del 13) and standard risk (t(11;14), 
t(6;14) and trisomies) (Mikhael, et al 2013, Rajkumar 2016). However, the early common 
primary pathogenic events of hyperdiploidy and IgH translocations are believed to be 
insufficient to cause active symptomatic MM, as asymptomatic MGUS patients can 
harbour these abnormalities and show no clinical symptoms (Chapman, et al 2011, 
Fonseca, et al 2002). The acquisition of secondary genetic events of non-synonymous 
single nucleotide variations (NS-SNVs), copy number variations (CNVs) and epigenetic 
changes are also required to initiate MGUS and PC malignancy leading to MM disease 
progression (Chesi and Bergsagel 2011, Morgan, et al 2012).  In addition to the oncogenic 
mutations occurring in the PC, there has been significant advancement in the 
understanding of an important role played by the BM microenvironment in supporting MM 
disease progression through proliferation, survival and drug resistance of MM PCs (Abe 
2011, Lawson, et al 2015, Manier, et al 2012, Mitsiades, et al 2006, Noll, et al 2012). 
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1.3 A New Paradigm In Multiple Myeloma Development 
New high-resolution Next Generation Sequencing (NGS) techniques represent an 
important advance in genomics, providing researchers with powerful tools for genetic 
analysis at single nucleotide resolution, enabling the identification of critical disease 
mutations and disease vulnerability. To date, no single gene mutation or combination of 
mutations have been identified as being common to all MMs at presentation (Weston-Bell, 
et al 2013). These findings suggest that multiple diverse genetic aberrations, and molecular 
pathways, are responsible for the onset of disease. Furthermore, the genetic abnormalities 
that are characteristic of each transformational stage of MM (MGUS, SMM and MM) have 
not been fully identified. This has been attributed to the low-resolution cytogenetic 
techniques previously used, which possess relatively low sensitivity of identification.  
 
Of particular interest is the elucidation of how these key genetic aberrations contribute 
to tumour evolution in MM. Defining these critical disease mutations will provide insight 
into the possible mechanisms underlying disease progression, and identify key biomarkers 
of disease risk and provide novel therapeutic targets. Evaluation of the available 
cytogenetic and NGS studies reveals evidence for the existence of multiple tumour 
evolution models within MM. As a result three models of tumour evolution in MM are 
postulated:  
• Linear model 
• Expansionist model 











1.3.1 Linear Model of Tumour Evolution 
Classical cancer biology theory proposes a linear model of evolution, where tumours are 
derived from a unicellular origin with clonal growth pattern as a result of sequential 
accumulation of genetic mutations (Bahlis 2012).  
 
As discussed earlier, the development of MM is considered to be a multistage 
transformational process where patients with MGUS progress through an intermediate 
SMM transition stage before developing symptomatic MM. Initial genome analyses by 
Chapman, et al., identified MM tumour-specific mutations by comparing corresponding 
tumour to normal PCs using Whole Genome Sequencing (WGS) and Whole Exome 
Sequencing (WES) techniques.  An average of 35 NS-SNVs and 21 chromosomal 
rearrangements that disrupted protein coding regions were identified in MM (Chapman, et 
al 2011). Following this, Walker, et al., carried out the first WGS study comparing a small 
number of premalignant MM stages (MGUS n = 4, SMM n = 4) and symptomatic MM 
stages (MM n = 26, PCL n = 2) to reveal tumour acquired NS-SNVs as a function of 
disease progression, where genetic complexity increases through the stages of MM. MGUS 
PCs were found to harbour a median of 13 NS-SNVs which increased to 28, 31 and 59 
through SMM, MM and PCL, respectively (Walker, et al 2014). These findings are 
consistent with a linear model of tumour evolution in MM, where the sequential 
acquisition of NS-SNVs reaches a mutational threshold in the SMM PC, resulting in 






















Figure 2. The linear model of tumour evolution: The sequential acquisition and 
accumulation of multiple genetic mutations (represented by distinct bolts increasing 
through MGUS (red), SMM (red + black) and MM (red + black + green + yellow)) in PCs 









































1.3.2 Expansionist Model of Tumour Evolution 
The expansionist model of tumour evolution infers that all necessary genetic mutations are 
present in a subset of PCs at the MGUS disease stage, and it is their subsequent expansion 
that leads to MM disease progression.  
Studies using low-resolution molecular cytogenetic techniques have detected the 
same genetic mutations throughout all stages of MM transformation. Fluorescence in situ 
hybridisation (FISH) analysis has identified IgH translocations, chromosome 13q and 17p 
deletions and gain of 1q throughout all stages of MGUS, SMM and MM (Chiecchio, et al 
2009, Lopez-Corral, et al 2011). Interestingly, the number of PCs harbouring these specific 
genetic abnormalities increased with disease progression, suggesting that clonal PC 
expansion was due to selective advantages (Avet-Loiseau, et al 1999, Chiecchio, et al 
2009, Lopez-Corral, et al 2011). Notably also, sequential analysis of 5 patients (2 MGUS-
MM, and 3 SMM-MM) revealed a higher proportion of PC harbouring the genetic 
abnormality that was observed at MGUS/SMM diagnosis upon progression to MM 
(Lopez-Corral, et al 2011). Further high resolution CNV analysis using high density single 
nucleotide polymorphism (SNP) arrays have indicated an increasing genetic complexity as 
disease progresses towards MM, with a progressive increase in the median number of 
CNVs through MGUS, SMM and MM from 5 to 7.5 to 12, respectively (Lopez-Corral, et 
al 2012). Frequent abnormalities observed in MM include gains on chromosome 1q, 3p, 
6p, 9p, 11q, 19p, 19q and 21q together with deletions on chromosome 1p, 6q, 8p, 12p, 13q, 
14q, 16q, 17p, 17q and 22q (Lopez-Corral, et al 2012, Walker, et al 2012). Alterations of 
11q and 21q gains and, 16q and 22q deletions were previously viewed to be MM specific, 
however, it has been shown that these alterations are present within minor subclones at the 
MGUS stage (Lopez-Corral, et al 2012). Furthermore, WGS of sequential SMM-MM has 
demonstrated little difference in the median number of NS-SNVs present at both stages, 
with 28 to 31 respectively, reported (Walker, et al 2014). These findings suggest that the 
predominant PC clone may already be present at the SMM stage, and it is the outgrowth 
that leads to the initiation of MM disease progression. Interestingly, a recent WES and 
genotyping study of paired random bone marrow-focal lesion samples has revealed 
insights into spatial heterogeneity, where both similarities and differences of site specific 
SNVs and CNVs were observed to contribute to disease progression (Weinhold, et al 
2015). In some paired samples up to 90% of variants were shared between both site 
samples, and a prominent pattern of the outgrowth of subclonal bone marrow sample 
CNVs as clonal events in focal lesions samples was observed (Weinhold, et al 2015). 
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Taken together, these findings support an expansionist model of MM evolution, where a 
subpopulation of MGUS PCs harbour all the required genetic mutations, and their 







































Figure 3. The expansionist model of tumour evolution: All necessary genetic mutations 
are present in a subpopulation of MGUS PCs (represented by all the distinct bolts (red + 









































1.3.3 Intraclonal Heterogeneity Model of Tumour Evolution 
The intraclonal heterogeneity model of tumour evolution posits a genetically 
heterogeneous clonal structure at the asymptomatic MGUS disease stage, where 
“Darwinian” competition occurs between distinct PC subclones in response to selective 
pressures, leading to the outgrowth of dominant PC subclones and subsequent MM disease 
progression (Greaves and Maley 2012, Nowell 1976). 
 
Initial cytogenetic studies have indicated a genomic complexity where only a 
proportion of the clonal PC population carried any specific abnormalities at each stage of 
MM disease (Chiecchio, et al 2009, Lopez-Corral, et al 2011, Lopez-Corral, et al 2012). 
The advent of NGS techniques has allowed genetic analysis at single nucleotide resolution 
resulting in a higher power of detection of clonal architecture. A specific mutation being 
clonal or subclonal within a tumour sample can be determined by the proportion (of 
mutated reads) of total tumour cells that harbour the specific mutation, adjusted to any 
normal (non-tumour) contamination and the copy number of the locus. From this a 
phylogenetic tree of clonal/subclonal fractions can then be constructed to estimate the 
intraclonal evolution that may be occurring within the tumour. Initial sequencing studies 
on MM patients using WGS and WES have led to the discovery of frequent significantly 
mutated genes (“driver” genes), and the existence of a heterogeneous genetic landscape, 
where coexisting clones of differing genetic architecture arise during the evolution of MM 
(Bolli, et al 2014, Egan, et al 2012, Lohr, et al 2014, Walker, et al 2012). These “driver” 
genes are thought to influence clonal fitness (selective advantage and dominance) of 
malignant PC clones harbouring these mutants, driving MM disease progression in a 
branching manner. 
 
While MGUS is known to be a benign disease stage that is far less genetically 
complex than MM, intraclonal heterogeneity has been demonstrated through all stages of 
MM, suggesting that disease progression is mediated via competition between subclones 
and outgrowth of the fittest of these subclones from the earliest stage of MM (Bolli, et al 
2014, Egan, et al 2012, Lohr, et al 2014, Walker, et al 2012). Large cohort sequencing 
studies in MM have identified recurrently mutated genes associated with disease 
pathogenesis. The initial study of 38 MM tumours with matched normal genomes 
identified significant frequent somatic mutations occurring in MM, involving genes KRAS, 
NRAS, TP53, BRAF and IRF4, and six newly discovered cancer-associated genes; CCND1, 
FAM46C, DIS3, PNRC1, ALOX12B, HLA-A and MAGED1 (Chapman, et al 2011). Further 
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large cohort NGS studies performed by Lohr et. al. (n = 203 patients), Bolli et. al. (n = 67 
patients) and Walker et. al. (n = 463 patients) have also identified the presence of 
mutations in KRAS, NRAS, TP53, BRAF, FAM46C, DIS3, IRF4, TRAF3 and CYLD (Bolli, 
et al 2014, Lohr, et al 2014, Walker, et al 2015), of which KRAS, NRAS, TP53, BRAF, 
FAM46C and DIS3 are now believed to be “driver” genes in MM disease progression. The 
RAS/MAPK pathway is frequently observed to be deregulated in MM, with recurrent 
mutations occurring in KRAS, NRAS and BRAF (Bolli, et al 2014, Lohr, et al 2014, 
Walker, et al 2015). Mutations in KRAS and NRAS tend to mainly occur with mutual 
exclusivity, however have been observed to co-exist in 2% of patients (Walker, et al 2015). 
Interestingly, these “driver” mutations have been identified as being present in clonal 
fractions in some patients and subclonal fractions in other patients, suggesting “driver” 
events may also arise during later stages of MM tumour evolution (Bolli, et al 2014, Lohr, 
et al 2014). Furthermore, although affecting the same pathway, they have been identified 
to occur subclonally or in a nested fashion, where one mutation clone is identified as a 
subclone of another (Lohr, et al 2014). While it would be expected that these subclonal 
populations would exhibit improved survival advantage, owing to the presence of 
mutations in multiple “driver” genes, they do not appear to have sufficient selective 
advantage for outgrowth to clonality (Lohr, et al 2014). This advancement in our 
understanding of the intraclonal heterogeneity in MM illustrates the consideration required 
towards therapeutic choices, where suboptimal outcome would be observed if a patient is 
treated for a “driver” mutation that exists only subclonally. These unique findings support 
an intraclonal heterogeneity model of MM evolution, where subclones harbour differing 
combinations of mutations, with the genetic landscape of subclones changing as MM 



















Figure 4. The intraclonal heterogeneity model of tumour evolution: Distinct PC 
subclones carry different combinations of genetic mutations (represented by MGUS 
subpopulations harbouring distinct combinations of coloured bolts), with the dominance of 
subclones changing with MM disease progression. Predominant subclones harbouring 
“driver” mutations, conferring increased fitness potential, are able to survive the 
microenvironment pressures and contribute to MM disease progression (represented by the 



































1.4 Single Cell Analysis of Multiple Myeloma 
In more recent years, novel single cell analysis techniques have provided a sophisticated 
method for unravelling tumour genomics and evolution at a more detailed level. By 
unravelling clonal diversity and frequency of genetic mutations, single cell analysis is able 
to provide a greater understanding of the genomic complexity and clonal architecture that 
is present at the individual cell level within a bulk tumour. Current platforms available for 
single cell capture and subsequent genomic interrogation include Fluorescence Activated 
Cell Sorting (FACS) based automated single cell deposition and the Fluidigm C1 
integrated fluidic chip (IFC) system (Fluidigm Corporation).  
The existence of clonal heterogeneity presents a complex situation when analysing 
tumours. Distinct clonal populations of cells cannot be identified by conventional tissue 
average data analysis (Gundry, et al 2012). Furthermore, random low abundance mutations 
are currently inaccessible by standard high throughput sequencing approaches because they 
cannot be distinguished from sequencing errors (Gundry, et al 2012). At the genomic level, 
it is difficult to identify whether mutations are present in the same tumour cells or arise 
from distinct clonal populations of cells present within the bulk tumour (Yadav and De 
2014). Consequently, isolated detection of dominant clonal populations of tumour cells 
could bias classification, prognosis and treatment of disease (Yadav and De 2014).  
Application of single cell analysis techniques in MM supports the existence of 
multiple independent subclones within tumours. Single cell studies of t(11;14) MM have 
described the existence of 2 to 6 different clones, which are related by linear and branching 
phylogenies, highlighting the presence of intraclonal heterogeneity at MM diagnosis 
(Melchor, et al 2014). Melchor and colleagues demonstrated the existence of subclonal 
heterogeneity with parallel evolution of the RAS/MAPK pathway in distinct single cells, 
giving rise to divergent subclonal populations of mutant NRAS clone lineage and mutant 
KRAS clone lineage (Melchor, et al 2014). Furthermore, single cell genotyping has 
revealed a subclonal substructure in MM with 3 main clones harbouring ATM mutations 
where 2 subclones exhibited other mutually exclusive mutations (Walker, et al 2012). 
Walker and colleagues also identified intraclonal heterogeneity of mutations in “driver” 
genes NRAS (present in 32% and 96% of tumour cells) and KRAS (20% and 72% of 
tumour cells) (Walker, et al 2012). Interestingly, activating KRAS mutations were present 
as minor subclones in one case, observed in 20% and 48% of tumour cells (Walker, et al 
2012). This suggests that subclones are continually at risk of developing “driver” 
mutations that can confer a growth and survival advantage leading to clonal dominance 
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over time (Walker, et al 2012). This advancement in the understanding of the intratumour 
heterogeneity in MM illustrates the consideration required towards therapy and its clinical 
implications. A recent study using in vitro modelling of MM cell lines that are bortezomib-
sensitive or -resistant has generated a novel gene expression profiling (GEP) signature that 
can predict drug response to proteasome inhibitors (Stessman, et al 2013). The analysis of 
this GEP at the single cell level in pre-treated MM cell lines and drug naïve patient 
samples was able to identify pre-existing single cell sub populations that were resistant to 
proteasome inhibitors, demonstrating the possible requirement of therapies tailored 
towards subclonal populations within bulk tumours (Mitra, et al 2016). This has also been 
developed into the computational software package SCATTome (single-cell analysis of 
targeted transcriptome) that can predict probability of drug response of single cells based 
on the MM expression signature (Mitra, et al 2016).  
Collectively, these NGS and single cell studies support clonal heterogeneity as a 
model of MM evolution where “Darwinian” competition between heterogeneous PC 
subclones initiates non-linear accumulation of mutations and outgrowth of dominant 
subclones driving MM disease progression. 
1.5 Limitations of Published Studies in Multiple Myeloma  
To date, a limited number of NGS studies of MM have been performed, with the first 
“Initial genome sequencing and analysis of multiple myeloma” carried out by Chapman et. 
al. in 2011 (Chapman, et al 2011). The majority of these studies involved single time point 
studies of MM PC samples or have relied on the use of unpaired MGUS and MM PC 
samples. Consequently, these studies are only able to provide a detailed indication of the 
genetic landscape at the MM disease stage and an indirect indication of genetic mutations 
associated with MM disease progression.  
WES analysis of serial samples (n = 15), collected at disease progression or relapse 
post-treatment with later time point samples collected at relapse/progression after further 
lines of treatment has revealed major patterns of tumour evolution associated with MM 
progression: 1. no change in clonal composition, 2. differential clonal response, with 
proportions of subclones changing over time, 3. linear evolution, with a new subclone 
emerging over time, and 4. branching evolution, with the emergence of new clones and 
decline of other clones (Bolli, et al 2014). Only one study has investigated paired SMM-
MM samples (n = 4), finding that intraclonal heterogeneity is a typical feature in MM, 
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where SMM is a transition state where subclonal structure is evolving (Walker, et al 2014). 
Interestingly, only one unique NS-SNV was identified in MM, demonstrating that most of 
the required mutations for transition to symptomatic MM are already present. Additionally, 
comprehensive analysis of paired presentation and relapse/progression samples after 
combination high dose therapy (n = 33), using WES as well as gene expression and copy 
number profiles has revealed a majority of patients (n = 22) relapse through a branching 
tumour evolution pattern, with others showing linear evolution and differential response 
(Weinhold, et al 2016). Furthermore an increase in bi-allelic inactivation of tumour 
suppressor genes (mainly TP53 and FAM46C) was associated with relapse, with double hit 
events in TP53: del(17p)/TP53mut or del(17p)/TP53del characterising a subgroup of patients 
with worse outcome after relapse (Weinhold, et al 2016). Further serial sample studies of 
this nature and/or sampling of different sites from the same patient are required for a 
greater understanding of genetic heterogeneity in MM disease progression.  
A comprehensive approach would be to perform NGS studies of sequential paired 
MGUS-MM samples from the same patient. At present, no longitudinal progression studies 
of paired MGUS-MM PC samples have been performed. This is due, in large part, to the 
difficulty in establishing a cohort of patient samples from individuals when they were first 
diagnosed with MGUS, and subsequently symptomatic MM. Additionally due to the nature 
of premalignant disease, MGUS samples contain a low number of tumour PCs compared to 
normal healthy PCs, which results in high contamination and low yield of tumour PCs on 
isolation. The thorough genomic analysis of both bulk tumours and single cells on paired 
MGUS-MM patients represents a unique approach to identify key “driver” genes that are 
mutated and/or aberrantly expressed during disease progression. This approach would 
derive gene signatures indicative of pathways that are deregulated during the MGUS to 
MM transition. Furthermore, genomic data derived from such a study may allow for the 
identification of biomarkers that can predict which MGUS patient will progress to MM.  
1.6 Epigenetics in Multiple Myeloma Development 
Extensive studies of MM have been performed using cytogenetic and genomic approaches, 
however, relatively little is known about the role of epigenetics in driving MM disease 
progression. The rate of epigenetic change in cancers has been estimated to be orders of 
magnitude higher than that of genetic change occurring, and could be a major determinant 
of clonal evolution (Greaves and Maley 2012). The key epigenetic mechanisms known to 
alter and regulate gene expression are DNA methylation and histone modifications. 
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Changes in DNA methylation status, such as hypermethylation leading to gene 
inactivation and hypomethylation inducing genomic instability, have been observed in 
many cancer types (Kulis and Esteller 2010). Methylome studies comparing MM and its 
transition stages (MGUS, SMM and PCL) with normal PCs, have shown an increase in the 
number of differentially methylated gene loci associated with disease progression (Heuck, 
et al 2013, Salhia, et al 2010, Walker, et al 2011). The presence of genetic 
hypomethylation has been implicated as an important and early mechanism which drives 
MM disease progression (Salhia, et al 2010). Hypomethylation is associated with genomic 
instability and often coupled with altered chromatin structure, changes in DNA 
methyltransferase activity, loss of imprinting and an increased frequency of CNVs 
(Walker, et al 2011). Further studies have identified distinct profiles of epigenetic 
modifications linked with MM disease transition stages, with global hypomethylation 
occurring at MGUS-MM transition and hypermethylation occurring at MM-PCL transition 
(Walker, et al 2011). Specifically, DNA methyltransferase DNMT3A was observed to be 
underexpressed in MM due to the actions of hypermethylation, providing insight into the 
possible mechanism of hypomethylation observed in premalignant stages of MM (Heuck, 
et al 2013). Gene ontology enrichment analysis has revealed that hypomethylation in MM 
may favour bone invasion by increasing interactions with the bone marrow extracellular 
matrix, initiating adhesive interactions and the formation of lytic bone lesions (Salhia, et al 
2010). Interestingly, highlighting the heterogeneity also observed at the methylation level, 
gene-specific hypermethylation has also been associated with MGUS-MM transition, with 
77 affected genes having roles in developmental, cell cycle and transcriptional regulatory 
pathways identified (Walker, et al 2011). Further gene-specific hypermethylation has been 
identified at MM-PCL transition, with 1802 affected genes that are associated with cell 
signalling and cell adhesion pathways (Walker, et al 2011). Hypermethylation is proposed 
to deregulate adhesion of MM PCs to the bone marrow, facilitating independence of 
malignant PCs from the bone marrow niche, leading to PC egress from the marrow and 
entry into the peripheral circulation and development of PCL (Walker, et al 2011). 
Furthermore, a recent study has also identified hypermethylation of developmentally 
regulated B cell enhancers as a new type of epigenetic modification associated with the 
pathogenesis of MM (Agirre, et al 2015). 
Initial methylome analysis had revealed that methylation status is not associated 
with specific genetic alterations (Salhia, et al 2010). In contrast, other studies have 
identified specific MM cytogenetic subgroups which exhibit individual methylation 
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profiles with a t(4;14) group, two separate t(11;14) groups and two separate hyperdiploid 
groups described (Walker, et al 2011). The t(4;14) cytogenetic subgroup displays frequent 
hypermethylation, akin to that observed in PCL, signifying that the methylation status may 
influence the aggressive clinical phenotype usually observed in both cases (Walker, et al 
2011). However, the mechanisms that cause abnormal DNA methylation patterns in MM 
are yet to be determined (Dimopoulos, et al 2014). 
Complex epigenetic mechanisms involving histone modifications are also reported 
to contribute to the pathogenesis of cancer (Plass, et al 2013). While DNA methylation is 
relatively constant, histone modifications are dynamic in nature. The main regulatory 
mechanism of the epigenome is histone acetylation, which is maintained by the interplay of 
two enzymes; histone acetyl transferases (HATs) catalysing the addition and histone 
deacetylases (HDACs) catalysing the removal of acetyl groups on lysine residues of 
histones.  
In MM, HDAC inhibitors have been reported to have potent anti-myeloma activity 
both in vitro and in vivo (Smith, et al 2010). However, a clear understanding of which 
HDACs are expressed by MM PCs is lacking (Smith, et al 2010). Alternatively, histone 
methylation has been implicated to play an important role in MM development. For 
example, the high risk cytogenetic t(4;14) subgroup exhibits dysregulated expression of 
Fibroblast Growth Factor Receptor 3 (FGFR3) and Multiple Myeloma Set Domain 
(MMSET), a histone methyl transferase (Kalff and Spencer 2012).  Universal expression of 
MMSET in t(4;14) MM suggests that MMSET is critical for myeloma pathogenesis and/or 
progression (Marango, et al 2008). Interestingly, further to its histone methyl transferase 
activity, MMSET has been identified to enhance the activity of HDACs (HDAC1 and 
HDAC2) and therefore plays a role in altering histone acetylation. MMSET has been 
shown to be beneficial to the survival of MM PCs as in vitro MMSET knockdown affects 
genes involved in key survival processes such as cell cycle, apoptosis and adhesion (Brito, 
et al 2009). These findings reveal insights into new epigenetic therapeutic strategies in 







1.7 Current Therapies and Impacts in Multiple Myeloma 
Although MM remains a largely incurable disease, advances in clinical research have 
produced effective treatment methods for disease control. Different strategies are 
employed for asymptomatic and symptomatic disease stages where MGUS/SMM stages 
require clinical monitoring while active MM is treated immediately and, in most cases, 
aggressively to induce disease remission (Palumbo and Anderson 2011). In the past 
decade, the survival of MM patients has more than doubled due to the introduction of new 
effective drug classes including immunomodulatory drugs (lenalidomide, thalidomide, 
pomalidomide, daratumumab and elotuzumab), histone deacetylase inhibitors 
(panobinostat) and proteasome inhibitors (bortezomib, carfilzomib and ixazomib), and the 
increased use of ASCT (Gertz 2014, MMRF 2015, Palumbo and Anderson 2011). Patient 
risk status is evaluated based on the factors of age/performance, renal function and 
presence or absence of high-risk genetic abnormalities, which all plays an important role in 
the treatment selection (Gertz 2014). Treatment comprises of three phases: induction, 
consolidation and maintenance. Current induction treatments for newly diagnosed patients, 
who are eligible for ASCT, include two-drug combination therapy of dexamethasone with 
lenalidomide (Rd), thalidomide or bortezomib. Three-drug combination treatments for 
newly diagnosed patients include the use of bortezomib with: bortezomib-
cyclophosphamide-dexamethasone (VCD), bortezomib-thalidomide-dexamethasone 
(VTD) or bortezomib-lenalidomide-dexamethasone (VRD) (Rajkumar 2016). These 
combination treatment strategies are used to induce a complete response in patients before 
ASCT, followed by maintenance treatment with thalidomide or lenalidomide (Palumbo 
and Anderson 2011). For patients ineligible for transplantation, preferred treatments 
include melphalan based combinations of melphalan-prednisone-thalidomide (MPT), Rd 
(for elderly patients) or bortezomib based combinations VRD, VCD or VTD (Rajkumar 
2016). In more recent years the treatment of relapsed MM patients (who have undergone 
previous lines of treatment) has seen promising results with the clinical trials and approval 
of monoclonal antibodies daratumumab (targeting cell surface protein CD38) and 
elotuzumab (targeting cell surface protein CD319) in 2015. Daratumumab has shown great 
efficacy in clinical trials with the ability to induce a deep response as both a monotherapy 
(Lonial, et al 2016, Usmani, et al 2016) and in combination therapy with bortezomib-
dexamethosone (Palumbo, et al 2016) or lenalidomide-dexamethosone (Dimopoulos, et al 
2016). Similarly, elotuzumab has shown efficacy in its clinical trial as a combination 
therapy with lenalidomide-dexamethosone, but does not show any single-agent activity 
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(Lonial, et al 2015, Rajkumar 2016). These novel and combination therapies have been 
observed to provide a durable response and greater progression free survival for MM 
patients, although there are no current studies performed that investigate how a patient 
tumour composition may change genetically with the administration of these new 
treatments. 
 
Heterogeneity is thought to be characteristic of MM, and the administration of 
therapy acts as a potent source of artificial selection, which changes the dynamics of 
cancer clones (Fig. 5). The therapeutic strategies employed to control tumour growth are 
genotoxic and result in massive death of aggressive tumour PC clones with “driver” 
mutations, but also provides a selective pressure for the proliferation of indolent tumour 
PC clones with “passenger” mutations that may resist treatment (Brioli, et al 2014, 
Greaves and Maley 2012). Thus, therapy can initiate a selective bottleneck facilitating the 
death or survival of different subclones based on fitness (Brioli, et al 2014, Greaves and 
Maley 2012). Indolent clones surviving treatment may mutate further, acquiring “driver” 
mutations, thereby conferring improved fitness and malignant potential, which in turn, 
leads to disease relapse (Brioli, et al 2014, Greaves and Maley 2012). Clonal tiding, the 
rise and fall in dominance of subclones as selective pressures change, has been associated 
with the occurrence of MM disease relapse (Melchor, et al 2014). As a result, distinct 
clones may dominate at different times during the disease course making MM disease 
























Figure 5. The impact of therapy on intraclonal heterogeneity in MM: The introduction 
of treatment presents a new selective pressure on a heterogeneous MM tumour, in 
conjunction with those already existing due to the bone marrow microenvironment, 
immune system and competing clonal architecture. While therapy is effective in 
eliminating dominant PC populations harbouring critical “driver” mutations, it may be 
ineffective against indolent PC populations which do not have “driver” mutations. These 
residual PC clones surviving treatment may mutate further, acquiring “driver” mutations, 















































In view of these new findings, the impact of therapy on clonal evolution and 
disease progression in MM should be considered at the outset of treatment. To date, a 
limited number of studies have investigated the changing clonal architecture in MM 
associated with treatment. Longitudinal WGS study of a single patient tumour through 
transformation stages - diagnosis, first relapse, second relapse and secondary PCL - has 
revealed substantial tumour heterogeneity, with clonal tiding in response to selective 
pressures from treatment, and resulting clonal evolution (Egan, et al 2012). These findings 
have been validated by WES analysis of a patient tumour at diagnosis and first relapse 
where 81 novel NS-SNVs were identified (33 shared at diagnosis and relapse, while 48 
were new) following relapse after first line therapy (Weston-Bell, et al 2013). Genomic 
analysis of paired diagnosis-relapse samples (n = 24) using the Genome-Wide Human SNP 
array has identified patients exhibiting branching, non linear evolution following therapy 
driven by the survival of a minor subclone which expanded at relapse (Magrangeas, et al 
2013). Similarly, targeted genomic mutation panel sequencing of sequential pre- and post-
therapy MM samples (n = 25) investigating the most commonly mutated genes in MM has 
revealed clonal evolution in the majority of patients, including clonal expansion, retraction 
and/or extinction (Kortum, et al 2015). To this end, the complete extinction of subclones 
(with mutations of KRAS and TP53) and emergence of new subclones (with mutations of 
FAM46C, FAT1, SPEN and TP53) was identified following therapy (Kortum, et al 2015). 
Conversely, however, WES on paired high-risk SMM-MM post-treatment samples has also 
identified that therapy is able to reduce clonal complexity of disease (Walker, et al 2014). 
These observations suggest inherent disease complexity at relapse in response to changing 
selective pressures attributed to the different chemotherapeutic agents and illustrates the 
need for tumour clones to be monitored for regressing or reappearing subclones which may 
contribute to disease aggressiveness following specific treatment regimes. 
It has been suggested that combinatory treatment regimens should be utilised for a 
deeper response to reduce both bulk tumour and eliminate clonal and subclonal 
populations. It has also been suggested that continued therapy versus selective therapy at 
specific stages of progression for disease control may provide better treatment outcomes. 
Unfortunately, there is no evidence to support the notion that continuous therapy is more 
effective than repeated therapy following disease relapse (Gertz 2014). Ultimately, 
improvements in the outcomes of future treatment will need to take into account the 
plasticity of MM PCs and altering dominance of genetically distinct subclones that occur 




1.8 Summary and Objectives  
In recent years, rapid advances in genomic technologies, including the application of NGS 
and single cell analysis techniques, has led to a revolution in our understanding of MM 
biology and provides direct evidence that MM is a genetically complex disease. Studies 
also suggest that MM development can be accounted for by a number of tumour 
development models including the linear model, expansionist model and intraclonal 
heterogeneity model. In addition, these methods have shown that MM development is 
associated with significant recurrent probable “driver” mutations in KRAS, NRAS, TP53, 
BRAF, FAM46C and DIS3 which are central to MM disease pathogenesis. Additionally, 
these new insights will impact current therapeutic strategies used to control MM disease. 
At this stage, research has mainly been performed on unpaired MGUS/SMM/MM samples, 
which limits our full understanding of the key “drivers” of MGUS to MM transition. 
Furthermore, few studies have examined the impact of treatment on intraclonal 
heterogeneity. With the progress of NGS technologies and the development of more cost-
effective methods, thorough analysis of paired MGUS-MM samples and analysis of post-
treatment samples should reveal the genetic and molecular mechanisms that play a central 
role in MM tumour development and disease progression. Ultimately, these insights will 
heavily influence the future therapeutic strategies used to control MM disease development 
and relapse. 
This project aims to characterise the underlying genomic complexity and tumour evolution 
associated with disease progression from MGUS/SMM to MM in paired patient samples. 
These samples were isolated from patients when they were first diagnosed with MGUS or 
SMM and subsequently when they were diagnosed at MM. 
 
The studies outlined in this thesis address the following aims: 
1. To identify the somatic variants associated with the progression of MGUS/SMM to 
MM using Whole Exome Sequencing (WES) 
2. To infer the subclonal tumour evolution model characteristic of disease progression 
from MGUS/SMM to MM 
3. To identify the transcriptomic and methylomic changes associated with the 
progression of MGUS/SMM to MM using RNA sequencing (RNAseq) and Whole 







1. Abe, M. (2011) Targeting the interplay between myeloma cells and the bone 
marrow microenvironment in myeloma. Int J Hematol, 94, 334-343. 
 
2. Agirre, X., Castellano, G., Pascual, M., Heath, S., Kulis, M., Segura, V., 
Bergmann, A., Esteve, A., Merkel, A., Raineri, E., Agueda, L., Blanc, J., 
Richardson, D., Clarke, L., Datta, A., Russinol, N., Queiros, A.C., Beekman, R., 
Rodriguez-Madoz, J.R., San Jose-Eneriz, E., Fang, F., Gutierrez, N.C., Garcia-
Verdugo, J.M., Robson, M.I., Schirmer, E.C., Guruceaga, E., Martens, J.H., Gut, 
M., Calasanz, M.J., Flicek, P., Siebert, R., Campo, E., Miguel, J.F., Melnick, A., 
Stunnenberg, H.G., Gut, I.G., Prosper, F. & Martin-Subero, J.I. (2015) Whole-
epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-
specific enhancers. Genome Res, 25, 478-487. 
 
3. Avet-Loiseau, H., Facon, T., Daviet, A., Godon, C., Rapp, M.J., Harousseau, J.L., 
Grosbois, B. & Bataille, R. (1999) 14q32 translocations and monosomy 13 
observed in monoclonal gammopathy of undetermined significance delineate a 
multistep process for the oncogenesis of multiple myeloma. Intergroupe 
Francophone du Myelome. Cancer Res, 59, 4546-4550. 
 
4. Bahlis, N.J. (2012) Darwinian evolution and tiding clones in multiple myeloma. 
Blood, 120, 927-928. 
 
5. Bergsagel, P.L. & Chesi, M. (2013) V. Molecular classification and risk 
stratification of myeloma. Hematol Oncol, 31 Suppl 1, 38-41. 
 
6. Bergsagel, P.L., Kuehl, W.M., Zhan, F., Sawyer, J., Barlogie, B. & Shaughnessy, 
J., Jr. (2005) Cyclin D dysregulation: an early and unifying pathogenic event in 
multiple myeloma. Blood, 106, 296-303. 
 
7. Bolli, N., Avet-Loiseau, H., Wedge, D.C., Van Loo, P., Alexandrov, L.B., 
Martincorena, I., Dawson, K.J., Iorio, F., Nik-Zainal, S., Bignell, G.R., Hinton, 
J.W., Li, Y., Tubio, J.M., McLaren, S., S, O.M., Butler, A.P., Teague, J.W., Mudie, 
L., Anderson, E., Rashid, N., Tai, Y.T., Shammas, M.A., Sperling, A.S., Fulciniti, 
M., Richardson, P.G., Parmigiani, G., Magrangeas, F., Minvielle, S., Moreau, P., 
Attal, M., Facon, T., Futreal, P.A., Anderson, K.C., Campbell, P.J. & Munshi, N.C. 
(2014) Heterogeneity of genomic evolution and mutational profiles in multiple 
myeloma. Nat Commun, 5, 2997. 
 
8. Brioli, A., Melchor, L., Cavo, M. & Morgan, G.J. (2014) The impact of intra-clonal 





9. Brito, J.L., Walker, B., Jenner, M., Dickens, N.J., Brown, N.J., Ross, F.M., 
Avramidou, A., Irving, J.A., Gonzalez, D., Davies, F.E. & Morgan, G.J. (2009) 
MMSET deregulation affects cell cycle progression and adhesion regulons in 
t(4;14) myeloma plasma cells. Haematologica, 94, 78-86. 
 
10. Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, 
A.C., Harview, C.L., Brunet, J.P., Ahmann, G.J., Adli, M., Anderson, K.C., Ardlie, 
K.G., Auclair, D., Baker, A., Bergsagel, P.L., Bernstein, B.E., Drier, Y., Fonseca, 
R., Gabriel, S.B., Hofmeister, C.C., Jagannath, S., Jakubowiak, A.J., Krishnan, A., 
Levy, J., Liefeld, T., Lonial, S., Mahan, S., Mfuko, B., Monti, S., Perkins, L.M., 
Onofrio, R., Pugh, T.J., Rajkumar, S.V., Ramos, A.H., Siegel, D.S., Sivachenko, 
A., Stewart, A.K., Trudel, S., Vij, R., Voet, D., Winckler, W., Zimmerman, T., 
Carpten, J., Trent, J., Hahn, W.C., Garraway, L.A., Meyerson, M., Lander, E.S., 
Getz, G. & Golub, T.R. (2011) Initial genome sequencing and analysis of multiple 
myeloma. Nature, 471, 467-472. 
 
11. Chesi, M. & Bergsagel, P.L. (2011) Many multiple myelomas: making more of the 
molecular mayhem. Hematology Am Soc Hematol Educ Program, 2011, 344-353. 
 
12. Chiecchio, L., Dagrada, G.P., Ibrahim, A.H., Dachs Cabanas, E., Protheroe, R.K., 
Stockley, D.M., Orchard, K.H., Cross, N.C., Harrison, C.J., Ross, F.M. & Forum, 
U.K.M. (2009) Timing of acquisition of deletion 13 in plasma cell dyscrasias is 
dependent on genetic context. Haematologica, 94, 1708-1713. 
 
13. Dimopoulos, K., Gimsing, P. & Gronbaek, K. (2014) The role of epigenetics in the 
biology of multiple myeloma. Blood Cancer J, 4, e207. 
 
14. Dimopoulos, M.A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N.J., Usmani, S.Z., 
Rabin, N., Orlowski, R.Z., Komarnicki, M., Suzuki, K., Plesner, T., Yoon, S.S., 
Ben Yehuda, D., Richardson, P.G., Goldschmidt, H., Reece, D., Lisby, S., 
Khokhar, N.Z., O'Rourke, L., Chiu, C., Qin, X., Guckert, M., Ahmadi, T., Moreau, 
P. & Investigators, P. (2016) Daratumumab, Lenalidomide, and Dexamethasone for 
Multiple Myeloma. N Engl J Med, 375, 1319-1331. 
 
15. Dispenzieri, A., Kyle, R.A., Katzmann, J.A., Therneau, T.M., Larson, D., Benson, 
J., Clark, R.J., Melton, L.J., 3rd, Gertz, M.A., Kumar, S.K., Fonseca, R., Jelinek, 
D.F. & Rajkumar, S.V. (2008) Immunoglobulin free light chain ratio is an 
independent risk factor for progression of smoldering (asymptomatic) multiple 
myeloma. Blood, 111, 785-789. 
 
16. Egan, J.B., Shi, C.X., Tembe, W., Christoforides, A., Kurdoglu, A., Sinari, S., 
Middha, S., Asmann, Y., Schmidt, J., Braggio, E., Keats, J.J., Fonseca, R., 
Bergsagel, P.L., Craig, D.W., Carpten, J.D. & Stewart, A.K. (2012) Whole-genome 
sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals 
genomic initiating events, evolution, and clonal tides. Blood, 120, 1060-1066. 
 
 34 
17. Fluidigm Corporation (2014) Reveal Hidden Variation - C1 Single-Cell DNA 
Sequencing. 
 
18. Fonseca, R., Bailey, R.J., Ahmann, G.J., Rajkumar, S.V., Hoyer, J.D., Lust, J.A., 
Kyle, R.A., Gertz, M.A., Greipp, P.R. & Dewald, G.W. (2002) Genomic 
abnormalities in monoclonal gammopathy of undetermined significance. Blood, 
100, 1417-1424. 
 
19. Fonseca, R., Bergsagel, P.L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, 
A.K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., Neri, A., Barlogie, B., 
Kuehl, W.M., Liebisch, P., Davies, F., Chen-Kiang, S., Durie, B.G., Carrasco, R., 
Sezer, O., Reiman, T., Pilarski, L., Avet-Loiseau, H. & International Myeloma 
Working, G. (2009) International Myeloma Working Group molecular 
classification of multiple myeloma: spotlight review. Leukemia, 23, 2210-2221. 
 
20. Gertz, M.A., Rajkumar, S. V. (2014) Multiple Myeloma Diagnosis and Treatment. 
(ed. by Springer). 
 
21. Ghobrial, I.M. (2012) Myeloma as a model for the process of metastasis: 
implications for therapy. Blood, 120, 20-30. 
 
22. Gonzalez, D., van der Burg, M., Garcia-Sanz, R., Fenton, J.A., Langerak, A.W., 
Gonzalez, M., van Dongen, J.J., San Miguel, J.F. & Morgan, G.J. (2007) 
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. 
Blood, 110, 3112-3121. 
 
23. Greaves, M. & Maley, C.C. (2012) Clonal evolution in cancer. Nature, 481, 306-
313. 
 
24. Gundry, M., Li, W., Maqbool, S.B. & Vijg, J. (2012) Direct, genome-wide 
assessment of DNA mutations in single cells. Nucleic Acids Res, 40, 2032-2040. 
 
25. Hajek, R., Okubote, S.A. & Svachova, H. (2013) Myeloma stem cell concepts, 
heterogeneity and plasticity of multiple myeloma. Br J Haematol, 163, 551-564. 
 
26. Heuck, C.J., Mehta, J., Bhagat, T., Gundabolu, K., Yu, Y., Khan, S., Chrysofakis, 
G., Schinke, C., Tariman, J., Vickrey, E., Pulliam, N., Nischal, S., Zhou, L., 
Bhattacharyya, S., Meagher, R., Hu, C., Maqbool, S., Suzuki, M., Parekh, S., Reu, 
F., Steidl, U., Greally, J., Verma, A. & Singhal, S.B. (2013) Myeloma is 
characterized by stage-specific alterations in DNA methylation that occur early 
during myelomagenesis. J Immunol, 190, 2966-2975. 
 
27. International Myeloma Working Group (2003) Criteria for the classification of 
monoclonal gammopathies, multiple myeloma and related disorders: a report of the 




28. Kalff, A. & Spencer, A. (2012) The t(4;14) translocation and FGFR3 
overexpression in multiple myeloma: prognostic implications and current clinical 
strategies. Blood Cancer J, 2, e89. 
 
29. Klein, U., Goossens, T., Fischer, M., Kanzler, H., Braeuninger, A., Rajewsky, K. & 
Kuppers, R. (1998) Somatic hypermutation in normal and transformed human B 
cells. Immunol Rev, 162, 261-280. 
 
30. Kortum, K.M., Langer, C., Monge, J., Bruins, L., Zhu, Y.X., Shi, C.X., Jedlowski, 
P., Egan, J.B., Ojha, J., Bullinger, L., Kull, M., Ahmann, G., Rasche, L., Knop, S., 
Fonseca, R., Einsele, H., Stewart, A.K. & Braggio, E. (2015) Longitudinal analysis 
of 25 sequential sample-pairs using a custom multiple myeloma mutation 
sequencing panel (M(3)P). Ann Hematol, 94, 1205-1211. 
 
31. Kulis, M. & Esteller, M. (2010) DNA methylation and cancer. Adv Genet, 70, 27-
56. 
 
32. Kyle, R.A., Buadi, F. & Rajkumar, S.V. (2011) Management of monoclonal 
gammopathy of undetermined significance (MGUS) and smoldering multiple 
myeloma (SMM). Oncology (Williston Park), 25, 578-586. 
 
33. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Larson, D.R., Plevak, M.F., Offord, 
J.R., Dispenzieri, A., Katzmann, J.A. & Melton, L.J., 3rd (2006) Prevalence of 
monoclonal gammopathy of undetermined significance. N Engl J Med, 354, 1362-
1369. 
 
34. Landgren, O., Kyle, R.A., Pfeiffer, R.M., Katzmann, J.A., Caporaso, N.E., Hayes, 
R.B., Dispenzieri, A., Kumar, S., Clark, R.J., Baris, D., Hoover, R. & Rajkumar, 
S.V. (2009) Monoclonal gammopathy of undetermined significance (MGUS) 
consistently precedes multiple myeloma: a prospective study. Blood, 113, 5412-
5417. 
 
35. Lawson, M.A., McDonald, M.M., Kovacic, N., Hua Khoo, W., Terry, R.L., Down, 
J., Kaplan, W., Paton-Hough, J., Fellows, C., Pettitt, J.A., Neil Dear, T., Van 
Valckenborgh, E., Baldock, P.A., Rogers, M.J., Eaton, C.L., Vanderkerken, K., 
Pettit, A.R., Quinn, J.M., Zannettino, A.C., Phan, T.G. & Croucher, P.I. (2015) 
Osteoclasts control reactivation of dormant myeloma cells by remodelling the 
endosteal niche. Nat Commun, 6, 8983. 
 
36. Lohr, J.G., Stojanov, P., Carter, S.L., Cruz-Gordillo, P., Lawrence, M.S., Auclair, 
D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., Cibulskis, K., McKenna, A., 
Chapman, M.A., Straussman, R., Levy, J., Perkins, L.M., Keats, J.J., Schumacher, 
S.E., Rosenberg, M., Multiple Myeloma Research, C., Getz, G. & Golub, T.R. 
(2014) Widespread genetic heterogeneity in multiple myeloma: implications for 




37. Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., 
Walter-Croneck, A., Moreau, P., Mateos, M.V., Magen, H., Belch, A., Reece, D., 
Beksac, M., Spencer, A., Oakervee, H., Orlowski, R.Z., Taniwaki, M., Rollig, C., 
Einsele, H., Wu, K.L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., 
Bleickardt, E., Poulart, V., Anderson, K.C., Richardson, P. & Investigators, E.-. 
(2015) Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl 
J Med, 373, 621-631. 
 
38. Lonial, S., Weiss, B.M., Usmani, S.Z., Singhal, S., Chari, A., Bahlis, N.J., Belch, 
A., Krishnan, A., Vescio, R.A., Mateos, M.V., Mazumder, A., Orlowski, R.Z., 
Sutherland, H.J., Blade, J., Scott, E.C., Oriol, A., Berdeja, J., Gharibo, M., Stevens, 
D.A., LeBlanc, R., Sebag, M., Callander, N., Jakubowiak, A., White, D., de la 
Rubia, J., Richardson, P.G., Lisby, S., Feng, H., Uhlar, C.M., Khan, I., Ahmadi, T. 
& Voorhees, P.M. (2016) Daratumumab monotherapy in patients with treatment-
refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. 
Lancet, 387, 1551-1560. 
 
39. Lopez-Corral, L., Gutierrez, N.C., Vidriales, M.B., Mateos, M.V., Rasillo, A., 
Garcia-Sanz, R., Paiva, B. & San Miguel, J.F. (2011) The progression from MGUS 
to smoldering myeloma and eventually to multiple myeloma involves a clonal 
expansion of genetically abnormal plasma cells. Clin Cancer Res, 17, 1692-1700. 
 
40. Lopez-Corral, L., Sarasquete, M.E., Bea, S., Garcia-Sanz, R., Mateos, M.V., 
Corchete, L.A., Sayagues, J.M., Garcia, E.M., Blade, J., Oriol, A., Hernandez-
Garcia, M.T., Giraldo, P., Hernandez, J., Gonzalez, M., Hernandez-Rivas, J.M., 
San Miguel, J.F. & Gutierrez, N.C. (2012) SNP-based mapping arrays reveal high 
genomic complexity in monoclonal gammopathies, from MGUS to myeloma 
status. Leukemia, 26, 2521-2529. 
 
41. Magrangeas, F., Avet-Loiseau, H., Gouraud, W., Lode, L., Decaux, O., Godmer, P., 
Garderet, L., Voillat, L., Facon, T., Stoppa, A.M., Marit, G., Hulin, C., Casassus, 
P., Tiab, M., Voog, E., Randriamalala, E., Anderson, K.C., Moreau, P., Munshi, 
N.C. & Minvielle, S. (2013) Minor clone provides a reservoir for relapse in 
multiple myeloma. Leukemia, 27, 473-481. 
 
42. Manier, S., Sacco, A., Leleu, X., Ghobrial, I.M. & Roccaro, A.M. (2012) Bone 
marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol, 
2012, 157496. 
 
43. Marango, J., Shimoyama, M., Nishio, H., Meyer, J.A., Min, D.J., Sirulnik, A., 
Martinez-Martinez, Y., Chesi, M., Bergsagel, P.L., Zhou, M.M., Waxman, S., 
Leibovitch, B.A., Walsh, M.J. & Licht, J.D. (2008) The MMSET protein is a 
histone methyltransferase with characteristics of a transcriptional corepressor. 




44. Melchor, L., Brioli, A., Wardell, C.P., Murison, A., Potter, N.E., Kaiser, M.F., 
Fryer, R.A., Johnson, D.C., Begum, D.B., Hulkki Wilson, S., Vijayaraghavan, G., 
Titley, I., Cavo, M., Davies, F.E., Walker, B.A. & Morgan, G.J. (2014) Single-cell 
genetic analysis reveals the composition of initiating clones and phylogenetic 
patterns of branching and parallel evolution in myeloma. Leukemia, 28, 1705-1715. 
 
45. Mikhael, J.R., Dingli, D., Roy, V., Reeder, C.B., Buadi, F.K., Hayman, S.R., 
Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R.A., Lin, Y., Russell, S.J., Kumar, S., 
Bergsagel, P.L., Zeldenrust, S.R., Leung, N., Drake, M.T., Kapoor, P., Ansell, 
S.M., Witzig, T.E., Lust, J.A., Dalton, R.J., Gertz, M.A., Stewart, A.K., Rajkumar, 
S.V., Chanan-Khan, A., Lacy, M.Q. & Mayo, C. (2013) Management of newly 
diagnosed symptomatic multiple myeloma: updated Mayo Stratification of 
Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. 
Mayo Clin Proc, 88, 360-376. 
 
46. Mitra, A.K., Mukherjee, U.K., Harding, T., Jang, J.S., Stessman, H., Li, Y., 
Abyzov, A., Jen, J., Kumar, S., Rajkumar, V. & Van Ness, B. (2016) Single-cell 
analysis of targeted transcriptome predicts drug sensitivity of single cells within 
human myeloma tumors. Leukemia, 30, 1094-1102. 
 
47. Mitsiades, C.S., Mitsiades, N.S., Munshi, N.C., Richardson, P.G. & Anderson, K.C. 
(2006) The role of the bone microenvironment in the pathophysiology and 
therapeutic management of multiple myeloma: interplay of growth factors, their 
receptors and stromal interactions. Eur J Cancer, 42, 1564-1573. 
 
48. MMRF (2015) Multiple Myeloma Drugs Guide. 
 
49. Morgan, G.J., Walker, B.A. & Davies, F.E. (2012) The genetic architecture of 
multiple myeloma. Nat Rev Cancer, 12, 335-348. 
 
50. NCI (2014) SEER Stat Fact Sheets: Myeloma. National Cancer Institute at the 
National Institutes of Health. 
 
51. Noll, J.E., Williams, S.A., Purton, L.E. & Zannettino, A.C. (2012) Tug of war in 
the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC 
niche? Blood Cancer J, 2, e91. 
 
52. Nowell, P.C. (1976) The clonal evolution of tumor cell populations. Science, 194, 
23-28. 
 
53. Nutt, S.L., Hodgkin, P.D., Tarlinton, D.M. & Corcoran, L.M. (2015) The 
generation of antibody-secreting plasma cells. Nat Rev Immunol, 15, 160-171. 
 





55. Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A.K., Masszi, T., Beksac, M., 
Spicka, I., Hungria, V., Munder, M., Mateos, M.V., Mark, T.M., Qi, M., Schecter, 
J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Spencer, A., Sonneveld, P. & 
Investigators, C. (2016) Daratumumab, Bortezomib, and Dexamethasone for 
Multiple Myeloma. N Engl J Med, 375, 754-766. 
 
56. Perez-Persona, E., Vidriales, M.B., Mateo, G., Garcia-Sanz, R., Mateos, M.V., de 
Coca, A.G., Galende, J., Martin-Nunez, G., Alonso, J.M., de Las Heras, N., 
Hernandez, J.M., Martin, A., Lopez-Berges, C., Orfao, A. & San Miguel, J.F. 
(2007) New criteria to identify risk of progression in monoclonal gammopathy of 
uncertain significance and smoldering multiple myeloma based on multiparameter 
flow cytometry analysis of bone marrow plasma cells. Blood, 110, 2586-2592. 
 
57. Plass, C., Pfister, S.M., Lindroth, A.M., Bogatyrova, O., Claus, R. & Lichter, P. 
(2013) Mutations in regulators of the epigenome and their connections to global 
chromatin patterns in cancer. Nat Rev Genet, 14, 765-780. 
 
58. Rajkumar, S.V. (2016) Multiple myeloma: 2016 update on diagnosis, risk-
stratification, and management. Am J Hematol, 91, 719-734. 
 
59. Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., Blade, J., Merlini, G., Mateos, 
M.V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, 
B., Dispenzieri, A., Weiss, B., LeLeu, X., Zweegman, S., Lonial, S., Rosinol, L., 
Zamagni, E., Jagannath, S., Sezer, O., Kristinsson, S.Y., Caers, J., Usmani, S.Z., 
Lahuerta, J.J., Johnsen, H.E., Beksac, M., Cavo, M., Goldschmidt, H., Terpos, E., 
Kyle, R.A., Anderson, K.C., Durie, B.G. & Miguel, J.F. (2014) International 
Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. 
Lancet Oncol, 15, e538-548. 
 
60. Rajkumar, S.V., Kyle, R.A., Therneau, T.M., Melton, L.J., 3rd, Bradwell, A.R., 
Clark, R.J., Larson, D.R., Plevak, M.F., Dispenzieri, A. & Katzmann, J.A. (2005) 
Serum free light chain ratio is an independent risk factor for progression in 
monoclonal gammopathy of undetermined significance. Blood, 106, 812-817. 
 
61. Salhia, B., Baker, A., Ahmann, G., Auclair, D., Fonseca, R. & Carpten, J. (2010) 
DNA methylation analysis determines the high frequency of genic hypomethylation 
and low frequency of hypermethylation events in plasma cell tumors. Cancer Res, 
70, 6934-6944. 
 
62. Sawyer, J.R., Tian, E., Shaughnessy Jr, J.D., Epstein, J., Swanson, C.M., Stangeby, 
C., Hale, C.L., Parr, L., Lynn, M., Sammartino, G., Lukacs, J.L., Stein, C., Bailey, 
C., Zangari, M., Davies, F.E., Van Rhee, F., Barlogie, B. & Morgan, G.J. (2016) 





63. Shapiro-Shelef, M. & Calame, K. (2005) Regulation of plasma-cell development. 
Nat Rev Immunol, 5, 230-242. 
 
64. Singhal, S. & Mehta, J. (2006) Multiple myeloma. Clin J Am Soc Nephrol, 1, 
1322-1330. 
 
65. Smith, E.M., Boyd, K. & Davies, F.E. (2010) The potential role of epigenetic 
therapy in multiple myeloma. Br J Haematol, 148, 702-713. 
 
66. Stavnezer, J. (1996) Immunoglobulin class switching. Curr Opin Immunol, 8, 199-
205. 
 
67. Stessman, H.A., Baughn, L.B., Sarver, A., Xia, T., Deshpande, R., Mansoor, A., 
Walsh, S.A., Sunderland, J.J., Dolloff, N.G., Linden, M.A., Zhan, F., Janz, S., 
Myers, C.L. & Van Ness, B.G. (2013) Profiling bortezomib resistance identifies 
secondary therapies in a mouse myeloma model. Mol Cancer Ther, 12, 1140-1150. 
 
68. Usmani, S.Z., Weiss, B.M., Plesner, T., Bahlis, N.J., Belch, A., Lonial, S., 
Lokhorst, H.M., Voorhees, P.M., Richardson, P.G., Chari, A., Sasser, A.K., Axel, 
A., Feng, H., Uhlar, C.M., Wang, J., Khan, I., Ahmadi, T. & Nahi, H. (2016) 
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated 
relapsed or refractory multiple myeloma. Blood, 128, 37-44. 
 
69. Walker, B.A., Boyle, E.M., Wardell, C.P., Murison, A., Begum, D.B., Dahir, N.M., 
Proszek, P.Z., Johnson, D.C., Kaiser, M.F., Melchor, L., Aronson, L.I., Scales, M., 
Pawlyn, C., Mirabella, F., Jones, J.R., Brioli, A., Mikulasova, A., Cairns, D.A., 
Gregory, W.M., Quartilho, A., Drayson, M.T., Russell, N., Cook, G., Jackson, 
G.H., Leleu, X., Davies, F.E. & Morgan, G.J. (2015) Mutational Spectrum, Copy 
Number Changes, and Outcome: Results of a Sequencing Study of Patients With 
Newly Diagnosed Myeloma. J Clin Oncol, 33, 3911-3920. 
 
70. Walker, B.A., Wardell, C.P., Chiecchio, L., Smith, E.M., Boyd, K.D., Neri, A., 
Davies, F.E., Ross, F.M. & Morgan, G.J. (2011) Aberrant global methylation 
patterns affect the molecular pathogenesis and prognosis of multiple myeloma. 
Blood, 117, 553-562. 
 
71. Walker, B.A., Wardell, C.P., Melchor, L., Brioli, A., Johnson, D.C., Kaiser, M.F., 
Mirabella, F., Lopez-Corral, L., Humphray, S., Murray, L., Ross, M., Bentley, D., 
Gutierrez, N.C., Garcia-Sanz, R., San Miguel, J., Davies, F.E., Gonzalez, D. & 
Morgan, G.J. (2014) Intraclonal heterogeneity is a critical early event in the 
development of myeloma and precedes the development of clinical symptoms. 
Leukemia, 28, 384-390. 
 
72. Walker, B.A., Wardell, C.P., Melchor, L., Hulkki, S., Potter, N.E., Johnson, D.C., 
Fenwick, K., Kozarewa, I., Gonzalez, D., Lord, C.J., Ashworth, A., Davies, F.E. & 
Morgan, G.J. (2012) Intraclonal heterogeneity and distinct molecular mechanisms 
 
 40 
characterize the development of t(4;14) and t(11;14) myeloma. Blood, 120, 1077-
1086. 
 
73. Wang, L. & Young, D.C. (2001) Suppression of polyclonal immunoglobulin 
production by M-proteins shows isotype specificity. Ann Clin Lab Sci, 31, 274-
278. 
 
74. Weinhold, N., Ashby, C., Rasche, L., Chavan, S.S., Stein, C., Stephens, O.W., 
Tytarenko, R., Bauer, M.A., Meissner, T., Deshpande, S., Patel, P.H., Buzder, T., 
Molnar, G., Peterson, E.A., van Rhee, F., Zangari, M., Thanendrarajan, S., Schinke, 
C., Tian, E., Epstein, J., Barlogie, B., Davies, F.E., Heuck, C.J., Walker, B.A. & 
Morgan, G.J. (2016) Clonal selection and double-hit events involving tumor 
suppressor genes underlie relapse in myeloma. Blood, 128, 1735-1744. 
 
75. Weinhold, N., Chavan, S.S., Heuck, C., Stephens, O.W., Tytarenko, R., Bauer, M., 
Peterson, E.A., Ashby, T.C., Meissner, T., Stein, C.K., Johann, D., Johnson, S.K., 
Yaccoby, S., Epstein, J., van Rhee, F., Zangari, M., Schinke, C., Thanendrarajan, 
S., Davies, F.E., Barlogie, B. & Morgan, G.J. (2015) High Risk Multiple Myeloma 
Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and 
Random Bone Marrow; Implications for Targeted Therapy and Treatment 
Resistance. Blood. 
 
76. Weston-Bell, N., Gibson, J., John, M., Ennis, S., Pfeifer, S., Cezard, T., Ludwig, 
H., Collins, A., Zojer, N. & Sahota, S.S. (2013) Exome sequencing in tracking 
clonal evolution in multiple myeloma following therapy. Leukemia, 27, 1188-1191. 
 
77. Yadav, V.K. & De, S. (2014) An assessment of computational methods for 
estimating purity and clonality using genomic data derived from heterogeneous 
tumor tissue samples. Brief Bioinform. 
 
78. Zhou, Y., Barlogie, B. & Shaughnessy, J.D., Jr. (2009) The molecular 
characterization and clinical management of multiple myeloma in the post-genome 
era. Leukemia, 23, 1941-1956. 
 
79. Zweegman, S., Palumbo, A., Bringhen, S. & Sonneveld, P. (2014) Age and aging 
























Chapter 2  
 
Subclonal evolution in disease progression from 
MGUS/SMM to multiple myeloma is characterised by 






Chapter 2: Subclonal evolution in disease progression from 
MGUS/SMM to multiple myeloma is characterised by clonal 
stability  
	
Ankit K. Dutta1,2, J. Lynn Fink3*, John P. Grady3, Gareth J. Morgan4, Charles G. 
Mullighan5, Luen B. To6,7, Duncan R. Hewett1,2 & Andrew C.W. Zannettino1,2* 
 
1Myeloma Research Laboratory, Adelaide Medical School, Faculty of Health and Medical 
Sciences, The University of Adelaide, Adelaide, SA, 5005, Australia. 
2Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), 
Adelaide, SA, 5000, Australia. 
3Genomic Medicine Division, The University of Queensland, Diamantina Institute (UQDI) 
, Brisbane, QLD, 4102, Australia. 
4The Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 
72205, USA. 
5Department of Pathology and the Hematological Malignancies Program, St Jude 
Children’s Research Hospital, Memphis, TN, 38105, USA. 
6SA Pathology, Adelaide, SA, 5000, Australia.  





Running title: Clonal stability characterises progression to myeloma 
Keywords: MGUS, Smoldering MM, Myeloma, Next generation sequencing, Intraclonal 




Chapter 2 incorporates the original article published: Dutta, A.K., Fink, J.L., Grady, 
J.P., Morgan, G.J, Mullighan, C.G, To, L. B., Hewett, D.R. & Zannettino, A.C.W. 
(2018) Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma 
is characterised by clonal stability. Leukemia. https://doi.org/10.1038/s41375-018-0206-x 
	 43	
2.1 Abstract 
Multiple myeloma (MM) is a largely incurable haematological malignancy defined by the 
clonal proliferation of malignant plasma cells (PCs) within the bone marrow. Clonal 
heterogeneity has recently been established as a feature in MM, however, the subclonal 
evolution associated with disease progression has not been described. Here, we performed 
whole exome sequencing of serial samples from 10 patients, providing new insights into 
the progression from monoclonal gammopathy of undetermined significance (MGUS) and 
smouldering MM (SMM), to symptomatic MM. We confirm that intraclonal genetic 
heterogeneity is a common feature at diagnosis and that the driving events involved in 
disease progression are more subtle than previously reported. We reveal that MM 
evolution is mainly characterised by the phenomenon of clonal stability, where the 
transformed subclonal PC populations identified at MM are already present in the 
asymptomatic MGUS/SMM stages. Our findings highlight the possibility that PC extrinsic 





















Multiple Myeloma (MM) is a haematological malignancy characterised by the 
uncontrolled proliferation of neoplastic plasma cells (PCs) within the bone marrow (BM). 
MM accounts for ~10% of all haematological malignancies1, with a median survival rate of 
5.2 years2. Although 10 new therapeutic agents for MM have been approved in the last 20 
years, and patient outcomes have improved significantly, individual responses to therapy 
and overall survival are varied3. MM remains largely incurable, with relapse being a 
common feature of disease.  
The development of MM has been classically viewed as a multistage process 
involving the acquisition of multiple genetic mutations, with immunoglobulin heavy chain 
translocations and hyperdiploidy known to be common initiating events that deregulate 
normal PC behaviour leading to the development of monoclonal gammopathy of 
undetermined significance (MGUS)4-7. Further mutational load leads to an intermediate 
stage of smouldering multiple myeloma (SMM)4,8. However, these common initiating 
events are insufficient to cause MM transformation, as MGUS/SMM patients commonly 
harbour these abnormalities and show no clinical symptoms of MM9,10. Studies have 
shown that progression to MM is associated with additional genetic changes including 
aneuploidy, chromosomal translocations, single nucleotide variants, small insertions and 
deletions, and copy number variants affecting one or more genes, with mutations present at 
a frequency of 0.1 to 10 per megabase11.  
Recent studies show that MM patients display complex mutational landscapes 
involving intraclonal genetic heterogeneity at the bulk tumour level, where mutations are 
acquired in a non-linear branching pattern12-17. Intraclonal heterogeneity has been observed 
at all stages of MM, suggesting that disease progression may be mediated through inter-
subclone competition and outgrowth of the fittest of these subclones. Genomic studies on 
large cohorts of unmatched MGUS-SMM-MM patients have led to the discovery of 
recurrently mutated genes, of which KRAS, NRAS, TP53, BRAF, FAM46C and DIS3 are 
believed to be drivers of MM transformation10,18-20. While clonal heterogeneity is now an 
established feature in MM, the subclonal evolution associated with MGUS/SMM to MM 
progression remains poorly understood.  
A comprehensive approach to identifying the key somatic mutations and infer the 
subclonal evolution associated with MM transformation, involves the longitudinal study of 
sequential MGUS-MM or SMM-MM samples from the same patient. However, because 
MGUS is often an incidental finding, it is extremely rare to have diagnostic BM samples 
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from the same patient at both the MGUS and MM stages. In addition, because there are no 
cell line or mouse models of MGUS or SMM, there has been limited opportunity to study 
the specific genetic changes and molecular mechanisms that characterise the progression 
from MGUS/SMM to MM.  
Here, we report a longitudinal genomics investigation of MM, based on paired 
MGUS-MM (n = 5) or SMM-MM (n = 5) patient samples obtained from the same patient 
when initially diagnosed at MGUS/SMM, and subsequently when they developed MM. 
Using whole exome sequencing, we have obtained a detailed description of the genomic 
























2.3 Materials & Methods 
2.3.1 Clinical samples. 
Bone marrow mononuclear cell aspirates were collected from patients at MGUS/SMM, 
and subsequently at later diagnosis of MM (MGUS-MM (n = 5) and SMM-MM (n = 5)). 
The median time to progression of MGUS to MM was 3.2 years (range 1 - 13 years) and 
SMM to MM was 1.2 years (range 0.48 – 4.1 years). Where available, the cytogenetic 
status of patients is reported in Supplementary Table 1. Samples were collected from 
patients prior to treatment. All patients provided informed consent in accordance with the 
Declaration of Helsinki. Samples were cryopreserved by the South Australian Cancer 
Research Biobank (SACRB) at SA Pathology. The studies were approved by the Royal 
Adelaide Hospital Human Research Ethics Committee (HREC/13/RAH/569 No: 131133). 
Samples were collected over a period of 22 years, and we initially began this study with 
paired-samples from 18 patients. However, due to our strict criteria for sample purity and 
mutation calling resolution, final analysis was only performed on samples from 10 
patients. 
 
2.3.2 Cell sorting. 
PCs and non-tumour cells were purified using multicolour flow cytometry as previously 
described21. Briefly, approximately 1x105 mononuclear cells were prepared for single stain 
antibody control (CD138-PE (Beckman Coulter #A54190) and CD38-PE-Cy7 (Biolegend 
#303515)) and compensation/FMO tubes (1: unstained; 2: hydroxystilbamidine 
(FluoroGold; Life Technologies) only; 3: CD38-PE-Cy7+FluroGold; 4: CD138-
PE+FluroGold; and 5: CD38-PE-Cy7+CD138-PE). The sort sample was stained with 
CD138-PE and CD38-PE-Cy7 antibody at 1µL/100µL cells. Cells were stained with 
FluoroGold immediately prior to sorting. Viable PCs (CD138+CD38+ and FluoroGold 
negative) and non-tumour cells were sorted on the FACSAria Fusion sorter (BD 
Biosciences). FACS purity check was carried out on sorted cells, using 100-500 cells from 
each sample. 
 
2.3.3 DNA isolation, QC and sequencing. 
DNA was isolated from purified PC and non-tumour populations using the All Prep 
DNA/RNA Micro Kit (QIAGEN) as per manufacturers’ instructions. Yields and quality 




115ng of gDNA were used as input for fragmentation on the Covaris E220, followed by 
end-repair/A-tailing and ligation of SureSelect Adapter Oligos (Agilent). Pre-Capture PCR 
amplification of 10 cycles, or 12 cycles for low input samples, were performed. A total of 
750ng of each sample was hybridised to SureSelect XT Clinical Research Exome (Agilent) 
probes overnight. Captured DNA was amplified with 11 cycles of post-capture PCR 
incorporating index barcodes. Sequencing was performed on the Illumina HiSeq4000 
(2x100 bp paired-end reads) and NextSeq 500 (2x150 bp paired-end reads). Samples were 
sequenced to a minimum depth of ~140X mean coverage. Isolated non-tumour cells were 
also sequenced to a similar average depth (138x). 
 
2.3.4 Analysis of data. 
Sequencing reads were mapped to the human decoy genome (hs37d5) using Novoalign 
(v3.02.08), followed by post-processing according to GATK best practices22. Somatic 
single nucleotide and small indel variants were called using MuTect223 and multiSNV24. 
Variants were filtered based on: 10+ reads covering the variant site; 5+ reads covering the 
variant in the tumour sample. Variants were annotated with SnpEff25. 
 
R 3.3.2 was used throughout for analyses. Somatic copy number variants were called using 
CNVkit26 v0.7.11 and custom in-house methods developed to support highly aneuploid 
genomes to perform segmentation and calculate log2 changes. 
 
Clonal evolution was investigated using PhyloWGS27 and visualised using fish plot in R28. 
PhyloWGS is noted to inflate the number of subclones, thus we recognise that subclone 
numbers may be overestimated. All phylogenetic trees constructed were based on the 
assumption that there is a single founder clone.  
 
Additional information on sequencing and somatic mutation analysis is given in the 
supplementary methods. 
2.3.5 Data deposition. 
All raw sequencing reads have been deposited in the EGA repository (Accession number: 
EGAS00001002850). 
2.3.6 Code Availability. 




2.4.1 A changing spectrum of acquired mutations, not mutational load, is associated 
with MM progression. 
Whole exome sequencing was performed on paired MGUS/SMM to MM patients [detailed 
in Supplementary Table 1] to a minimum average depth of 140x [Supplementary Table 2]. 
A total of 1614 somatic non-synonymous single nucleotide variants (NS-SNVs) were 
identified across the MGUS/SMM samples (range 30-220) with a median 161 per patient. 
Interestingly, in the MM samples, we identified a total 1508 somatic NS-SNVs (range 59-
226), with a median 152 per patient. There was an average of 27 NS-SNVs that were 
shared between the MGUS/SMM and MM stage (range 0-53) [Supplementary Table 3]. 
We observed a moderately higher mutation load compared to previous larger cohort 
studies of MM, which identified median SNV numbers of 31 (range 15-46)4, and 52 
mutations per patient (range 2-488)18.  
 
Recent sequencing studies of unpaired MM samples have described an increasing 
median NS-SNV burden from MGUS to SMM to MM, with MGUS patients harbouring 
approximately half the number of NS-SNVs when compared to unmatched MM patients4, 
with an average of 35 at the MM stage10. Here, we observed the opposite upon progression 
from MGUS/SMM to MM, where 7 out of 10 patients showed a decrease in total 
mutational load [Figure 1a]. While the total mutational burden is not considerably 
different between MGUS/SMM and MM, the presence of intraclonal heterogeneity and 
changes in the spectrum of mutated genes between disease stages, suggests that there is 
waxing and waning of subclones over time29.  
 
We next examined the changing mutational landscape associated with 
MGUS/SMM to MM progression, to identify the genetic aberrations associated with this 
process, including both previously reported “drivers” of MM and frequently acquired 
mutations present at MM transition. To this end, we identified 2566 unique genes with 
acquired variants at MM transition across all patients. The most common genes harbouring 
mutations at MM include KRAS, KMT2D, RYR2, DNAH5, PCDH8, RP4-669P10.16, DIS3, 
FAT3, PKHD1 and SP140 [Figure 1b]. Moreover, we identified 15 previously reported 
recurrently mutated genes: KRAS, FAT3, DIS3, TRAF3, SP140, RB1, PTEN, ROBO1, 
PRDM1, NRAS, MYC, MAGED1, IRF4, HLA-A and CDK410,18-20,30 [Figure 1c], including 
mutations in 3 known “drivers” of MM: KRAS, NRAS and DIS3 [Supplementary Table 4]. 
In our samples, mutations in KRAS and NRAS, were mutually exclusive, consistent with 
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previous observations that report the rare co-occurrence of mutations in these genes (in 2% 
of patients)20.  
 
The RAS/MAPK pathway was highly mutated with 40% of patients at 
MGUS/SMM, and 70% at MM, harbouring mutations in KRAS and NRAS. DIS3 was 
mutated in 30% of patients at the MM stage only [Figure 1d]. This highlights that driver 
mutations can be acquired at both the asymptomatic stages and be maintained during 
progression to MM, or be acquired later at MM. However, we found that acquisitions of 
driver mutations are subclonal in nature. Low variant allele frequencies were identified for 
RAS pathway mutations (KRAS range 0.024 - 0.53, NRAS 0.03 - 0.28), suggesting that 
these mutations were present in subclonal PC populations during progression (P01, P02, 
P05 and P06) [Figure 1d]. Interestingly, acquisition of DIS3 mutations at the MM stage in 
patients P07 and P10 was observed to be clonal in nature31 [Figure 1d].  
 
We also characterised the copy number variation (CNV) landscape associated with 
MGUS/SMM to MM progression, finding copy changes to be widespread [Figure 2a]. 
This contrasts a recent small longitudinal study of SMM to MM transformation that 
showed that copy changes are a feature of early stage of MM disease and not associated 
with progression4. We observed that MGUS/SMM patients harbour a similar frequency of 
chromosomal loci copy gains and losses than MM patients, with a median of 70 at 
MGUS/SMM (range 19 to 114), and 67.5 at MM (range 43 to 103) [Supplementary Table 
5]. Upon progression, we observed known frequent chromosomal copy number 
abnormalities in MM, including amplifications on chromosome arms 1q, 3p, 6p, 9p, 11q, 
19p, 19q and 21q, coupled with losses on chromosome arms 1p, 6q, 8p, 13q, 16q and 22q 
across patients in the cohort [Figure 2b]. While we performed a gene level copy number 
analysis, we did not find any genes that were consistently gained or lost in our cohort upon 
progression. Interestingly, we also observed that many of the cytogenetic abnormalities 
associated with MM are present at MGUS/SMM stages and that standard cytogenetic 




















Figure 1. Pattern of genetic mutations in MGUS/SMM to MM progression. (a) Total 
NS-SNV mutational load associated with progression from MGUS/SMM to MM in 
individual patients (b) Waterfall diagram indicating the 10 most frequently mutated genes 
associated with progression from MGUS/SMM to MM (c) We identified mutations in 15 
reported recurrently mutated MM genes in our MGUS/SMM to MM samples. However, 
individual patients harbour a heterogeneous genetic architecture, with a combination of 
mutations in known driver (KRAS, NRAS and DIS3) and other candidate genes. Mutations 
in RAS/MAPK pathway genes are most prevalent. (d) Gradient diagram across all patients 
indicating the variant allele frequencies (VAF) of identified known cancer drivers. RAS 


































Figure 2. The chromosomal copy number variation landscape associated with 
MGUS/SMM to MM progression. (a) Chromosomal copy number landscape plot 
illustrating the proportion of patients with copy amplifications (blue) and deletions (red) of 
chromosomes across all patients associated with MGUS/SMM to MM progression. Grey 
traces the average in the cohort as a whole, where below 0 indicates loss and above 0 
represents gain. (b) Frequent previously reported copy number changes of MM were 
identified, including gains on 1q, 3p, 6p, 9p, 11q, 19p, 19q and 21q; and losses on 6q, 8p, 
13q, 16q and 22q being present at the asymptomatic stages and maintained with 
























2.4.2 The subclonal architecture required for MM progression exists at MGUS/SMM 
diagnosis 
While clonal heterogeneity is an established feature in MM, the subclonal evolution 
associated with disease progression has not been well explored. Due to the nature of our 
paired longitudinal patient samples, we were able to directly examine the relationship 
between genetic variegation and clonal structure to construct evolutionary trajectories 
accompanying progression to MM in 8 individual patients. 
 
Comparisons of unpaired MGUS/SMM and MM samples have shown that 
MGUS/SMM exhibits mutational similarity with MM, but many mutations were present in 
a smaller proportion of aberrant PCs32,33. Similarly, small paired-sample studies examining 
the evolution over time of asymptomatic monoclonal gammopathies (AMGs) to MM (n = 
4)34, and high risk SMM to MM patients (n = 4)4, have also found that most somatic 
changes required for MM were present at the asymptomatic stages, with the clinically 
dominant MM subclone present at the SMM stage. Therefore, the occurrence of clonal 
evolution in MM represents a change in clonal heterogeneity over time from the 
asymptomatic stages to MM13.  
 
In both MGUS-MM (P01, P04 and P10) and SMM-MM (P02, P03, P05, P06 and 
P08) progression, we find a prevailing model of evolution defined by clonal stability. This 
is where the transformed subclonal PC populations identified at MM were already present 
in the asymptomatic MGUS/SMM stages.  Progression to MM involved subtle changes in 
the existent subclonal structure from MGUS/SMM, coupled with a degree of emergence 
and/or extinction of child subclonal branches [Figure 3, 4]. Of note, we observed that 
subclonal evolution has already begun prior to MGUS/SMM sampling. While multiple 
subclonal populations are present at MGUS/SMM diagnosis, each patient harbours unique 










2.4.2.1 Subclonal tumour evolution in MGUS-MM patients 
Three patients (P01, P04 and P10) were initially diagnosed with MGUS, and subsequently 
with MM. Typically, an average of 7 subclones were identified in MGUS sample pairs. We 
describe two examples, with the full-annotated subclonal architecture for all MGUS-MM 
patients found in Supplementary Figure 1/Appendix 1.  
 
Patient P01 exhibited a modest increase in NS-SNV mutations with progression 
and was composed of eight subclones at diagnosis. The founder clone had a copy number 
change on chromosome 1. Interestingly, while P01 mainly exhibited stable progression of 
subclones from MGUS to MM, we observed KRAS mutations to be newly acquired in 
multiple child subclones. Subclone 7 [brown] harboured a mutation causing an amino acid 
change at Q61L, with a resultant neutral growth observed. Furthermore, we identified 
mutations occurring in a nested fashion, with outgrowth of subclone 8 [grey from <1% to 
~6%] harbouring mutations at G12D and G12S, with further emergence of child subclone 
9 [green] harbouring additional change at Q61H with MM progression. This was coupled 
with the extinction of child subclonal branches of subclone 2 [purple] [Figure 3a]. 
 
Patient P04 exhibited an interesting subclonal evolution pattern, where initially one 
subclone [subclone 2 purple] evolved from the founder clone, which was followed by 
substantial branching evolution resulting in six child subclones involved in MM 
progression. The founder clone harboured mutations in MYCBP2 (F22L) and TOP2A 
(K1199N) and copy number changes on chromosomes 9, 11, 13, 14 and 18. While most of 
the child subclones exhibit stability, subclone 3 [orange from <1% to ~18%] and subclone 
9 [green from <1% to ~9%] appear to have a selective advantage and showed emergence 
towards MM [Figure 3b]. Similarly, P10 was composed of eight subclones at MGUS with 
the neutral growth of subclonal populations coupled with the emergence of multiple 
subclones [subclone 4 yellow from ~3% to ~25%, and subclone 5 blue from ~1% to ~10%] 
and extinction of child subclone 3 [orange from ~5% to <1%] with progression 





















Figure 3. The subclonal tumour evolution associated with MGUS to MM progression. 
Fishtail plots illustrate the subclonal architecture in MGUS-MM of two patients (a: P01 
and b: P04), which was defined by the existence of between 5 to 8 PC subclones at MGUS 
diagnosis. These subclonal populations generally progress to MM in a stable manner, in 
combination with the coupled emergence and/or extinction of child subclones. Key 
mutations in the founder clone and subclones are highlighted, with mutations in driver 
genes identified at both the clonal and subclonal level. The full-annotated subclonal 























2.4.2.2 Subclonal tumour evolution in SMM-MM patients 
Five patients (P02, P03, P05, P06 and P08) were diagnosed for SMM, and then 
subsequently MM at a later time point. Generally, an average of 8 subclones were 
identified in SMM-MM pairs. We report two examples, with the full-annotated subclonal 
architecture for all SMM-MM patients found in Supplementary Figure 2/Appendix 1.  
 
Patient P02 was composed of eleven subclones at diagnosis and exhibited stable 
growth during progression with mainly the emergence of child subclone 5 and its branches 
[blue from ~5% to ~13%] and extinction of subclone 9 [dark green from ~6% to <1%] 
[Figure 4a]. The founder clone showed copy changes on chromosomes 6, 8 and 13, and 
mutations in HERPUD1 (STOP gain), FGFR3 (809S) and DAPK1 (K435R). Furthermore, 
we identified a KRAS mutation (A146P) in subclone 11, whose population proportion size, 
interestingly, did not change during MM progression.  
 
Patient P03 displayed an interesting evolution pattern with massive extinction of 
subclone 2 [purple] from ~47% to ~6%, and almost all of its child subclones, by MM 
diagnosis. The founder clone harboured mutations in NOD2 (STOP gain) and CNVs on 
chromosomes 1, 6, 9, 13 and 16. Furthermore, two individual subclones that contained 
distinct DIS3 mutants M566K and R689P were identified at SMM diagnosis in subclone 8 
[black] and child subclone 11 [dark purple], respectively [Figure 4b]. While recent single 
cell analysis has demonstrated parallel evolution of the RAS/MAPK pathway in MM 
through the occurrence of RAS mutations in individual clones leading to distinct subclonal 
populations35, here we uniquely identify parallel evolution of DIS3, with the resultant 
emergence of both subclonal lineages with MM progression. Additionally, subclone 13 and 
its child subclones exhibited outgrowth with a mutation in NEK2 (L39H) [light green from 
<1% to ~7%].  
 
Clonal stability in tumour evolution is also exemplified in other SMM-MM patients 
[P05, P06, and P08], which were characterised by 7, 5 and 8 subclones at diagnosis, 
respectively, and exhibited coupled emergence and extinction of child subclones in the 
progression to MM. In P05, there were initially two subclones that progressed to MM with 
the emergence and extinction of child clones from subclonal branch 5 [blue], combined 
with the neutral growth from subclonal branch 2 [purple] [Supplementary Figure 2c]. 
Similarly, in P06, with progression we observed the emergence of subclone 8 [black from 
<1% to ~23%] and its child subclone 9 [dark green from <1% to ~4%], and subclone 2 
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[purple from ~8% to ~28%] and its child subclones 6 [pink from <1% to ~10%] and 7 
[brown from <1% to ~6%]. The proportions of child subclonal population 3 [orange] 
remained unchanged between SMM and MM [Supplementary Figure 2d]. Patient P08 
exhibited neutral growth, which was coupled with the emergence of child subclone 9 
[green from <1% to ~5%] and extinction of child subclone 8 [black from ~6% to <1%] 
with MM progression [Supplementary Figure 2e]. 
 
Our analysis reveals conclusive evidence of intraclonal heterogeneity and 
subclonality from the earliest MGUS/SMM stages, where most of the transformed 
subclonal populations involved in progression to MM are already present at diagnosis. 
Notably, we do not observe a remarkable difference in the subclonality characteristic at the 
initial asymptomatic MGUS stage (average 7 subclones) and the intermediate SMM stage 
(average 8 subclones). This suggests that major subclonal remodelling is also not a 


































Figure 4. The subclonal tumour evolution associated with SMM to MM progression. 
Fishtail plots illustrating the subclonality in SMM-MM of two patients (a: P02 and b: 
P03), with the existence of between 5 to 11 PC subclones at the SMM stage. Notably, in 
comparison to the subclonal architecture at MGUS diagnosis, we observe a similar number 
of subclones present at SMM. Similar to the MGUS subclones, these SMM subclonal 
populations generally progress to MM in a stable manner, in combination with the coupled 
emergence and/or extinction of child subclones. Key mutations in MM genes in the 
founder clone and subclones are highlighted, where mutations in driver genes were found 
to be both clonal and subclonal in nature. The full-annotated subclonal genetic architecture 




















The longitudinal investigation of MGUS/SMM to MM samples using NGS has revealed a 
new understanding of the underlying genetic architecture and subclonal evolution 
associated with MM progression. Analysis of MGUS-MM, and SMM-MM transition has 
shown that intraclonal heterogeneity is present at the asymptomatic stages. We find that 
progression is associated with an altered landscape of acquired mutations, rather than an 
increased total mutational burden.  
 
Cancer progression models propose either the sequential accumulation of key 
genetic mutations throughout progressive disease and clonal expansions (“Darwinian” 
evolution), or punctuated bursts of large-scale chromosomal alterations (“Saltationist” 
evolution)36. The current understanding of MM transformation involves a sequential nature 
of evolution from the well-defined asymptomatic stages of MGUS and SMM, 
characterised by clonal expansion of PCs, and branching “Darwinian” evolution with the 
presence of 2 to 6 subclones, highlighting clonal heterogeneity at MM presentation10,18-
20,29,30,35,37-41. In this model it is recognised that progression from the asymptomatic stages 
is dependent on the rise and fall in dominance of PC subclones based on their clonal 
fitness. The acquisition of driver mutations confers a selective advantage and facilitates 
better survival properties allowing the subclones to survive the selective pressures of the 
microenvironment/immune system and progress to symptomatic MM. 
 
Notably, our study establishes MM disease progression to be characterised by the 
phenomenon of clonal stability, where substantial remoulding of the subclonal populations 
from the asymptomatic stages is not a necessary prerequisite for progression to MM. We 
found the existence of multiple PC subclones (range 5 to 11) at both MGUS and SMM that 
were intrinsic in the development and progression of MM. Furthermore, by comparing 
patients at MGUS and SMM stages we identified no significant difference in the number 
of PC subclones present at diagnosis (with an average of 7 versus 8, respectively). This is 
striking, as progression between the asymptomatic stages of MGUS and SMM is currently 
distinguished by an increased BM PC% and monoclonal protein level. We also found no 
correlation between the extent of subclonality and BM PC% at the MM stage in patients 
[Supplementary Figure 3]. Similarly, a recent study of four high risk SMM to MM 
transformation patients revealed that clonal progression was the key feature of MM onset, 
where the invasive clinically predominant clone typical of MM, was already present at 
SMM4. Similarly, in their investigation, Walker et. al. reported a shifting clonal structure 
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with the outgrowth and reduction of subclonal populations from SMM to MM4. Taken 
together, we hypothesise that patients who progress within a short time frame, 
MGUS/SMM to MM transformation does not always required the acquisition of many 
additional mutations and clonal selection. These MGUS/SMM patients appear to be 
sufficiently genetically complex to be on the threshold of transformation to MM, which 
may possibly be driven by extrinsic factors. 
 
Being able to define the crucial oncogenic events in the founder clonal population 
could facilitate treatment strategies for early intervention to arrest MM progression. 
However, as the subclones responsible for MM are evident at the asymptomatic stages this 
poses the question as to why these patients are not symptomatic. A strong possibility is that 
further to intrinsic genetic factors, extrinsic factors such as the tumour microenvironment 
may also play an important role in defining both the subclonal architecture and the overall 
tumour cell burden for progression to clinical malignancy. The complex interactions of the 
tumour microenvironment with subclones provide signals that may support tumour growth 
or dormancy, which may influence their transformation42-49. Of note, a recent study from 
our group which used the C57BL/KaLwRij mouse model of MM, demonstrated habitual 
clonal dominance, where only a few establishing MM cells subsequently contributed to 
tumour burden while most remained dormant. This illustrates the strong selection pressures 
present within the BM microenvironment which plays a role in defining the clonal 
architecture46. 
 
The current standard of care at the asymptomatic stages involves monitoring 
patients, with no treatment options until they progress to symptomatic MM. Here our study 
has demonstrated that there is no significant shift in subclonal structure associated with 
MM progression. As such, subclonal populations present at MGUS/SMM diagnosis would 
be just as amenable to treatment, and eradication of these subclonal populations prior to 
disease transformation could delay progression and may provide the prospect of a durable 
cure50. However, we recognise that intraclonal heterogeneity has been shown to be 
characteristic of MGUS/SMM/MM, with multiple subclones having differing survival 
properties, therefore the risk of further mutation and tumour evolution due to drug 
selection pressures would eventually lead to relapse. Furthermore, intraclonal 
heterogeneity with clonal selection may not be the only defining evolution associated with 
progression of MM, with a recent study illustrating the involvement of spatial 
heterogeneity with regional site seeding and outgrowth resulting in progression51. 
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Therefore, a combined longitudinal and spatial study of progression in patients would 
further elucidate genomic biomarkers of MM tumour evolution52, although the ability to 
sample from multiple sites in asymptomatic patients has significant ethical and practical 
challenges. 
 
Our findings reveal new insights into the genomic complexity and subclonal 
tumour evolution that is present from MGUS/SMM through to MM transformation. The 
existence of subclonality and clonal stability as a model of tumour evolution not only 
provides a more comprehensive understanding of the underlying biology of MM disease 
progression, but also new considerations required for patients at diagnosis and future 
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2.7 Supplementary  
2.7.1 Supplementary Methods 
2.7.1.1 Whole Exome Sequencing. 
Exome libraries were generated using the Nimblegen KAPA Hyper Library Prep kit (Kapa 
Biosystems, PN KP-KK8504) followed by the SureSelectXT Clinical Research Exome 
(CRE) (Agilent, S06588914) capture kit. 115ng of gDNA were used as input for 
fragmentation on the Covaris E220 followed End-Repair/A-Tailing and ligation of the 
SureSelect Adapter Oligos, excepting samples which had low input and required additional 
PCR cycles [Supplementary Table 6]. 10 cycles, or 12 cycles in the case low input 
samples, of Pre-Capture PCR amplification were performed to produce sufficient library 
for exome capture. Libraries were quantified on the LabChip GX II (LCGXII) using the 
5K HT DNA assay (Perkin Elmer, PN 760435 and CLS760675) and 750ng of each sample 
was input to the Agilent CRE capture workflow, hybridised to the CRE probes overnight. 
Following the capture washes and 11 cycles of Post-Capture PCR incorporating index 
barcodes, captured libraries were validated on the LCGXII using the 5K HT DNA assay 
(Perkin Elmer, PN 760435 and CLS760675).  An equimolar pool was prepared from the 
captured libraries and the pool validated on an Agilent HS DNA Bioanalyzer chip 
(Agilent, PN 5067-4626), and by qPCR using the KAPA Library Quantification Kits 
(Kapa Biosystems, PN KK4824), to assess quantity and quality of the samples ready for 
sequencing. Sequencing was performed on the Illumina HiSeq4000 (2x100 bp paired-end 
reads) and NextSeq 500 (2x150 bp paired-end reads). Samples were sequenced to a 
minimum depth of ~140X mean coverage. Isolated non-tumour cells were also sequenced 
to a similar average depth (138x). 
 
2.7.1.2 Analysis of Whole Exome Sequencing Data. 
2.7.1.2.1 Sequence alignment. 
Sequencing reads were mapped to the human decoy genome (hs37d5) using Novoalign 
(v3.02.08) followed by post-processing according to GATK best practices22.  
 
2.7.1.2.1 Somatic variant calling. 
Somatic single nucleotide and small indel variants were called using MuTect223 and 
multiSNV24. Variants were filtered using the following criteria: 10+ reads covering the 
variant site; 5+ reads covering the variant in the tumour sample. Variant annotation was 
performed with SnpEff25. 
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R 3.3.2 was used throughout for analyses. Somatic copy number variants were called using 
CNVkit26 v0.7.11 and custom in-house methods developed to support highly aneuploid 
genomes to perform segmentation and calculate log2 change between matched non-tumour 
and MGUS/SMM/MM. Log2 changes were corrected for sample purity to calculate ploidy 
at each stage. To investigate common copy number changes between MGUS/SMM and 
MM stages, for each patient and each gene the ploidy change was calculated between 
MGUS/SMM and MM, and a score generated for each gene by calculating the number of 
patients demonstrating ploidy increase minus the number of patients demonstrating ploidy 
decrease (ploidy change was threshold at 0.2 copies to reduce noise). Broad copy number 
changes were compared to cytogenetics data when available to examine concordance. 
Focal copy number changes were defined as regions < 3Mb in length53 
 
To investigate total copy number change at each stage, the CNVkit segmentation was used. 
Purity adjusted ploidy changes > 0.2 were summed for each patient. The Y chromosome, 
Immunoglobulin heavy region on chromosome 14, and T cell receptor A variable regions 
on chromosomes 7 and 14 were excluded from this analysis as they were frequently hyper-
segmented in the CNVkit analysis.  
 
2.7.1.3 Tumour heterogeneity and subclonal evolution. 
Clonal evolution was investigated using PhyloWGS27 and visualised using fish plot in R28. 
It is worth noting that PhyloWGS can inflate the number of subclones so, although we 
based our analysis on the inferred subclonal architecture, we recognise that the numbers of 
subclones may be overestimated. There are some mutation discrepancies between the 
subclonal trees and the SNVs called by MuTect2 due to threshold differences between the 
two analyses. PhyloWGS requires one time point to demonstrate that the mutation is 
present at a non trivial level, therefore a lower burden of proof is required to infer its 
existence between the two time points. However, if both time points demonstrate a low 
proportion then that mutant is not inferred in the subclonal tree. In our subclonal tumour 
evolution models, we did not consider polyclonal evolution, where multiple founder PC 
clones were present at the MGUS/SMM diagnosis stage, due to the computational 
difficulty in modeling polyclonal evolution. All phylogenetic trees constructed were based 





2.7.2 Supplementary Appendix 1 
2.7.2.1 Subclonal tumour evolution in MGUS-MM patients 
Patients P01, P04 and P10 were initially diagnosed with MGUS, and subsequently with 
MM. We observed that MGUS-MM patients exhibited an average time to progression 
(TTP) of ~5 years. All three patients showed a decrease in total non-synonymous SNVs 
associated with progression [Figure 1a]. Patients P04 and P10 were composed of eight and 
five subclones at MGUS diagnosis, respectively. Patient P04 exhibited an interesting 
subclonal evolution pattern, where initially one subclone [subclone 2 purple] evolved from 
the founder clone, which was followed by substantial branching evolution resulting in six 
child subclones involved in MM progression, and a rapid TTP of 1 year. The founder clone 
harboured mutations in MYCBP2 (F22L) and TOP2A (K1199N) and copy number changes 
on chromosomes 9, 11, 13, 14 and 18. While most of the child subclones exhibit stability, 
subclone 3 [orange] and subclone 9 [green] appear to have a selective advantage and 
showed emergence towards MM [Supplementary Figure 1b].  
 
In patient P10 we observed a decreased proportion of the founder clone, likely due 
to some normal PCs contamination [Supplementary Table 2]. We identified neutral growth 
of subclonal populations coupled with the emergence of multiple subclones [subclone 4 
yellow from ~3% to ~25%, and subclone 5 blue from ~1% to ~10%] and extinction of 
child subclone 3 [orange from ~5% to <1%] with progression. The founder clone showed 
multiple high impact mutations in DUSP27 (STOP gain), SP140 (F133I) and FAM110B 
(P339L) [Supplementary Figure 1c]. The TTP of P10 was noted to be 13 years, possibly 
representing an earlier diagnosis and sampling time for this patient.  
 
Patient P01 exhibited a slight decrease in NS-SNV mutations with progression and 
was composed of eight subclones at diagnosis. The founder clone had a copy number 
change on chromosome 1. Interestingly, while P01 mainly exhibited stable progression of 
subclones from MGUS to MM, we observed KRAS mutations to be newly acquired in 
multiple child subclones. Subclone 7 [brown] harboured a mutation causing an amino acid 
change at position Q61L, with a resultant neutral growth observed. Furthermore, we 
identified mutations occurring in a nested fashion, with outgrowth of subclone 8 [grey 
from <1% to ~6%] harbouring mutations at G12D and G12S, with further emergence of 
child subclone 9 [green] harbouring additional change at Q61H with MM progression. This 
was coupled with the extinction of child subclonal branches of subclone 2 [purple] 
[Supplementary Figure 1a].  
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2.7.2.2. Subclonal tumour evolution in SMM-MM patients 
Patients P02, P03, P05, P06 and P08 were diagnosed for SMM, and then subsequently MM 
at a later time point. SMM patients demonstrated an average TPP of 2 years. Patients were 
separated on the basis of total non-synonymous SNV burden associated with MM 
progression, where 3 patients showed a decrease (P02, P05 and P08) and 2 patients showed 
an increase (P03 and P06) [Figure 1a]. Patients P02 and P06 were composed of eleven and 
five subclones at diagnosis, respectively. Patient P02 exhibited stable growth during 
progression, with mainly the emergence of child subclone 5 and its branches [blue from 
~5% to ~13%] and extinction of subclone 9 [dark green from ~6% to <1%] 
[Supplementary Figure 2a]. The founder clone showed copy changes on chromosomes 6, 8 
and 13, and mutations in HERPUD1 (STOP gain), FGFR3 (809S) and DAPK1 (K435R). 
Furthermore, we identified a KRAS mutation (A146P) in subclone 11, whose population 
proportion size, interestingly, did not change during MM progression.  
 
Patient P06 displayed a small founder clone proportion, possibly due to variants 
such as structural changes unable to be characterised by WES, which harboured copy 
changes on chromosomes 3, 5, 6, 15, 17, 19 and 21, and point mutation in NRAS (Q61R). 
We mainly observed the emergence of subclone 8 [black from <1% to ~23%] with KLC3 
mutation (R442H) and its child subclone 9 [dark green from <1% to ~4%], and subclone 2 
[purple from ~8% to ~28%] and its child subclones 6 [pink from <1% to ~10%] with 
mutations in MYCBP2 (E730K), FGFR3 (A165T) and PRDM1 (G214R) and 7 [brown 
from <1% to ~6%] with progression. The proportions of child subclonal population 3 
[orange] remained unchanged between SMM and MM [Supplementary Figure 2d].  
 
Patient P08 exhibited neutral growth, which was coupled with the emergence of 
child subclone 9 [green from <1% to ~5%] and extinction of child subclone 8 [black from 
~6% to <1%] with MM progression. The founder clone had widespread mutations with 
CNVs in chromosome 2, 8, 9, 13, 16, 18, 19, 20 and 22, and SNVs in RB1 (G449E), 
PLEKHA7 (STOP gain), RBM4B (STOP gain), DDX55 (R222Q), CCDC105 (STOP gain), 
HIST1H3J (STOP gain) and MLIP (STOP gain) [Supplementary Figure 2e].  
 
Similar to P06, patient P05 showed a smaller founder clone proportion at diagnosis. 
There were initially two subclones present at the SMM stage, which progressed to MM 
with the emergence and extinction of child clones from subclonal branch 5 [blue], 
combined with the neutral growth from subclonal branch 2 [purple]. Subclone branch 5 
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[blue] and its child subclonal branches 9 [green] and 10 [light brown] harboured multiple 
stop mutations in genes NRG3, EZH2, KLHL20, SNX9, C8orf87, ACTL6A and MTA3. 
However, these child subclones became progressively extinct with MM progression, from 
~5% to ~2% and ~3% to <1%, respectively. While child subclones 7 [dark brown] and 8 
[black] exhibit emergence towards MM, from <1% to ~10% and <1% to ~5%, 
respectively. The founder clone harboured mutations in KRAS (G12V) and ICAM5 (R85L), 
and CNVs on chromosome 2 and 19 [Supplementary Figure 2c].  
 
Patient P03 displayed an interesting evolution pattern with massive extinction of 
subclone 2 [purple] from ~47% to ~6%, and almost all of its child subclones, by MM 
diagnosis. The founder clone harboured mutations in NOD2 (STOP gain) and CNVs on 
chromosomes 1, 6, 9, 13 and 16. Furthermore, two individual subclones that contained 
distinct DIS3 mutants M566K and R689P were identified at SMM diagnosis in subclone 8 
[black] and child subclone 11 [dark purple], respectively [Supplementary Figure 2b]. 
While recent single cell analysis has demonstrated parallel evolution of the RAS/MAPK 
pathway in MM through the occurrence of RAS mutations in individual clones leading to 
distinct subclonal populations24, here we uniquely identify parallel evolution of DIS3, 
with the resultant emergence of both subclonal lineages with MM progression. 
Additionally, subclone 13 and its child subclones exhibited outgrowth with a mutation in 





























Supplementary Table 1. Clinical cytogenetic data for MGUS/SMM to MM patients. 
Clinically recorded data at MM diagnosis for patients in the study. The median age of patients 
at MM diagnosis was 75.5 years. Molecular cytogenetics of patients was performed using 
FISH analysis on interphase spreads of bone marrow smears. Nil represents parameter not 
being present. N/A represents that data was not available. 
 
 
Supplementary Table 2. Estimated sample purity and exome sequencing coverage. Purity 
of FACS sorted patient PCs was assessed by FACS purity check post sort on sorted cells tube, 
with 100-500 cells through the flow cytometer for each sample. Mean depth of sequencing 
describing the average number of reads over bases in the targeted exome region of samples 


















Supplementary Table 3. The shared NS-SNVs between MGUS/SMM and MM, and 
unique NS-SNVs in MM patients. Analysis of the total mutational load reveals a median 
of 161 NS-SNVs at MGUS/SMM and 152 NS-SNVs at MM. The table describes the shared 













Supplementary Table 4. The full characterisation of driver mutations in MGUS/SMM to 
MM patients. Single nucleotide variants in previously reported driver genes were identified 
in KRAS, NRAS and DIS3. The table describes the genomic positions and subsequent impact 





















Supplementary Table 5. The copy number landscape of MGUS/SMM to MM 
patients. We identified numerous CNV changes in each patient at MGUS/SMM and 
MM. MGUS/SMM patients harboured a higher median number of changes than at 




Supplementary Table 6. Exome library preparation of low input samples requiring 
additional PCR cycles. Two samples had yields lower than the required 115ng gDNA input 
and required extra PCR amplification during library preparation to generate sufficient 
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Supplementary Figure 1. The subclonal tumour evolution associated with MGUS to MM 
progression. Fishtail plots annotated with the complete subclonal genetic architecture in three 
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Supplementary Figure 2. The subclonal tumour evolution associated with SMM to MM 
progression. Fishtail plots annotated with the complete subclonal genetic architecture in five 
















Supplementary Figure 3. The correlation of BM PC% and the subclones identified with 
progression in MGUS/SMM to MM patients. Progression to MM is characterised by an 
increase in BM PC% and monoclonal protein levels, however, we find no correlation between 












Supplementary Figure 4. A comparison of cytogenetic abnormalities with virtual 
karyotypes. Virtual karyotypes were generated from genome-wide copy number changes 
inferred from whole exome sequencing data at both MGUS/SMM and MM stages. 
Chromosomal copy amplifications are illustrated by red, while copy deletions are shown in 
blue. Several patients exhibit very similar karyotypes at both MGUS/SMM and MM. In some 
patients, hyperdiploidy is present at MGUS/SMM and is undetected by standard cytogenetics 
even at MM (molecular cytogenetics results listed to the right of each patient figure). Nil 
represents parameter not being present. N/A represents that data was not available. 
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3.1 Abstract  
Multiple myeloma (MM) is a largely incurable haematological malignancy characterised 
by the uncontrolled proliferation of neoplastic plasma cells (PCs) within the bone marrow. 
Recent studies have focused on the investigation of the genetic landscape in MM and its 
asymptomatic stages of monoclonal gammopathy of undetermined significance (MGUS) 
and smouldering multiple myeloma (SMM). While genetic analyses of patient samples 
have identified recurrently mutated genes and clonal heterogeneity which are characteristic 
of MM, our understanding of the transcriptomic and methylomic changes associated with 
progression from MGUS/SMM to MM remains poor. Here, we have performed RNA 
sequencing (n = 6) and whole genome bisulphite sequencing (n = 4) on serial samples from 
patients who progressed from MGUS or SMM to MM, to analyse the gene expression and 
methylation changes associated with disease transformation. Our findings suggest that 
progression from MGUS/SMM to MM was accompanied by relatively few changes in 
gene expression. Of the 250 differentially expressed genes that approached statistical 
significance, the majority of genes showed down regulation upon transition to MM. The 
top 10 differentially expressed genes included, THEMIS2, BTBD19, HBB, ATP8A2, 
CELSR1, CD69, TWF2, SLC20A1, ALG1L and SLC23A3. Mutated genes, previously 
identified in whole exome sequencing analyses of the same patients, were found to be 
expressed at low levels or not at all. In most cases, only the wild type allele of a gene 
harbouring heterozygous mutation was expressed. Analysis of the methylome revealed 
significant DNA hypomethylation in MGUS, SMM and MM PCs compared to normal 
PCs. Extreme DNA hypomethylation was acquired at the initiation of MGUS, and 
maintained with progression to SMM and MM. Our study suggests that most of the 
genomic changes of MM occur during the oncogenic transition from a normal PC to a 
MGUS/SMM PC, with minimal changes in the gene expression and DNA methylation 













Multiple myeloma (MM) is a haematological malignancy characterised by the clonal 
expansion of neoplastic plasma cells (PCs) within the bone marrow. MM is a genetically 
complex disease, characterised by heterogeneity that influences the disparate treatment and 
survival outcomes of patients1-6. Despite recent advances in therapeutic strategies, MM 
remains a largely incurable disease, with relapse being a common occurrence7.  
 
The initiation of MM involves a multistep transformational process, evolving from 
the asymptomatic stages of monoclonal gammopathy of undetermined significance 
(MGUS) and smouldering multiple myeloma (SMM)6. Genomic studies of large patient 
cohorts using next generation sequencing (NGS) techniques have compared the DNA 
mutational landscape between the asymptomatic stages of MGUS, SMM, and symptomatic 
MM, identifying recurrently mutated genes (“drivers”) and establishing intraclonal genetic 
heterogeneity and clonal evolution patterns1-3,5,6. While many studies have performed 
molecular cytogenetic and NGS analysis to characterise the genetic architecture of MM, 
the role of transcriptome and methylome changes associated with disease progression are 
poorly understood. Identification of mutations in genes which alter gene expression, 
influencing molecular pathways and oncogenic signalling, could inform the treatment 
strategies used for MM patients8,9.  
 
To date, analysis of the MM transcriptome has relied on array-based technologies 
which provide a global snapshot of the gene expression profile (GEP) in individual 
tumours for risk stratification and prognosis of patients10-12. GEPs have been used to define 
molecular heterogeneity and classify patients based on common expression signatures into 
7 distinct subgroups of MM: MF [MAF/MAFB], MS [MMSET], CD-1 and CD-2 
[CCND1/CCND3], HY [hyperdiploid], LB [low bone disease] and PR [proliferation]13. 
Studies have also investigated the association of expression profiles with disease 
progression, resulting in robust GEP signatures for stratification of high-risk MM patients, 
such as the UAMS-7012 and EMC-9211. However, due to the marked heterogeneity that 
characterises MM, GEPs only provide a broad-brush insight into the disease biology and 
major clones associated with MM progression. Thus, with the rapid advances in genomic 
technologies, GEP may not represent the best methodology to identify clinically relevant 
expression changes in patients. A recent study of MM patient samples using RNA 
sequencing (RNAseq) has demonstrated allele-specific expression of mutated genes in 
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MM14. This illustrates the need for the application of more current technologies such as 
RNAseq for transcriptomic interrogation of MM samples. 
 
Epigenetic mechanisms are known to play an integral role in regulating gene 
expression15. However, the key epigenetic mechanisms of DNA methylation and histone 
modification contribute to transformation in MM is not well understood. The rate of 
epigenetic change in cancers has been estimated to be orders of magnitude higher than that 
of genetic change, and could be a major determinant of clonal evolution16. Studies 
investigating the methylome in unmatched MGUS, SMM and MM patient samples in 
comparison to normal PCs, have illustrated that initiation of disease is characterised by 
global hypomethylation, which either increases or reduces upon disease progression17-20. 
Moreover, MM PCs were observed to exhibit extreme heterogeneity in DNA methylation 
patterns compared to MGUS PCs17.  
 
As current sequencing studies have focused on the genetic changes and intraclonal 
heterogeneity in MM, what remains unknown is the expression changes of recurrently 
mutated genes and their implications for MM transformation. Here, we report an 
integrative analysis of differential DNA methylation and gene expression in paired 
MGUS/SMM to MM patient samples. These patients were also the subjects of our 
previous whole exome sequencing analysis study, which identified clonal stability as a 
model of tumour evolution in MM21.  
 
Longitudinal analysis using RNAseq was carried out on paired MGUS-MM (n = 2), 
or SMM-MM (n = 4) PCs to assess the expression changes associated with MM 
transformation. Additionally, investigation of the methylome was carried out using whole 
genome bisulphite sequencing (WGBS) on normal PCs (NPCs: n = 3), and paired MGUS-
MM PCs (n = 1) or SMM-MM PCs (n = 3) for a greater understanding of the underlying 










3.3 Materials & Methods  
3.3.1 Clinical samples. 
Bone marrow mononuclear cell aspirates were collected from patients at MGUS/SMM, 
and subsequently at later diagnosis of MM (MGUS-MM (n = 2) and SMM-MM (n = 4)). 
Samples were collected from patients prior to treatment. All patients provided informed 
consent in accordance with the Declaration of Helsinki. Samples were cryopreserved by 
the South Australian Cancer Research Biobank (SACRB) at SA Pathology. The studies 
were approved by the Royal Adelaide Hospital Human Research Ethics Committee 
(HREC/13/RAH/569 No: 131133). 
 
3.3.2 Cell sorting. 
PCs were purified using multicolour flow cytometry as previously described22. Briefly, 
approximately 1x105 mononuclear cells were prepared for single stain antibody control 
(CD138-PE (Beckman Coulter #A54190) and CD38-PE-Cy7 (Biolegend #303515)) and 
compensation/FMO tubes (1: unstained; 2: hydroxystilbamidine (FluoroGold; Life 
Technologies) only; 3: CD38-PE-Cy7+FluroGold; 4: CD138-PE+FluroGold; and 5: CD38-
PE-Cy7+CD138-PE). The sort sample was stained with CD138-PE and CD38-PE-Cy7 
antibodies at 1µL/100µL cells. Cells were stained with FluoroGold immediately prior to 
sorting. Viable PCs (CD138+CD38+ and FluoroGold negative) were sorted on the 
FACSAria Fusion sorter (BD Biosciences). FACS purity check was carried out on sorted 
cells, using 100-500 cells from each sample. 
 
3.3.3 Nucleic acids isolation and QC. 
DNA was isolated from purified PC populations using the All Prep DNA/RNA Micro Kit 
(QIAGEN) as per manufacturers’ instructions. Yields and quality was assessed using the 
NanoDrop 8000 and Qubit 2.0 fluorometer (Thermo Fisher Scientific). 
 
RNA was isolated from purified PC using the All Prep DNA/RNA Micro Kit (QIAGEN) 
and RNAaqueous-Micro Kit (Thermo Fisher Scientific) as per manufacturers’ instructions. 
Yields and quality was assessed using the Qubit 2.0 fluorometer (Thermo Fisher Scientific) 






3.3.4 RNA sequencing and Analysis. 
Between 33 to 380ng of RNA was used to generate RNA libraries using the NEXTflex 
Rapid RNA-Seq Kit (BIOO Scientific) according to manufacturers’ instructions. 
Sequencing was carried out on the Illumina NextSeq500 (2x75 bp paired-end reads) with 
approximately 90 million reads per sample. 
 
RNA sequencing reads were aligned to the human reference genome (hg19) using the 
STAR 2-pass method as previously described23. Variant calling was performed using the 
GATK best practices24 and were annotated using ANNOVAR25. For gene expression 
analyses, read counts were quantified using Rsubread26. The TMM method within edgeR27 
was used to normalise the expression data, and FactoMineR28 was used for principle 
component analysis. The Benjamini Hochberg method was used to assess potential false 
discovery from multiple comparison testing29. The PANTHER (Protein Analysis Through 
Evolutionary Relationships, http://www.pantherdb.org) classification system was used to 
interpret pathway level analysis30-32.  
 
3.3.5 Whole Genome Bisulphite Sequencing and Analysis 
Approximately 50ng of DNA was used for bisulphite library preparation using the Ovation 
Methyl-Seq System (NuGen) according to manufacturers’ instructions. Sequencing was 
performed on the Illumina NextSeq500 (2x150bp paired-end reads). Samples were 
sequenced to an average coverage of ~30x. 
 
Prior to alignment, reads were trimmed to a minimum of 15bp to improve mapping 
efficiency and to remove any contaminating adaptor sequences using AdapterRemoval 
v2.1.7. The human reference genome (GRCh37) was obtained from the Illumina igenomes 
link and was converted into the bisulphite sequence using Bismark v0.18.1. Trimmed reads 
were aligned to the bisulphite converted reference genome using Bismark v0.18.1 and 
Bowtie2 v2.2.5 v, which was also used for cytosine methylation calling. Differential 
methylation analyses were performed using BiSeq. Differentially methylated regions 
(DMRs) were considered to be significant if they were within clusters with a false 
discovery rate (FDR) < 0.05. Principle component analysis was performed using the 






3.4.1 The progression of MGUS/SMM to MM is associated with minimal variation in 
gene expression. 
To characterise the transcriptomic landscape associated with progression to MM, we 
performed RNAseq on 6 paired MGUS/SMM to MM patient sample sets, with an average 
of approximately 90 million reads per sample. The median time to progression of MGUS 
to MM was 3.2 years (range 1 – 5.4 years), and SMM to MM was ~1 year (range 0.5 – 4.1 
years). The median age of MM diagnosis in the cohort was 79.5 years, which was higher 
than the established median of 65 years33 [Supplementary Table 1].  
 
To date, our understanding of the transcriptomic landscape of MM is derived from 
the GEP analyses of unmatched MGUS/SMM/MM samples isolated from different 
patients34-36. As such, current studies are affected by the significant intrinsic natural 
variation in gene expression patterns that exist between unrelated individuals. To 
overcome this limitation of inter-patient transcriptional “noise” and identify changes in 
gene expression associated with the natural history of disease transformation, we analysed 
matched MGUS/SMM to MM samples. Indeed, principal component analysis revealed that 
while each patient exhibited great variability in their overall expression patterns, paired 
samples from each individual patient clustered closely together [Figure 1]. Pairwise XY 
scatterplot analysis of gene expression in individual MGUS to MM, or SMM to MM 
patients demonstrated little variation between each stage of disease [Figure 2]. The median 
correlation coefficient across all MGUS/SMM to MM cases was 0.915, indicating relative 
homogeneity in gene expression pattern in each paired sample case. Overall, this shows 
that there is limited change in the expression of genes associated with the progression of 
MGUS/SMM to MM. Furthermore, this highlights the limitation of previous studies using 
unmatched patient sample comparisons, where the majority of gene expression differences 
identified would be occurring in grouped samples from MGUS/SMM/MM from different 
patients. Similarly, a previous expression study of normal PCs (NPCs) in comparison to 
PCs from MGUS and MM patient samples using microarray analysis has revealed that 
most gene expression changes occur during the initiation of MGUS (i.e. NPCs vs. MGUS). 
These studies also showed that the expression differences between MGUS and MM are 
much smaller than that between NPCs and MGUS or MM PCs, with only 74 differentially 
expressed genes distinguishing MGUS from MM36. Taken together, these data suggest that 

















Figure 1. The transcriptomic landscape associated with MGUS/SMM to MM 
transformation. Principal component analysis illustrates intra-patient clustering of 
expression profiles in the progression of MGUS/SMM to MM in individual patients. 



















































Figure 2. The relationship of gene expression changes associated with MGUS/SMM to 
MM progression. XY scatterplots illustrate the similarity in gene expression between the 
asymptomatic stages of MGUS/SMM and MM in paired MGUS-MM (a: P01, b: P04) and 
SMM-MM patients (c: P02, d: P03, e: P05, f: P08). The median R2 value was 0.915, 
demonstrating homogeneity in expression between disease stages. R2 correlation values are 
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3.4.2 MGUS/SMM to MM progression is associated with specific expression changes.  
The clustering of matched samples allowed gene expression changes associated with 
transition that would otherwise be masked by inter-patient variability. Differential gene 
expression testing between MGUS/SMM and MM groups, identified 250 genes reaching 
statistical significance (i.e. raw p value < 0.05, before controlling the false discovery rate 
using the Benjamini Hochberg method29) [Supplementary Table 3]. Overall, the majority 
of differential expression changes involved a reduction in gene expression upon MM 
transformation, with only 109 genes that were upregulated [Supplementary Table 3a], and 
141 genes that were downregulated [Supplementary Table 3b]. The mean log fold change 
of upregulated genes was +1.65, while the mean log fold change of downregulated genes 
was -2.35. These findings highlight that of the group of genes that do change at transition, 
there is predominantly a downregulation in gene expression, which is consistent with 
previous GEP studies of MM36. Pathway analysis revealed gene expression signatures 
associated with the transition of MGUS/SMM to MM, with 196 differentially expressed 
genes affecting 69 biological pathways [Supplementary Figure 1]. Overall, we did not 
observe pronounced pathway enrichment due to the similar transcriptional profiles 
identified between the MGUS/SMM and MM stages. Of genes that showed highly 
increased expression (> +2 fold change) upon progression to MM, there were 5 affected 
pathways including apoptosis signalling, angiogenesis, Wnt signalling, cadherin signalling 
and Alzheimer disease-presenilin pathways [Figure 3a]. Genes that were highly down 
regulated (> -2 fold change) upon MM transition, associated with 21 affected molecular 
pathways, including Metabotropic glutamate receptor group I and III, inflammation 
mediated by chemokine and cytokine signalling and heterotrimetic G-protein signalling-Gi 






































Figure 3. Deregulation of molecular pathways associated with MGUS/SMM to MM 
progression. (a) The upregulation of genes with differential expression of > 2 fold, was 
associated with 5 biological pathways including apoptosis signalling [red], angiogenesis 
[yellow], Wnt signalling [blue], cadherin signalling [orange] and Alzheimer disease-
presenilin [green]. (b) Genes that were highly downregulated, with differential expression 
of > -2 fold upon MM transition, were most associated with biological pathways including 
Metabotropic glutamate receptor group I and III [dark greens], inflammation mediated by 
chemokine and cytokine signalling [red] and heterotrimetic G-protein signalling-Gi alpha 















Investigating MGUS-MM and SMM-MM transition on an individual patient-by-
patient basis, we identified dynamic fold changes in gene expression associated with 
progression. We found genes whose expression levels demonstrated fold increases (2x), or 
fold decreases (0.5x) associated with MM progression. The top 10 genes differentially 
expressed, based on fold change and frequency, between MGUS/SMM and MM included 
THEMIS2, BTBD19, HBB, ATP8A2, CELSR1, CD69, TWF2, SLC20A1, ALG1L and 
SLC23A3 [Figure 4]. At MGUS to MM progression, we observed fold increases in 
expression of THEMIS2, BTBD19, TWF2 and SLC23A3. Conversely, fold decreases in the 
expression levels of ATP8A2, ALG1L, HBB and CELSR1 were identified. In the 
progression of SMM to MM, we identified fold increases in the expression of THEMIS2, 
BTBD19, TWF2, SLC20A1 and SLC23A3. Fold decreases were found in the expression of 
HBB, ATP8A2, CELSR1 and ALG1L. Interestingly, all SMM-MM patients exclusively 
showed fold decreases in CD69 expression. Due to the nature of our small and rare sample 
size, differentially expressed genes between MGUS/SMM and MM samples did not reach 
statistical significance. These findings reveal a number of genes and pathways deregulated 
upon MM progression, and highlight the need to perform a comprehensive larger cohort 






























Figure 4. Waterfall diagram illustrating fold changes in gene expression associated 
with MGUS/SMM to MM progression. The top 10 differentially expressed genes, based 
on fold change and frequency, upon MM transition showing fold increase of at least 2x 
(THEMIS2, BTBD19, TWF2, SLC20A1 and SLC23A3) or fold decrease of at least 0.5x 



































3.4.3 The progression of MGUS/SMM to MM is characterised by the maintenance of 
hypomethylation acquired at the asymptomatic disease stage. 
We next examined the DNA methylation landscape associated with MM transformation in 
paired MGUS/SMM to MM patient samples (n = 4) and NPCs (n = 3) [Supplementary 
Table 2]. WGBS was performed to a depth of approximately 30x to assess the methylation 
profiles of MGUS, SMM, MM and NPC samples. For disease stage specific comparison, 
additional single samples with sufficient DNA from our WES cohort were included: 1 
MGUS sample (P11), 1 SMM sample (P05), and 3 MM samples (P04, P06 and P10) 
[Supplementary Table 2]. 
 
Analysis of the methylation status of MGUS/SMM and MM PCs in comparison to 
NPCs revealed that both the asymptomatic and symptomatic stages of disease were 
characterised by extreme DNA hypomethylation. The average methylation of CpG sites 
across NPC samples was 77.5%, which is consistent with levels previously reported of 
~80% CpG methylation in mammalian cells37-39. However, a significant decrease in CpG 
methylation was observed at each stage of disease, with MGUS, SMM and MM exhibiting 
an average methylation of 43% (NPC vs. MGUS p = 0.0011), 45.6% (NPC vs. SMM p = 
0.017) and 41.7% (NPC vs. MM p = 0.000165), respectively [Figure 5]. Interestingly, we 
observed that in the progression from MGUS to SMM and MM, a similar range of 
hypomethylation was maintained as that initially acquired at MGUS. These findings are in 
stark contrast to previous studies of the MM methylome in unmatched samples, which 
have identified global hypomethylation as a key feature in the transition of MGUS to 
MM19, with disease transformation characterised by a progressive increase in 
hypomethylation17-19. A previous study of unmatched MGUS (n = 16) and MM (n = 104) 
PCs compared to NPCs (n = 3) demonstrated that 98.3% of CpG sites in MM PCs were 
























Figure 5. The initiation of MGUS is characterised by significant hypomethylation, 
which is maintained through progression to SMM and MM. Analysis of the overall 
methylome in asymptomatic MGUS/SMM and symptomatic MM in comparison to non-
disease, demonstrates disease onset and progression is characterised by significant 
hypomethylation of CpG sites. While an average of 77.5% of CpG sites were methylated 
in NPCs, an average of 43%, 45.6% and 41.7% were methylated at MGUS, SMM and 
MM, respectively (NPC vs. MGUS p = 0.0011, NPC vs. SMM p = 0.017, NPC vs. MM p 
= 0.000165). Interestingly, the range of methylation remains constant between 































CpG sites were smoothed into clusters that were then used to identify differentially 
methylated regions (DMRs) between sample groups. Differential methylation testing 
comparing NPCs with MGUS/SMM, and MM PCs, identified a total of 190,401 DMRs 
between MGUS/SMM and NPCs, and 177,535 DMRs between MM and NPCs. Thus, 
there was only a small decrease in the overall number of DMRs observed between NPCs 
and MGUS/SMM, and NPCs and MM PCs. Overall, all statistically significant DMRs 
identified between NPCs and MGUS/SMM/MM were located on chromosomes 14, 16, 17, 
18, 20, 21, 22, 3, 4, 5, 8, Y and X. Interestingly, however, upon progression from 
MGUS/SMM to MM, we found no statistically significant DMRs (MGUS vs. MM p = 
0.9911, and SMM vs. MM p=0.6843). Analysis of the change in methylation near 
promoters within 2000bp of the transcription start site of all genes found within DMRs, 
revealed that the average level of methylation decreased in MGUS/SMM/MM near the 
transcription start site of genes as it does for NPCs, whereas NPCs maintained a higher 
level of methylation [Figure 6].  
 
Investigating the methylome profile of patients on an individual basis, principal 
component analysis revealed intra-patient clustering [Figure 7]. CpG sites within the top 
100 DMRs were plotted as a representative analysis of the relationship between the 
asymptomatic stages of MGUS/SMM and MM in each patient. Pairwise XY scatterplot 
comparisons of paired MGUS/SMM to MM samples illustrated minimal variation in the 
methylation profiles associated with disease progression [Figure 8]. A median correlation 
coefficient of 0.90 was calculated, demonstrating a strong positive linear relationship and 
homogeneity in methylation patterns. Conversely, stage specific comparison of NPCs with 
MGUS, SMM or MM demonstrated considerable heterogeneity of methylation, with a 
median correlation coefficient of 0.36, highlighting the greater difference in CpG 
methylation patterns between the transition of NPCs to MGUS/SMM/MM [Supplementary 


































Figure 6. Promoter methylation analysis of all genes identified within DMRs between 
NPCs and MGUS/SMM and MM PCs. Comparison of the average level of methylation 
within 2000bp of the transcription start site of genes within DMRs, between disease stages 
and NPCs, demonstrates a similar drop in the average level of methylation towards the 




























































Figure 7. The methylomic landscape associated with MGUS/SMM to MM 
transformation. Principal component analysis of the methylome profiles of MGUS/SMM 
to MM patients demonstrates clustering of paired samples from individual patients, with no 
significant differential methylation associated with progression to MM. Normal samples 
are represented by squares; MGUS/SMM group is represented by circles; MM group is 





































































































Figure 8. The relationship in methylation landscape associated with MGUS/SMM to 
MM progression. XY scatterplots illustrate minimal variation in methylation patterns 
between the asymptomatic stages of MGUS/SMM and MM in paired MGUS-MM (a: P01) 
and SMM-MM patients (b: P02, c: P03, d: P08). The median R2 value was 0.90, 
demonstrating relative homogeneity in CpG methylation between disease stages. R2 
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3.4.4 Gene ontology pathways associated with the transformation to MM. 
Gene ontology (GO) analysis was performed to identify the effects of differentially 
methylated regions found between NPCs and MGUS/SMM and MM PCs. Epigenetic 
deregulation significantly affected 321 genes, with roles in cellular processes such as 
immunoglobulin complex assembly, immunoglobulin receptor binding, phagocytosis, 
complement activation and B cell receptor signalling [Figure 9].  
 
Previous study by Salhia et al., examining the pathways associated with differentially 
methylated genes in MGUS, SMM and MM, identified that extracellular matrix adhesion 
and remodelling were the most significantly affected pathways18. Associated dysregulation 
of cellular processes such as proteolysis and adhesion/extracellular matrix modifications 
suggested that hypomethylation, during myelomagenesis, may favour bone invasion by 
increasing interactions with the bone marrow extracellular matrix, initiating the required 
adhesive forces underlying bone invasion and the formation of lytic lesions18. Interestingly, 
a further study by Walker et. al., also revealed gene-specific hypermethylation associated 
with the transition of MGUS to MM, with 77 genes that have biological roles in 


































Figure 9. Gene Ontology analysis of pathways associated with DMRs identified 
between NPCs and MGUS/SMM and MM. Gene Ontology reveals the top ranked 
cellular pathways/processes affected by differential methylation in MGUS/SMM and MM, 
compared to NPCs. There were 321 genes significantly affected by differential 










































3.4.5 Allelic specific expression of genes associated with MGUS/SMM to MM 
progression.  
NGS studies have identified recurrently mutated genes in MM1-3,5, however ultimately, it is 
expression of these mutated genes in MM PCs that determines the phenotype of the tumour 
cells. Mutations in genes that are not expressed in PCs are more likely to be passenger 
mutations rather than driver mutations of disease. Our previous WES analysis of these 
paired samples identified 15 previously reported mutated genes. We assessed normalized 
RNAseq read counts (FPKM: Fragments Per Kilobase of transcript per Million mapped 
reads) as a measure of expression levels, finding most genes were generally not expressed, 
or expressed at low levels across all patients at both MGUS/SMM and MM. This included 
KRAS, DIS3, TRAF3, SP140, RB1, PTEN, PRDM1, NRAS, MYC, MAGED1, IRF4, HLA-A 
and CDK4. Patient-specific expression showed that, on average, most genes exhibited < 
100 transcript counts [Figure 10a]. PRDM1, MAGED1, IRF4 and HLA-A were observed to 
have high expression levels, consistently showing > 100 counts. Conversely, FAT3 and 
ROBO1, were identified to not be expressed at all. There were no DMRs identified in the 
analysis between MGUS/SMM and MM, indicating transcriptional changes are unlikely to 
be caused directly at those genes.  
 
We then assessed allelic exclusivity of expression of mutated genes in patients in 
our RNAseq data. WES analysis revealed patients that harboured mutations at the genetic 
level included KRAS (P01 MGUS-MM, P02 SMM-MM and P05 SMM-MM), DIS3 (P03 
MM), TRAF3 (P02 MM, P03 MM), RB1 (P08 SMM-MM), MYC (P01 MM), IRF4 (P03 
MM) and CDK4 (P01 MM) [Figure 10a stars]. While these genes were identified to have 
DNA mutations, it was generally observed these mutants were expressed at similar levels 
to patients that didn’t harbour the mutant. Assessing mutant allele specific expression, we 
mostly observed wild-type allele transcript expression, with only KRAS and DIS3 having 
mutant allele expression in 2 patients (KRAS: P05 MM; and DIS3: P03 MM) [Figure 11]. 
Intriguingly, one of the DIS3 transcript variants in P03 was unique to that of the two that 
were identified by WES. This suggests that this mutation was not detected in exome data 
due to the mutation residing in a minor subclone and had a low variant allele frequency 
(VAF). Furthermore, of genes with frequently acquired mutations at MM progression in 
our WES study, KMT2D was also expressed. KMT2D harboured genetic mutations in 4/6 
patients (P01, P03, P05 and P08), and was also observed to be highly expressed at both 
MGUS/SMM and MM stages [Figure 10b]. However, mutant KMT2D was only expressed 















Figure 10. Expression of previously reported recurrently mutated genes in MM, 
identified in our MGUS/SMM to MM cohort. (a) RNAseq transcript counts show 13 
recurrently mutated genes were expressed at both MGUS/SMM and MM. Average 
expression levels demonstrate most are expressed at low levels, or not at all (FAT3 and 
ROBO1). PRDM1, MAGED1, IRF4 and HLA-A were observed to have high expression 
levels (consistently > 100 counts). (b) Of the 10 most common genes harbouring mutations 
at MM in our WES data, only 4 genes exhibited expression including KRAS, DIS3, SP140 













   
  
  























Figure 11. Correlation of WES data with RNAseq expression data. DNA mutations in 
recurrently mutated MM genes were identified in specific patients, however, these mutants 
were expressed at similar levels to patients that didn’t harbor the mutant. Alignment of 
whole exome sequencing data with transcript expression data reveals most identified 
genetic mutations were lowly expressed, with only 3 genes: KRAS, DIS3 and KMT2D 


































The application of NGS technologies in genetic analyses of large cohorts of MM patient 
samples has established intraclonal genetic heterogeneity as a feature of disease. We have 
previously performed WES of longitudinal MGUS/SMM to MM patients, identifying 
clonal heterogeneity throughout all stages of disease, with progression being characterised 
by a model of clonal stability. Here, genomic analysis of a subset of these paired patient 
samples has revealed new insights into the transcriptomic and methylomic landscape 
associated with disease progression to MM. By using matched samples, we were able to 
negate any intrinsic inter-patient differences to determine the gene expression patterns 
between MGUS/SMM and MM, and methylation changes that accompany the transition of 
NPCs through to MGUS/SMM and MM. 
Overall, we found minimal variation in the expression of genes associated with the 
progression of MGUS/SMM to MM. PCA of the transcriptome of each individual patient 
clustered very closely between the MGUS/SMM and MM stages. This highlights the 
limitation of previous studies using unmatched patient sample comparisons to identify 
common gene expression changes associated with MGUS/SMM to MM transition. We 
found 250 genes that were reaching significance in differential expression testing (raw p < 
0.05), with a majority being downregulated upon MM transition. Due to the rare nature and 
small sample size of our matched cohort, gene expression changes did not reach statistical 
significance. Similarly, previous gene expression profiles of unmatched MGUS/MM 
samples have noted that MGUS can be clearly defined from NPCs, however, MGUS and 
MM samples appear to be identical at the gene expression level20,34,36,40.  Pathway analysis 
identified changes in gene expression associated with molecular processes such as 
angiogenesis41,42, Wnt signalling43,44 and cadherin signalling45,46, which are 
characteristically deregulated during MM disease progression. These pilot studies into the 
transcriptomic landscape associated with MGUS/SMM to MM progression have revealed 
an indication of the genes and pathways that are deregulated in the longitudinal 
progression to MM, and highlights the need for further, larger paired cohort studies to 
validate key changes associated with MM progression. 
Patient-by-patient analysis revealed that a number of the top 10 differentially 
expressed genes consistently exhibited at least a fold change in expression in more than 
half of the patients. THEMIS2 showed fold increase in one MGUS to MM, and two SMM 
to MM patients, and a recent study characterising its function has found that its 
overexpression results in enhanced downstream activation of MAPK kinases suggesting an 
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increase in the RAS signalling pathway47. HBB exhibited fold decrease in two MGUS to 
MM, and two SMM to MM patients and its level of expression in breast and prostate 
cancer cells has previously been correlated with adverse clinical outcomes48. CD69 was 
identified to exclusively show at least a one-fold decrease in all SMM to MM patients. 
Previous in vitro and patient data has shown that the absence, or decrease in CD69 
expression, is linked with poor prognosis and resistance to the proteasome inhibitor 
bortezomib, and thus may guide clinical therapeutic choices for these specific SMM 
patients49. Indeed, the median time to progression of SMM patients in this cohort was ~1 
year, indicating their high-risk nature and poor prognosis. 
We then sought to characterise the DNA methylation profile associated with the 
progression of MGUS/SMM to MM. Our data is partially concordant with the current 
understanding of the MM methylome during progression. To this end, previous unpaired 
studies comparing MGUS, SMM, MM or PCL samples with NPCs showed that extensive 
hypomethylation was an important early event in disease progression. The transformation 
from MGUS to MM was characterised by global hypomethylation18-20, and this was 
associated with altered chromatin structure, changes in DNA methyltransferase activity, 
loss of imprinting and increased frequencies of CNVs19. The resulting aberrant 
transcription and chromosomal instability within PC clones was postulated to contribute to 
disease progression, and is one of the critical differences distinguishing MGUS from 
MM19.  
Notably however, while these previous studies showed progressive 
hypomethylation upon MM transition, we revealed minimal variation in the methylation 
profiles of patients at the asymptomatic stages of MGUS or SMM, compared to MM. 
Moreover, the initiation of MGUS was characterized by extreme hypomethylation, a 
phenotype that was maintained with progression to SMM and MM. By contrast, one 
previous study used methylation data to clearly distinguish disease stages, where MGUS 
was defined by predominant hypomethylation and the later MM stage by acquired 
hypermethylation20. It is conceivable that global hypomethylation identified at MGUS, 
maybe relates to the need for proliferating oncogenic PCs to have open chromatin and 
active gene transcription which could facilitate the MM transformation process18,19. The 
initial investigation of the MM methylome showed increasing global hypomethylation with 
disease stages, and therefore proposed that the overall degree of methylation may have 
prognostic value18. However, our analysis shows that this may not be beneficial for 
patients that progress in a short time frame, where the levels of hypomethylation acquired 
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at MGUS is maintained during disease progression. The differences between the present 
study and previously reported findings may relate to sample dilution from non-tumour 
cells, as these previous studies have relied on CD138+ magnetic-activated cell sorting 
(MACS) sorting only. In contrast, we have used FACS to purify the CD138+ and 38++ 
tumour PC populations from MGUS/SMM/MM BM samples, to minimise any sample 
heterogeneity. 
It is possible that only subtypes of MM exhibit hypermethylation, and indeed 
heterogeneity in methylation has been shown for different cytogenetic groups of MM17,19. 
Studies of other cancer types have shown the association of hypermethylation with 
treatment resistance, via the inactivation of various cell cycles and genes involved in 
chemo-sensitivity. As such, in these patients, DNA demethylating agents could be 
proposed to be effective in reducing the methylation levels in tumour cells to levels 
comparable to normal non-tumour cells. In vitro studies in human MM cell lines have 
shown that DNA methylase inhibitor decitabine (5-aza-2-deoxycytidine) can inhibit 
proliferation; with a hypomethylating effect in hypermethylated MM without any adverse 
affects20. However, as our study, along with others, show that hypomethylation is 
maintained, or increased, with disease progression, the use of DNA methylase inhibitors 
would only be effective in hypermethylated subgroups of MM17-20.  
We assessed recurrently mutated genes in MM, finding that most mutated genes of 
MM have low or no expression in MM PCs, and in the instance where genes were 
expressed, this was generally associated with the occurrence of differential allelic 
expression. Differential and limited expression of mutant alleles has also been previously 
shown in a larger set of MM patient samples (n = 10 patients, 14 samples) analysed by 
RNAseq14. Notably, this would have significant implications when considering the use of 
targeted treatment strategies, which are solely based on driver mutations status revealed by 
genetic sequencing data only.  
In conclusion, our studies reveal new insights into the gene expression and 
methylation patterns associated with the progression of MGUS/SMM to MM. 
Interestingly, PCs from patients at the asymptomatic stages of disease, appear to be as 
genetically complex as PCs recovered from the MM stage. Further, exhibiting minimal 
variation in gene expression, with wild type allele specific expression of mutants, and 
significant hypomethylation that is acquired at MGUS/SMM. These studies highlight the 
importance of transcriptomic and epigenetic interrogation of patient PCs to inform 
prognosis and treatment stratification. 
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3.6 Supplementary  























Supplementary Table 1. Clinical cytogenetic data for MGUS/SMM to MM patients 
with RNAseq. Clinically recorded data at MM diagnosis for patients in the study. The 
median age of patients at MM diagnosis was 79.5 years old. Molecular cytogenetics of 
patients was performed using FISH analysis on interphase spreads of bone marrow 
smears. Nil represents parameter not being present. N/A represents that data was not 
available. 
 
Supplementary Table 2. Clinical cytogenetic data for MGUS/SMM to MM patients 
with WGBS. Clinically recorded data at MM diagnosis for patients in the study. 
Molecular cytogenetics of patients was performed using FISH analysis on interphase 
spreads of bone marrow smears. Nil represents parameter not being present. N/A 




Genes Symbol logFC logCPM LR p Value FDR 
ENSG00000130812 ANGPTL6 5.59773003 0.362576511 4.608683591 0.031810444 1 
ENSG00000213657 RPL31P44 5.094653224 0.264262573 5.020705009 0.025045969 1 
ENSG00000213901 SLC23A3 4.565223007 1.092082408 8.327880903 0.003904117 1 
ENSG00000260396 NA 4.521783271 0.628406087 4.687573004 0.030381531 1 
ENSG00000129173 E2F8 4.446364925 1.697791267 7.381120584 0.006591209 1 
ENSG00000143228 NUF2 4.081469523 1.265613637 5.107143182 0.023827524 1 
ENSG00000265218 ENSG00000265218 3.873487561 0.535305572 7.097647153 0.007718521 1 
ENSG00000106070 GRB10 3.760016403 1.625397912 4.071128404 0.043622125 1 
ENSG00000263033 ENSG00000263033 3.739649174 0.596568017 4.078834776 0.043423594 1 
ENSG00000105374 NKG7 3.716842278 5.504708007 6.441167048 0.011150537 1 
ENSG00000258891 ENSG00000258891 3.073077177 1.121849217 5.350413476 0.020717357 1 
ENSG00000235560 ENSG00000235560 3.070651553 1.06236116 4.209655004 0.040194511 1 
ENSG00000252061 RNU6-415P 3.056835205 1.836723997 4.39496998 0.036045094 1 
ENSG00000155254 MARVELD1 3.009516417 3.53762875 3.985138022 0.04590334 1 
ENSG00000267554 ENSG00000267554 2.981053864 1.546698827 5.247137875 0.021982901 1 
ENSG00000237765 FAM200B 2.740824089 1.478501314 6.894846179 0.00864446 1 
ENSG00000206650 SNORA70G 2.682573707 1.007744817 4.615122446 0.031691233 1 
ENSG00000170190 SLC16A5 2.659007198 2.659935649 6.23907012 0.012496207 1 
ENSG00000100453 GZMB 2.636159743 4.329505166 5.549395363 0.018487072 1 
ENSG00000222009 BTBD19 2.515115933 3.8061088 12.30553519 0.000451617 1 
ENSG00000260417 ENSG00000260417 2.480131459 1.246217355 5.240923471 0.02206156 1 
ENSG00000154920 EME1 2.440482556 1.915432918 4.140957832 0.041857479 1 
ENSG00000099985 OSM 2.417570983 1.494434748 4.537262615 0.033164587 1 
ENSG00000260274 ENSG00000260274 2.404916132 1.056828284 4.604203654 0.031893663 1 
ENSG00000221886 ZBED8 2.373231786 0.776523997 4.049509159 0.04418419 1 
ENSG00000163251 FZD5 2.248344449 1.852410979 4.883267943 0.02711823 1 
ENSG00000259781 HMGB1P6 2.192382482 1.871208518 4.073790972 0.043553424 1 
ENSG00000260006 NA 2.182465038 2.846382402 7.682994347 0.00557436 1 
ENSG00000241634 ENSG00000241634 2.155798765 4.074640484 5.202191131 0.022558435 1 
ENSG00000186642 PDE2A 2.155159979 1.468172633 4.501825758 0.033858684 1 
ENSG00000170160 CCDC144A 2.150131996 5.618496323 4.0111624 0.045199978 1 
ENSG00000140379 BCL2A1 2.004935153 3.53176948 5.880745842 0.015307336 1 
ENSG00000162073 PAQR4 1.967387502 2.606875637 5.657893393 0.017376982 1 
ENSG00000135378 PRRG4 1.909978623 2.521457866 5.227194951 0.022236365 1 
ENSG00000272016 NA 1.862981329 3.074052598 5.34304043 0.020805156 1 
ENSG00000156831 NSMCE2 1.831393241 3.154126284 4.576160522 0.032419779 1 
ENSG00000204519 ZNF551 1.760167606 3.45577717 5.967170679 0.014574647 1 
ENSG00000163521 GLB1L 1.755546949 2.910539378 4.0918879 0.043089487 1 
ENSG00000007384 RHBDF1 1.746786161 2.44065237 4.325874782 0.037537115 1 
ENSG00000247596 TWF2 1.673407196 3.560156351 8.723244961 0.003141784 1 
ENSG00000166592 RRAD 1.527594213 3.200898839 4.216526071 0.040032041 1 
ENSG00000185158 LRRC37B 1.526029938 3.309693689 3.865427699 0.049290629 1 
ENSG00000106991 ENG 1.525475514 3.827272591 4.378246705 0.036400422 1 
ENSG00000261474 ENSG00000261474 1.455249643 2.056027838 4.918104082 0.026576667 1 
ENSG00000141441 GAREM1 1.393411092 3.697500714 4.92204574 0.026516101 1 
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ENSG00000260065 NA 1.386707083 3.276824785 5.688229197 0.017079081 1 
ENSG00000168528 SERINC2 1.385178092 3.111496391 6.492203687 0.010834858 1 
ENSG00000059915 PSD 1.348355238 3.204416065 6.328145739 0.01188365 1 
ENSG00000159674 SPON2 1.285530958 5.196369142 5.338024476 0.020865106 1 
ENSG00000151725 CENPU 1.282862563 3.111251171 5.498284358 0.01903514 1 
ENSG00000167984 NLRC3 1.264543285 4.027507446 4.254748556 0.039140742 1 
ENSG00000166886 NAB2 1.258994642 4.239620787 8.042922978 0.004568177 1 
ENSG00000234925 ATP5HP4 1.246794796 3.153536453 4.93436922 0.02632767 1 
ENSG00000257242 LINC01619 1.231701382 4.052566143 5.499565064 0.019021204 1 
ENSG00000116514 RNF19B 1.19590434 4.648284417 4.561813684 0.032692435 1 
ENSG00000090339 ICAM1 1.166667393 6.699785553 8.281076687 0.004006037 1 
ENSG00000119403 PHF19 1.166257851 4.526416958 5.184712214 0.022786446 1 
ENSG00000184207 PGP 1.156251989 3.901283167 6.00182375 0.014291098 1 
ENSG00000128039 SRD5A3 1.117616883 3.706187836 4.946065234 0.02615012 1 
ENSG00000146757 ZNF92 1.078053681 3.869228731 3.978004628 0.046098141 1 
ENSG00000168826 ZBTB49 1.075403941 3.391477533 4.684985801 0.030427315 1 
ENSG00000162702 ZNF281 1.073593106 4.122926474 4.060181582 0.043905778 1 
ENSG00000130775 THEMIS2 1.031872191 8.13617753 13.82926278 0.000200194 1 
ENSG00000186594 MIR22HG 1.01283964 5.569450039 5.422431079 0.019879661 1 
ENSG00000197872 FAM49A 0.989629942 5.548124839 6.445291446 0.011124679 1 
ENSG00000162971 TYW5 0.987417058 3.909111358 4.529033559 0.033324432 1 
ENSG00000101445 PPP1R16B 0.966767518 6.03598865 5.766007181 0.016339117 1 
ENSG00000243317 C7orf73 0.95172681 3.841854925 3.879552073 0.048877596 1 
ENSG00000167553 TUBA1C 0.936073097 5.003187147 5.050792863 0.024614672 1 
ENSG00000181467 RAP2B 0.921544818 5.541995314 5.001715988 0.025322201 1 
ENSG00000182541 LIMK2 0.920040786 4.832437155 7.964049997 0.004771553 1 
ENSG00000120063 GNA13 0.916721676 6.574926601 6.542520044 0.010532605 1 
ENSG00000173846 PLK3 0.907355807 6.309176292 4.112954779 0.042555951 1 
ENSG00000158019 BABAM2 0.903782247 4.189787631 3.982641709 0.045971411 1 
ENSG00000263244 ENSG00000263244 0.900103969 6.521734646 6.898919526 0.008624786 1 
ENSG00000183696 UPP1 0.889747433 5.174400937 4.082448513 0.043330825 1 
ENSG00000146112 PPP1R18 0.888695895 6.8322549 6.785610064 0.009189562 1 
ENSG00000168389 MFSD2A 0.879138461 4.60020596 4.429007589 0.035333046 1 
ENSG00000189159 JPT1 0.868240646 3.708887728 3.947055711 0.046953452 1 
ENSG00000144136 SLC20A1 0.866610591 5.816218597 8.720482028 0.003146548 1 
ENSG00000020633 RUNX3 0.861212016 6.69306518 4.587644364 0.032203244 1 
ENSG00000176890 TYMS 0.859750802 4.180663644 4.183890505 0.040809917 1 
ENSG00000164615 CAMLG 0.850187442 4.15655429 4.45490277 0.034801197 1 
ENSG00000160856 FCRL3 0.846897549 4.962550147 4.286441355 0.038417496 1 
ENSG00000101365 IDH3B 0.844103263 5.61575824 8.28705444 0.00399287 1 
ENSG00000117632 STMN1 0.84105229 5.068401108 4.853227979 0.027594445 1 
ENSG00000117614 SYF2 0.814464041 5.01080814 5.441791499 0.019660494 1 
ENSG00000054967 RELT 0.802782033 5.92571288 5.781929724 0.016191755 1 
ENSG00000127554 GFER 0.76586362 4.115137122 4.23856659 0.039515516 1 
ENSG00000059728 MXD1 0.765267415 5.689713318 5.31367617 0.021158664 1 
ENSG00000034152 MAP2K3 0.763509686 6.072777207 4.411075166 0.03570633 1 
ENSG00000137193 PIM1 0.761691184 7.842099377 5.882592484 0.015291291 1 
ENSG00000196950 SLC39A10 0.755886339 4.83105715 5.424983591 0.019850622 1 
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ENSG00000070495 JMJD6 0.739648438 5.476770449 5.88673918 0.015255323 1 
ENSG00000167470 MIDN 0.734117142 7.010780925 4.042867302 0.044358394 1 
ENSG00000141543 EIF4A3 0.726748769 5.724494984 7.651092656 0.005673795 1 
ENSG00000101558 VAPA 0.719601535 6.034219757 4.875957239 0.027233332 1 
ENSG00000080371 RAB21 0.717771907 5.256629701 4.79632292 0.028520546 1 
ENSG00000154358 OBSCN 0.703502616 6.306876813 4.189430232 0.040676766 1 
ENSG00000115685 PPP1R7 0.694582031 4.98493528 4.145528404 0.041744625 1 
ENSG00000117868 ESYT2 0.691788109 6.316277694 4.830224389 0.027964991 1 
ENSG00000175376 EIF1AD 0.690428953 5.80840658 4.67764417 0.030557627 1 
ENSG00000164081 TEX264 0.680190517 5.386480396 4.023427237 0.04487244 1 
ENSG00000165609 NUDT5 0.668390669 4.713849585 4.253822407 0.039162091 1 
ENSG00000171222 SCAND1 0.634605978 5.725477751 3.934479473 0.047305778 1 
ENSG00000162413 KLHL21 0.616725409 6.014719633 4.190839969 0.040642955 1 
ENSG00000135801 TAF5L 0.597008775 4.824529436 4.392673775 0.036093667 1 
ENSG00000100664 EIF5 0.553810713 8.644360299 3.870303916 0.049147621 1 






































Genes Symbol logFC logCPM LR p Value FDR 
ENSG00000272140 ENSG00000272140 -5.952498835 1.885835518 5.287043455 0.021484665 1 
ENSG00000225796 MTND4P23 -5.908020984 0.736226569 6.320774208 0.011933152 1 
ENSG00000270878 ENSG00000270878 -5.581537232 0.2483212 7.761508681 0.005337136 1 
ENSG00000197385 ZNF860 -5.46259309 2.017194426 5.232892022 0.022163651 1 
ENSG00000228171 ENSG00000228171 -5.210151138 1.091689302 3.928802477 0.047465733 1 
ENSG00000223648 IGHV3-64 -5.092070201 3.39540472 5.641912445 0.017536069 1 
ENSG00000189366 ALG1L -5.022309004 0.473919404 8.507505761 0.003536845 1 
ENSG00000198785 GRIN3A -4.984021898 0.633707833 3.894154205 0.048454431 1 
ENSG00000128606 LRRC17 -4.919132696 0.909072344 4.364904446 0.036686541 1 
ENSG00000211950 IGHV1-24 -4.917608925 2.272410422 17.50352622 2.87E-05 0.422420029 
ENSG00000269305 NA -4.914212362 0.62749366 7.351700971 0.006699934 1 
ENSG00000260423 LINC02367 -4.776349445 0.732204719 5.297240222 0.02135924 1 
ENSG00000207770 NA -4.751101012 0.814754393 5.426290494 0.019835771 1 
ENSG00000250327 RPSAP70 -4.729113515 0.713329432 4.116640882 0.042463314 1 
ENSG00000163554 SPTA1 -4.615834282 1.751636027 3.991562758 0.045728633 1 
ENSG00000234840 LINC01239 -4.581231634 2.56883438 4.638841538 0.031256095 1 
ENSG00000211938 IGHV3-7 -4.571456261 2.984870593 5.843946071 0.015630733 1 
ENSG00000234536 NA -4.438132327 0.63957825 4.302819958 0.038049233 1 
ENSG00000171084 FAM86JP -4.433154584 1.011104527 4.404055325 0.035853577 1 
ENSG00000211659 IGLV3-25 -4.358518469 2.36349412 5.785031476 0.016163208 1 
ENSG00000238061 ENSG00000238061 -4.335698786 0.691866138 5.675683214 0.01720164 1 
ENSG00000164695 CHMP4C -4.188786663 1.444276807 6.964395709 0.008314751 1 
ENSG00000269578 ENSG00000269578 -4.094618848 0.444702767 4.712863376 0.029937747 1 
ENSG00000234709 UPF3AP3 -3.73491562 0.334353817 4.018241914 0.04501061 1 
ENSG00000225151 GOLGA2P7 -3.724560156 0.832866737 4.660441203 0.030865259 1 
ENSG00000118402 ELOVL4 -3.687809517 1.523571922 5.477522507 0.019262541 1 
ENSG00000151304 SRFBP1 -3.649866163 2.075693602 3.916218546 0.047822335 1 
ENSG00000198711 SSBP3-AS1 -3.586417747 0.793069981 6.21147422 0.012692489 1 
ENSG00000223599 ENSG00000223599 -3.516669336 0.987193931 4.541262318 0.033087184 1 
ENSG00000080224 EPHA6 -3.449710341 1.725517255 5.625815801 0.017697827 1 
ENSG00000184984 CHRM5 -3.440548036 0.948070667 4.524186708 0.033418956 1 
ENSG00000219470 ENSG00000219470 -3.433551561 0.033822024 6.071087439 0.013741234 1 
ENSG00000198513 ATL1 -3.417146908 1.46065116 4.805097119 0.028375667 1 
ENSG00000113966 ARL6 -3.369941472 1.054492685 5.224853904 0.022266317 1 
ENSG00000232233 LINC02043 -3.2854874 1.582357566 4.926557736 0.026446949 1 
ENSG00000143858 SYT2 -3.097979752 0.884021841 4.237430372 0.039541972 1 
ENSG00000226002 GTF2IP14 -2.959822123 0.960959013 3.963487913 0.046497265 1 
ENSG00000211956 IGHV4-34 -2.934554149 2.352190274 5.336977647 0.02087764 1 
ENSG00000134297 PLEKHA8P1 -2.88388571 0.519689112 5.574769694 0.018221061 1 
ENSG00000153558 FBXL2 -2.86762063 1.256166107 5.104906608 0.023858263 1 
ENSG00000125869 LAMP5 -2.866917217 6.334825109 5.148179659 0.023270756 1 
ENSG00000244734 HBB -2.82839705 3.951500023 11.63621708 0.0006468 1 
ENSG00000211949 IGHV3-23 -2.80124484 4.287558188 6.601742862 0.0101879 1 
ENSG00000160791 CCR5 -2.750873225 2.119348898 7.094637499 0.007731493 1 
ENSG00000139160 ETFBKMT -2.717965905 2.168615593 4.131744811 0.042085937 1 
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ENSG00000132932 ATP8A2 -2.697925 4.537678402 9.836896781 0.001710458 1 
ENSG00000112782 CLIC5 -2.685038654 2.891668225 4.655566046 0.030953025 1 
ENSG00000246273 SBF2-AS1 -2.618815409 1.189189091 3.903858138 0.048175355 1 
ENSG00000117322 CR2 -2.583033599 1.16451107 4.834473741 0.027896154 1 
ENSG00000226549 SCDP1 -2.580823945 3.337616185 4.273558498 0.038709784 1 
ENSG00000169403 PTAFR -2.579930264 5.550437296 3.868643752 0.049196261 1 
ENSG00000211898 IGHD -2.556609483 4.070314768 4.19429458 0.040560225 1 
ENSG00000110848 CD69 -2.529781658 4.358278124 8.829270831 0.002964368 1 
ENSG00000064989 CALCRL -2.525758131 3.393464976 6.963530368 0.008318773 1 
ENSG00000160539 PLPP7 -2.495545958 2.259401839 4.94660077 0.02614202 1 
ENSG00000176125 UFSP1 -2.474866362 1.347517488 5.89234079 0.015206874 1 
ENSG00000241527 CA15P1 -2.467551177 1.863774615 5.41572513 0.019956163 1 
ENSG00000167693 NXN -2.43453088 2.050326983 3.898570389 0.048327215 1 
ENSG00000233695 GAS6-AS1 -2.39540206 1.987592662 4.835110074 0.027885861 1 
ENSG00000211651 IGLV1-44 -2.377708208 3.584987505 6.526161559 0.010629911 1 
ENSG00000188191 PRKAR1B -2.343549651 3.283215504 4.073781691 0.043553663 1 
ENSG00000163794 UCN -2.329110748 1.570406646 4.165018154 0.041266971 1 
ENSG00000243466 IGKV1-5 -2.31385205 4.439275156 5.002730249 0.025307367 1 
ENSG00000233806 LINC01237 -2.266151637 2.800753973 7.932544317 0.004855348 1 
ENSG00000211959 IGHV4-39 -2.260361407 6.90392344 4.009818725 0.045236014 1 
ENSG00000075275 CELSR1 -2.25479695 4.71732946 9.620450668 0.001924225 1 
ENSG00000153140 CETN3 -2.245813645 2.306627964 3.865332661 0.049293421 1 
ENSG00000250654 ENSG00000250654 -2.236569125 1.392633527 4.098230781 0.042928112 1 
ENSG00000198477 NA -2.232627109 2.130492298 4.054868732 0.044044143 1 
ENSG00000144908 ALDH1L1 -2.1930315 3.714049151 5.570093796 0.018269782 1 
ENSG00000012124 CD22 -2.169659144 3.864959183 3.963126129 0.046507258 1 
ENSG00000268041 ENSG00000268041 -2.125264856 2.659605612 4.797994676 0.028492883 1 
ENSG00000163520 FBLN2 -2.097246847 4.926336827 7.543944366 0.006021209 1 
ENSG00000168916 ZNF608 -2.091355427 3.522837759 4.660715459 0.03086033 1 
ENSG00000187870 RNFT1P3 -2.040096722 4.557979814 4.659198899 0.0308876 1 
ENSG00000241127 YAE1D1 -1.928511982 1.832404908 4.510552852 0.033686351 1 
ENSG00000110811 P3H3 -1.89152959 4.39257172 5.69200071 0.017042414 1 
ENSG00000204248 COL11A2 -1.879514501 3.007209998 4.477083642 0.034352292 1 
ENSG00000199568 RNU5A-1 -1.818473095 4.106512986 4.811932394 0.028263335 1 
ENSG00000163126 ANKRD23 -1.786419112 2.824102778 4.650998986 0.031035481 1 
ENSG00000259712 ENSG00000259712 -1.786291136 1.458067007 3.994183505 0.045657569 1 
ENSG00000154553 PDLIM3 -1.769447687 3.872653354 5.793752614 0.016083222 1 
ENSG00000214456 PLIN5 -1.760757379 2.274869889 5.125223195 0.023580538 1 
ENSG00000129282 NA -1.746849353 2.377494774 3.943638971 0.047048898 1 
ENSG00000248996 ENSG00000248996 -1.741823284 1.637791611 4.009452404 0.045245844 1 
ENSG00000148926 ADM -1.71153944 5.917847554 4.422795963 0.035461884 1 
ENSG00000137338 PGBD1 -1.697145114 2.579139013 4.132971321 0.042055447 1 
ENSG00000112379 ARFGEF3 -1.676225349 4.610654505 6.034009692 0.014032821 1 
ENSG00000122778 KIAA1549 -1.667278508 2.968993317 4.058820985 0.043941169 1 
ENSG00000211662 IGLV3-21 -1.645088037 12.25352334 6.628454926 0.010036228 1 
ENSG00000211666 IGLV2-14 -1.639183161 5.650023863 4.122668158 0.042312295 1 
ENSG00000240041 IGHJ4 -1.576767407 3.325330077 4.498448639 0.033925619 1 
ENSG00000203814 HIST2H2BF -1.546617402 3.514633843 6.560335342 0.010427671 1 
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ENSG00000149403 GRIK4 -1.507817066 5.201427158 6.612655837 0.010125654 1 
ENSG00000117407 ARTN -1.467584203 3.847478148 5.411262018 0.020007247 1 
ENSG00000262943 ALOX12P2 -1.353814106 3.184684189 4.006832188 0.045316219 1 
ENSG00000211892 IGHG4 -1.350690295 8.517813894 5.960853562 0.014626958 1 
ENSG00000161277 THAP8 -1.340221363 2.349664214 4.321048402 0.037643723 1 
ENSG00000237638 LINC02245 -1.328971929 3.629445924 3.85837259 0.049498318 1 
ENSG00000179909 ZNF154 -1.318921941 4.240688648 4.534494647 0.033218263 1 
ENSG00000155189 AGPAT5 -1.303248593 3.200331411 4.745309845 0.029378263 1 
ENSG00000215424 MCM3AP-AS1 -1.260328798 3.25277696 4.680153558 0.030513021 1 
ENSG00000203772 SPRN -1.258429576 3.103016704 4.191139008 0.040635787 1 
ENSG00000237940 LINC01238 -1.251744801 3.328418042 5.394611304 0.020199024 1 
ENSG00000211677 IGLC2 -1.234687676 7.751354291 5.513697877 0.018868114 1 
ENSG00000187824 TMEM220 -1.215489622 2.624393088 3.930592401 0.047415239 1 
ENSG00000048162 NOP16 -1.193773706 3.834441305 5.83191734 0.015737962 1 
ENSG00000133740 E2F5 -1.139307269 4.515135523 7.838967665 0.00511318 1 
ENSG00000139737 SLAIN1 -1.133077728 3.420055415 3.944186446 0.047033591 1 
ENSG00000092096 SLC22A17 -1.115029514 6.028606206 8.132447627 0.004348001 1 
ENSG00000163534 FCRL1 -1.107910974 5.283049201 4.34092371 0.037206732 1 
ENSG00000213398 LCAT -1.099954761 4.585586113 4.12000928 0.042378846 1 
ENSG00000171444 MCC -1.069469943 7.31792472 4.210730196 0.040169042 1 
ENSG00000100154 TTC28 -1.049628994 4.863663331 4.20191939 0.040378252 1 
ENSG00000171044 XKR6 -0.995645929 3.073036969 4.03918769 0.044455215 1 
ENSG00000196562 SULF2 -0.947931233 8.515725284 7.248259759 0.007096976 1 
ENSG00000162600 OMA1 -0.930762683 4.266898095 4.041425761 0.044396299 1 
ENSG00000238164 TNFRSF14-AS1 -0.927582561 4.494708225 3.847726469 0.049813471 1 
ENSG00000253797 UTP14C -0.898538735 3.287708227 4.121031254 0.042353253 1 
ENSG00000134809 TIMM10 -0.895119223 3.479561631 4.429104376 0.035331043 1 
ENSG00000138074 SLC5A6 -0.887615885 5.432692276 6.140326571 0.013213291 1 
ENSG00000137936 BCAR3 -0.858841419 5.156230483 4.593684495 0.03208996 1 
ENSG00000197798 FAM118B -0.846777058 3.497312751 4.041443968 0.04439582 1 
ENSG00000103995 CEP152 -0.845395614 4.477584202 4.677824302 0.030554423 1 
ENSG00000144827 ABHD10 -0.833234171 3.807547552 4.119629316 0.042388365 1 
ENSG00000145088 EAF2 -0.819394884 6.300140577 3.908097283 0.048053974 1 
ENSG00000079950 STX7 -0.770904878 4.936922778 4.870972328 0.027312107 1 
ENSG00000133874 RNF122 -0.747238275 5.776211338 4.516240757 0.033574526 1 
ENSG00000178425 NT5DC1 -0.747028468 4.223160216 4.715964134 0.029883803 1 
ENSG00000117226 GBP3 -0.724020218 4.689972501 4.44398236 0.035024458 1 
ENSG00000130396 AFDN -0.718105402 5.424790542 5.339377681 0.020848915 1 
ENSG00000068654 POLR1A -0.684453578 5.947250436 5.051632511 0.024602748 1 
ENSG00000140563 MCTP2 -0.67325732 6.05901058 5.013957439 0.025143766 1 
ENSG00000066933 MYO9A -0.663896209 5.142943611 4.156665878 0.041470961 1 
ENSG00000168421 RHOH -0.663137789 6.988708035 3.875009239 0.04901004 1 
ENSG00000001631 KRIT1 -0.661329675 5.512385589 5.446314854 0.019609649 1 
ENSG00000196914 ARHGEF12 -0.648104834 6.891782884 4.749061265 0.029314282 1 
ENSG00000178764 ZHX2 -0.624249954 6.05272826 3.871665269 0.049107774 1 
ENSG00000125746 EML2 -0.608988324 6.011431403 4.617960034 0.031638845 1 
ENSG00000117899 MESD -0.551249111 5.772087115 4.043527302 0.044341051 1 
ENSG00000197943 PLCG2 -0.528799517 8.013474191 5.117448066 0.023686425 1 
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Supplementary Table 3. List of differentially expressed genes associated with MM 
progression. Differential gene expression testing between MGUS/SMM and MM groups, 
identified 250 genes approaching statistical significance (i.e. raw p < 0.05, before 
controlling the false discovery rate using the Benjamini Hochberg method29). There were 
(a) 109 genes upregulated, and (b) 141 genes downregulated upon progression to MM. NA 





















Supplementary Table 4. Normalised gene expression (FPKM) of genes differentially 
expressed at MM transition. There were 10 top differentially expressed genes, based on 
fold change and frequency, upon MM transition showing fold increase (THEMIS2, 
BTBD19, TWF2, SLC20A1 and SLC23A3) or fold decrease (HBB, ATP8A2, CELSR1, CD69 





Supplementary Figure 1. Dysregulation of biological pathways associated with 
differentially expressed genes identified between MGUS/SMM to MM. Pathway 
analysis revealed gene expression signatures associated with the transition of MGUS/SMM 
to MM. There were 196 differentially expressed genes mapped, with their deregulation 
affecting 69 biological pathways. Pathways associated with genes that were highly up 














Supplementary	 Figure	2.	The relationship in methylation landscape in normal PCs 
versus MGUS, SMM and MM stages. XY scatterplots illustrate great variation in the 
methylation pattern between normal and disease stages of (A) MGUS, (B) SMM and (C) 
MM, with a skewing towards greater methylation observed in NPC. The median R2 value 
was 0.36, demonstrating heterogeneity in CpG methylation between stage specific 
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Multiple myeloma (MM) is a largely incurable haematological malignancy characterised 
by the clonal proliferation of antibody secreting plasma cells (PCs) within the bone 
marrow. Increasingly, research has focused on the identification of key genetic mutations 
that underlie disease transformation from MGUS/SMM to MM. However to date, no single 
gene mutation, or combination of mutations, have been identified as being common to all 
MM patients at presentation1. Multiple large cohort genomic studies of MM patients have 
been carried out finding SP140 to be recurrently mutated in ~3-12% of patients. However, 
the precise role of mutated SP140 in MM development is unknown. Here, we demonstrate 
evidence of RNA editing of Sp140 in the murine MM PC line, 5TGM1. RNA-specific 
nucleotide variants were identified in exon 2, including c.166 C>T (i.e. U) non-
synonymous variant; and c.180 G>A synonymous variant. Screening of multiple non-PC 
murine cell lines determined that these editing changes were not a PC-specific 
phenomenon. Despite Sp140 exon 2 sequence being conserved at c.166 in the human 
genome, screening of human MM cell line cDNA revealed no evidence of RNA editing in 
SP140. In relation to 5TGM1 cells, the non-synonymous C>T (i.e. U) change at c.166 
predicted a STOP gain, prompting us to investigate whether the classical C>U deamination 
enzymes Apobec1 and Apobec3, were responsible for the RNA editing of Sp140. CRISPR-
Cas9 gene editing was used to generate a 5TGM1 cell line in which Apobec1 or Apobec3 
were knocked out. While Apobec1 and Apobec3 were efficiently knocked down in these 
cells, no consequent change in RNA editing of Sp140 phenotype was observed, suggesting 
other mechanisms are responsible for the RNA editing of Sp140. The discovery that RNA 
editing of Sp140 occurs in the 5TGM1 MM PC line warrants further exploration into the 
mechanisms that underlie this phenomenon, and suggests that RNA editing may influence 















Genomic studies of MM patient samples have demonstrated intraclonal heterogeneity as a 
feature of disease through MGUS, SMM and MM, suggesting that progression is 
characterised by the acquisition of key genetic mutations which confer a selective 
advantage to tumour cells2-5. Significantly mutated genes that were identified in these 
studies include KRAS, NRAS, BRAF, TP53, DIS3 and FAM46C, which are believed to be 
drivers of MM due to their recurrent nature2-5. Additionally, 28 novel candidate genes 
harbouring recurrent mutations associated with MM disease were also identified, including 
IRF4, CDK4, ROBO1, FAT3, EGR1, PEG3, LTB, TGDS, SNX7, RASA2, USP29, TRAF3, 
CYLD, RB1, CCND1, PNRC1, ALOX12B, HLA-A, MAGED1, PRDM1, ACTG1, MAPK, 
NF1, NFKBIA, CDKN2C, PTEN, NFKBI and SP1402,3,5. While many mutated genes have 
been identified to be associated with MM, few have been biologically interrogated for their 
causative roles in MM disease development.  
 
SP140 is a nuclear body protein involved in the antigen response of mature B 
cells2,6. Further investigation has revealed its function as a bromodomain and plant 
homeodomain containing epigenetic reader7, with single nucleotide variants (SNVs) in 
SP140 significantly associating with immune diseases such as Crohn’s disease8,9 and 
chronic lymphocytic leukaemia10. SNVs identified in SP140 resulted in aberrant mRNA 
transcription and reduced protein levels. Genomic studies of MM patients have found that 
SP140 is mutated in ~3-12% of patients, whose plasma cells (PCs) harbour a range of 
SP140 gene alterations including missense, nonsense, frameshift and splice site 
changes2,3,11,12. Two of these studies have suggested SP140 as a novel candidate tumour 
suppressor gene in MM, due to the significant frequency of inactivating mutations2,3. 
Moreover, Bolli et. al. showed that mutations in SP140 correlated with shorter relapse-free 
survival of MM patients2. 	
 
Murine models of human disease play an important role in the screening and 
characterisation of mutant candidate genes in both in vitro and in vivo preclinical settings. 
In MM, the most commonly used mouse MM PC line is 5TGM113. This well characterised 
cell line is amenable to genetic modification and can be used for both the in vitro and in 
vivo characterisation of the function of candidate genes of interest. The 5T MM models 
were originally identified in aging C57BL/KaLwRij mice that spontaneously developed 
benign B cell monoclonal proliferative disorders, which resembled human disease, 
including a monoclonal expansion of PCs within the bone marrow14. The 5TGM1 cell line 
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is a subclonal cell line of the 5T33 MM model13, a model which was developed by serial 
transplantation of bone marrow cells from aging C57BL/KaLwRij mice which displayed 
evidence of a serum monoclonal protein spike, into young recipients15. The 5TGM1-
C57BL/KaLwRij in vivo model is the main preclinical model of MM used in the laboratory 
as it replicates many of the features of human MM disease16-18. Genetically modified 
5TGM1 PCs are inoculated into 6-8 week old C57BL/KaLwRij mice, with subsequent 
effects on disease development monitored over a 4 week period. While MM is typically 
known as a single disease type in humans, recent genomic studies have demonstrated a 
marked genetic heterogeneity between patients, suggesting that MM is rather a collection 
of monoclonal gammopathies with different genetic subtypes which all share a common 
clinical phenotype19. As the 5TGM1 and C57BL/KaLwRij models are frequently used for 
in vitro and in vivo studies of MM, respectively, it would be advantageous to know which 
specific genetic subtype is being modelled in these studies for translatable outcomes in that 
patient group. 
 
RNA sequencing (RNAseq) has been used widely to examine gene expression, 
however, there are limited studies investigating variant detection. Mining transcriptome 
sequencing data of 5TGM1 MM PCs, we investigated the mutation status of mRNAs of 
genes that are recurrently mutated in MM patients. To this end, we found that Sp140 
mRNA harboured a high impact SNV mutation that induced a STOP gain in exon 2 (c.166 
C>T). Unexpectedly, validation studies of this SNV within 5TGM1 cells revealed the 
phenomenon of RNA editing, where the point mutation was identified in the screening of 
RNA but was not found in genomic DNA of 5TGM1 cells. 
 
Recent studies have shown that modifications at the transcriptomic level are linked 
with cancer20-22. Of particular interest, is the molecular mechanism of RNA editing, which 
is catalysed by two known editing enzyme families: apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide like (APOBECs) and adenosine deaminases acting on RNA 
(ADARs). To date, the association of cancer and editing changes have been reported in an 
A>I context by ADARs. ADAR editing enzymes have been implicated in hepatocellular 
carcinoma23, glioblastoma24, prostate cancer25, colorectal cancer26, non-small-cell lung 
cancer27, chronic myeloid leukaemia20 and MM22. Examples in liver and lung cancers have 
shown that overexpression of ADAR1 lead to recoding changes in AZIN1 that activates 
both the development and progression of disease, thus demonstrating the oncogenic 
potential of RNA editing enzymes23,27. Similarly, APOBECs are a class of cytidine 
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deaminases known to catalyse C>U RNA editing changes, where currently APOBEC1, 
APOBEC3A and APOBEC3G are known to cause recoding changes28. In this study, we 
identified a high impact C>T (ie. U) RNA editing change of Sp140, and hypothesized that 
Apobec family enzymes are the likely enzymatic candidates inducing this phenotype.  
 
As outlined in our Whole Exome Sequencing (WES) study of serial MGUS/SMM 
to MM patients in Chapter 2, we also found that SP140 mutations were newly acquired at 
MM in 30% of patients. In Chapter 3, which details our transcriptomic and methylomic 
analysis of serial MGUS/SMM to MM patients, we found that SP140 was expressed in 
tumour PCs but did not harbour any point mutations. Here, we investigated the extent of 
RNA editing of Sp140/SP140 in 6 murine (5TGM1, NIH-3T3, NS1, BA/F3, FDCP1 and 
RAW264.7) and 9 human MM cell lines (KMS-18, MM.1R, MM.1S, NCI-H929, RPMI 
8226, U266, JJN3, MOLP-8 and EJM) to determine the tissue specificity of this RNA 
editing event and its prevalence in human MM. Moreover, CRISPR-Cas9 gene editing was 
used to generate 5TGM1 cell lines in which Apobec1 or Apobec3 were knocked out, to 


















4.3 Materials & Methods 
4.3.1 Sequencing and analysis 
RNA sequencing of 5TGM1 cells was previously performed by Dr. K. Mrozik. Briefly, 
total cellular RNA was extracted from cells using 1mL TRIzol as per manufacturer’s 
instructions (Thermo Fisher Scientific). All RNA samples were dissolved in nuclease-free 
water (30µL). Yields and quality were assessed using the Qubit 2.0 fluorometer (Thermo 
Fisher Scientific) and 2200 Tapestation System (Agilent). The range of RIN scores of 
extracted RNA samples was 8.0 – 8.3. RNA libraries were generated using the TruSeq 
Stranded mRNA Sample Preparation Kit, using the LS (low sample) protocol according to 
manufacturers’ instructions (Illumina). Sequencing was carried out on the Illumina 
NextSeq500 (2x75 bp paired-end reads) with approximately 100 million reads per sample. 
 
Gene analysis was performed by Dr. C. Kok. Quality of raw RNA sequencing reads was 
assessed using the FastQC package (Babraham Bioinformatics). Sequencing reads were 
aligned to the mus musculus mm10 genome assembly using the Subread aligner package. 
Uniquely mapped reads were retained and the number of reads that mapped were counted 
using featureCounts. Transcripts were filtered from downstream analysis if they did not 
meet the threshold of at least 1 count per million mapped reads, in at least 2 samples. 
Reads counts per gene were converted to log2 counts per million (CPM) with the voom 
function of the limma package. Single nucleotide variants were called using the Genome 
Analysis Tool Kit (GATK) best practices pipeline (Broad Institute), and variant annotation 
was performed using ANNOVAR29. 
 
4.3.2 Cell culture 
4.3.2.1 Murine cell lines 
All cell culture media was supplemented with additives consisting of 2mM L-glutamine, 
1mM sodium pyruvate, 15mM HEPES, 50 U/mL penicillin and 50µg/mL streptomycin 
(Sigma-Aldrich). The 5TGM1 MM cell line was cultured in Iscove’s Modified Dulbecco’s 
Media (IMDM) supplemented with 20% fetal calf serum (FCS) and additives. NIH-3T3, 
NS1 and RAW264.7 cell lines were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FCS and additives. BA/F3 cells were cultured in 
Roswell Park Memorial Institute media (RPMI-1640) supplemented with 10% FCS, 
additives and 10% (v/v) conditioned media from the WEHI-3B cell line, as a source of IL-
3 (a gift from K. Asari of the SAHMRI Cancer Theme group). FDCP1 cells were cultured 
in DMEM supplemented with 10% FCS, additives and 10% (v/v) conditioned media of the 
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WEHI-3B cell line for IL-3. Cell cultures were maintained in humidified incubation 
chambers at 37°C with 5% CO2.  
 
4.3.2.2 Human MM cell lines 
All human cell lines were cultured in RPMI-1640 supplemented with 10% FCS, with the 
exception of the EJM cell line, which was cultured in IMDM supplemented with 10% 
FCS. Cell cultures were maintained in humidified incubator at 37°C with 5% CO2. 
 
4.3.3 Nucleic acids isolation 
4.3.3.1 DNA isolation 
Genomic DNA was extracted from cell lines using the DNeasy Blood & Tissue kit, 
according to the manufacturer’s instructions (QIAGEN). Quantity and quality of isolated 
DNA was determined using the Nanodrop 8000 Spectrophotometer (Thermo Fisher 
Scientific) and all samples were stored at -80°C until required. 
 
4.3.3.2 RNA isolation 
Total RNA was extracted from cell lines using TRIzol (Life Technologies). RNA yields 
and quality were assessed using the Nanodrop 8000 Spectrophotometer (Thermo Fisher 
Scientific) and all samples were stored at -80°C until required. 
 
4.3.4 Validation 
4.3.4.1 Confirming SNVs in 5TGM1 cell line 
cDNA (20µL) was generated from 1.5µg of total RNA extracted from 5TGM1 cells using 
SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific). Sp140 exon 2 was then 
PCR-amplified using Sp140RT-F: 5’- CCAGAGGACCAGAATGAAGAGG -3’ and 
Sp140RT-R: 5’- TCCCGGCTAAACTTCTTCTGT -3’ primers and 2µL cDNA with 
Phusion High-Fidelity DNA Polymerase (New England BioLabs), as per manufacturers’ 
instructions for 50µL total reaction volume, on a Veriti 96-Well Thermocycler (Applied 
Biosystems) for 35 cycles with 98°C denaturation, 60°C annealing and 72°C extension. 
The PCR product was resolved on a 2% agarose gel and subsequently excised, and purified 
using the Ultra Clean PCR Purification Kit (MoBio Laboratories) before direct Sanger 
sequencing using PCR primers (as above), at the Australian Genome Research Facility 
(AGRF Adelaide Node). 
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DNA was screened by direct purified PCR product screening, as described above with 
gDNA PCR primers designed to amplify Sp140 exon 2 (F: 5’- 
CCAGCCATTGGTAGCATCTTG -3’; R: 5’- GCTTGCTGTCAGGACTGAGT -3’). 
 
Same molecule analysis of tandem editing of RNA was validated by PCR product cloning 
and colony sequencing. Sp140 exon 2 was PCR amplified using cDNA primers, before 
adenylation using AmpliTaq Gold (Thermo Fisher Scientific). Amplicons were then 
ligated into the pGEM-T vector (Promega Corporation). JM109 competent cells were 
transformed and plated onto Luria broth with ampicilin agar plates for colony growth 
overnight at 37°C. Bacterial colonies (n = 10) were randomly selected, cultured overnight 
and then plasmid minipreps were carried out using alkaline lysis miniprep (QIAGEN). 
Double digest, using restriction enzymes NdeI and SacII, was used to confirm successful 
ligation of the exon 2 PCR product into the vector. Extracted DNA was quantitated on the 
Nanodrop 8000 (Thermo Fisher Scientific), prior to direct Sanger sequencing using T7 
forward and SP6 reverse vector primers at the Australian Genome Research Facility 
(AGRF Adelaide Node). 
 
DNA and RNA of Sp140 exon 7 was screened by direct purified PCR product screening, 
as described above in 4.3.4.1 Validation: Confirming SNVs in 5TGM1 cell line, with PCR 
primers designed to exon 7 gDNA (F: 5’- CAGGATGCCTCCCTTTCTCC -3’; R: 5’- 
GAAAGACCCACAGACGCTGT -3’) and cDNA (F: 5’- 
GGCCACAACTGGTCAAAACC -3’; R: 5’- GGTTCTTTTTCATCACTCCCTTCA -3’). 
 
4.3.5 Screening 
4.3.5.1 Murine cell lines 
Screening of Sp140 exon 2 changes were carried out on 6 mouse cell lines: 5TGM1, NIH-
3T3, NS1, BA/F3, FDCP1 and RAW264.7. Nucleic acids were isolated and quantitated as 
described above. RNA and DNA were screened by direct purified PCR product 
sequencing, using gDNA and cDNA PCR primers as described above in 4.3.4.1 
Validation: Confirming SNVs in 5TGM1 cell line.  
 
4.3.5.2 Human MM cell lines 
Screening of SP140 exon 2 changes was carried out on 9 human MM cell lines: KMS-18, 
MM.1R, MM.1S, NCI-H929, RPMI 8226, U266, JJN3, MOLP-8 and EJM. Nucleic acids 
were isolated and quantitated as described above. RNA was screened by direct purified 
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PCR product screening, as described using above in 4.3.4.1 Validation: Confirming SNVs 
in 5TGM1 cell line, with cDNA PCR primers (F: 5’- GGCAAGTGGAGACAGCAATC -
3’; R: 5’- CTTGTCACTGGGACCAGGTT -3’). 
 
4.3.6 Generation of Apobec1 sgRNA expression vectors  
Plasmid vector pSpCas9(BB)-2A-GFP (also known as px458) was a gift from Feng Zhang 
and was obtained from Addgene (plasmid #48138)30. The Cerulean2 reporter was 
amplified from the LeGO-iCer2 lentiviral vector (Addgene plasmid #27346, gift of Boris 
Fehse)31 and a T2A self-cleaving peptide sequence was also added using two rounds of 
hemi-nested PCR. An initial 30 cycles of PCR using T2A-Cer2-Forward (5’-
GTCGAGGAGAATCCTGGCCCAGTGAGCAAGGGCGAGGAGCTG-3’) and EcoRI-
TdT-Cer2-Reverse (5’-GCCGGAATTCTTACTTGTACAGCTCGCTCAT-3’) primers 
was followed by another 30 cycles of PCR using EcoRI-T2A-Forward (5’- 
AAAGGAATTCGGCAGTGGAGAGGGCAGAGGAAGT-
CTGCTAACATGCGGTGACGTCGAGGAGAATCCTGGCCCA -3’) and EcoRI-TdT-
Cer2-Reverse primers. Both rounds of PCR used Phusion High-Fidelity DNA Polymerase 
(New England Biolabs) and a Tm of 58oC. The PCR product was ligated into px458 using 
the EcoRI sites, replacing the EcoRI-site-flanked T2A-GFP cassette, to generate px458-
Cer2. sgRNAs to exon 6 of mouse Apobec1 (ensembl.org transcript 
ENSMUST00000112586.7) were designed using the MIT CRISPR design software 
(http://crispr.mit.edu/).  The following oligonucleotide pairs, specific for each sgRNA, 
were ligated into px458-Cer2 using the tandem BbsI sites downstream of the U6 promoter 
as per Ran, et al.30. sgRNA emboldened. 
Apobec1_sgRNA#1_top: 5’-CACCGAAGAAGACTTCAAACTCGTG-3’  
Apobec1_sgRNA#1_bottom: 5’-AAACCACGAGTTTGAAGTCTTCTTC-3’ 
Apobec1_sgRNA#2_top: 5’-CACCGTCTCTTTCCGAAGCTCCCGG-3’  
Apobec1_sgRNA#2_bottom: 5’-AAACCCGGGAGCTTCGGAAAGAGAC-3’ 
 
4.3.6.1 Transfection of 5TGM1 cells 
4mL of 5TGM1 BMx1 cells at 2x105 per mL in IMDM (20% FCS) were transfected with 
either 4µg px458-sgRNA plasmid, or 4µg px458-empty vector (no sgRNA) plasmid and 
20µL Polyfect (QIAGEN) according to manufacturer’s recommendations. 48 hours after 
transfection, GFP+Cerulean+ cells were isolated using flow cytometry. Ten days later, 
single transfected cells (clones) were deposited into 96 well plates by flow cytometry and 
clones were expanded prior to mutation screening.  
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4.3.6.2 Mutation screening 
DNA was isolated from each clone using DNeasy Blood and Tissue kit (QIAGEN) 
according to manufacturer’s instructions. Exon 6 of mouse Apobec1 (ensembl.org 
transcript ENSMUST00000112586.7) was amplified using mApobec1.het.F (5’- 
GTCATCTCAGCCTGGAATATG -3’) and mApobec1.het.R (5’- 
GGCTCAGAAACTCTGTAATGG -3’) primers using Phusion High-Fidelity DNA 
Polymerase (New England Biolabs) at a Tm of 70oC. PCR products were purified using an 
UltraCleanTM PCR clean-up kit (MoBio Laboratories) prior to Sanger sequencing at the 
Australian Genome Research Facility (AGRF Adelaide Node). 
  
4.3.7 Generation of Apobec3 sgRNA expression vectors  
The GFP reporter gene was excised from lentiviral vector FgH1tUTG (a gift from Marco 
Herold, Addgene plasmid # 70183)32 and replaced with the Plum reporter gene using 
Gibson assembly following the Miller laboratory recommendations (http://miller-
lab.net/MillerLab/protocols/) by Yu Chinn Joshua Chen at University of Adelaide. Two 
different guide RNAs were designed using the MIT CRISPR design software 
(http://crispr.mit.edu/) to sequences just upstream of each of those encoding the two active 
sites (AS) of mouse Apobec3. The following oligonucleotide pairs were used to clone the 
sgRNAs targeting AS1 and AS2 encoded by exons 3 and 7, respectively, of mouse 
Apobec3 (ensembl.org transcript ID ENSMUST00000109620.9). The 4 bp CACC- and 
AAAC- overhangs enabled ligation into BsmBI digested FgH1UTPlum. 
AS1-antisense-F 5’ CACCGACATTCGAAACAGGGGCTCC 3’  
AS1-antisense-R 5’ AAACGGAGCCCCTGTTTCGAATGTC 3’ 
AS1-sense-F 5’ CACCGAGATCACCTGGTATATGTCC 3’ 
AS1-sense-R 5’ AAACGGACATATACCAGGTGATCTC 3’ 
AS2-antisense-F 5’ CACCGACAGTTTGGGCAGGGGCTCC 3’  
AS2-antisense-R 5’ AAACGGAGCCCCTGCCCAAACTGTC 3’ 
AS2-sense-F 5’ CACCGCAATCACCTGCTACCTCACC 3’ 
AS2-sense-R 5’ AAACGGTGAGGTAGCAGGTGATTGC 3’ 
 
4.3.7.1 Viral packaging and 5TGM1 infection 
5TGM1 cells were transduced with FUCas9Cherry (a gift from Marco Herold: Addgene 
plasmid # 70182) to constitutively express Cas9. Viral particles containing FuCas9cherry 
were generated following Lipofectamine 2000 (Invitrogen) transfection of HEK293T cells 
concomitantly with psPAX2 (gift from Didier Trono, Addgene plasmid # 12260) and 
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pECO (Clontech) packaging constructs. 5TGM1 cells were infected with lentiviral 
particles by centrifugation at 1000g for 1 hour with 8µg/ml polybrene. Forty hours later, 
cherry-positive 5TGM1 cells that had been successfully transduced with Cas9 library were 
isolated by flow cytometry. 5TGM1-FuCas9cherry were then transduced with similarly 
packaged FgH1tUTPlum-Apobec3-sgRNA or FgH1tUTPlum-empty vector lentiviral 
vectors and Cherry+Plum+ cells were isolated by flow cytometry. sgRNA expression was 
induced by the addition of doxycycline hyclate (Sigma-Aldrich) to 1µg/ml for 48 hours, 
and individual mCherry+Plum+ cells were deposited into a 96 well plate by flow cytometry. 
These 5TGM1 clones were expanded prior to mutation screening.  
 
4.3.7.2 Mutation screening 
DNA was isolated from each clone using DNeasy Blood and Tissue kit (QIAGEN) 
according to manufacturer’s instructions. Exon 3 or exon 7 of mouse Apobec3 
(ensembl.org transcript ID ENSMUST00000109620.9) was amplified using either Exon3-
F (5’ AACAGGGCTCAGAGTGCTAG 3’) and Exon3-R (5’ 
ACACACCCTTCACCATATGG 3’) or Exon7-F (5’ TGGGAATGTGGAGTTAGTGG 
3’) and Exon7-R (5’ GGCTTGTCATATTGAGGCTG 3’) primers and Phusion High-
Fidelity DNA Polymerase (New England Biolabs) at Tms of 70oC or 67oC, respectively. 
PCR products were purified using an UltraClean PCR clean-up kit (MoBio Laboratories) 
prior to Sanger sequencing at the Australian Genome Research Facility (AGRF Adelaide 
Node).   
 
4.3.8 Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
cDNA was generated from RNA isolated from murine cell lines using Superscript III First-
Strand Synthesis System (Life Technologies). qPCR was performed using RT2 SYBR 
Green qPCR Mastermix (QIAGEN) on the Bio-Rad CFX Connect machine (Bio-Rad) 
using primers targeting Apobec1 (F: 5’- CTGTAGCTGTTGATCCCAC -3’; R: 5’- 
CTAAGAAGTTGACTTCAACG -3’), Apobec3 (F: 5’- CAGCAGAATCTTTGCAGG -3’; 
R: 5’- CAGAATCTCCTGAAGCTTAG -3’) and housekeeping control β-actin, ActB (F: 
5’-TTGCTGACAGGATGCAGAAG-3’; R: 5’-AAGGGTGTAAAACGCAGCTC-3’). 







4.4.1 Sp140 exhibits high impact mutations in the transcriptome of 5TGM1 cells  
Transcriptomic sequencing data of murine 5TGM1 MM PCs was examined for any 
nucleotide variants in genes that have previously been reported to be recurrently mutated in 
MM patients2-5 [Supplementary Table 1]. Genome Analysis Toolkit (GATK) annotated 
RNAseq data was filtered to reveal that 11 out of the 34 reported significantly mutated 
genes in human MM patients also harboured nucleotide variants in 5TGM1 MM PCs. This 
included KRAS, NRAS, TP53, BRAF, DIS3, SP140, RASA2, PNRC1, HLA-A, NF1 and 
PTEN, which harboured SNVs. These variants of interest were then analysed using the 
Ensembl Variant Effect Predictor tool (https://asia.ensembl.org/Tools/VEP) to determine if 
any of the identified SNVs resulted in changes to the protein synthesis sequence. To this 
end, variants in 5 genes: TP53, BRAF, SP140, HLA-A (H2-Q7) and NF1 had potential 
consequences on protein sequence [Supplementary Table 2]. Of these, Sp140 was found to 
harbour high impact base changes inducing a STOP gain [c.166C>T resulting in p.R56*] 
and STOP loss [c.478T>A resulting in *160K] in exons 2 and 7, respectively [Figure 1]. 
Of note, as this is RNA data, nucleotide Thymidine (T) should be interpreted as nucleotide 
Uracil (U). RNAseq sequencing reads were explored in the Integrative Genomics Viewer 
(IGV) to confirm the identified point mutations of interest, which showed an approximate 
50:50 ratio for each nucleotide change [Supplementary Fig. 1]. We hypothesised that the 
STOP gain mutation in exon 2 would result in the formation of a truncated Sp140 protein, 
while the STOP loss mutation in exon 7 would generate a larger than expected protein. In 
both cases, the abnormal proteins may contribute to MM pathogenesis. Due to the nature 
of our discovery in the RNAseq data, we went on to validate our findings using Sanger 










4.4.2 Sp140 is a target of RNA editing in 5TGM1 PCs 
Sanger sequencing validation of the RNA SNVs was carried out on the same samples that 
were prepared for RNAseq. cDNA was generated for PCR amplification of both exon 2 
and exon 7 regions, before sequencing was performed to confirm the identified variants 
affecting Sp140. Sequence traces of the exon 2 amplicon showed heterozygous alterations 
from the reference genome at both identified SNV sites c.166C>T (i.e. U) (nonsense) and 
c.180G>A (synonymous) [Figure 2a, 2b]. Exon 7 amplicon trace showed the identified 






Figure 1. Identification of Sp140 SNVs in the transcriptome of 5TGM1 MM PCs. (a) 
Variant Effect Predictor characterises 3 SNVs found in 5TGM1 MM PC mRNA transcripts. 
Notably, 2 variants are proposed to induce high impact consequences in Sp140 protein 
formation through STOP gain in exon 2 and STOP loss in exon 7. (b) SNV locations in 




















In order to assess whether the nucleotide changes were due to mutations present at 
the DNA level, genomic DNA (gDNA) sequencing was performed on PCR amplified 
gDNA from exon 2 and exon 7. While the initial VEP analysis of RNAseq data had 
detected a point mutation in exon 7 with potential consequences, validation of gDNA 
revealed it to be a homozygous SNV at the genomic level [Figure 3a].  Ensembl genome 
browser also revealed that this site is a catalogued STOP loss T/A variant in mouse 
(dbSNP rs1131936885). Subsequently, we focused our efforts on the identified STOP gain 
variant in exon 2. Notably, gDNA sequencing did not verify the identified SNVs in exon 2, 
demonstrating a clean sequencing trace supporting the reference allele at both positions 
[Figure 3b]. Moreover, we confirmed that this result was not restricted to a particular 
primer pair set, with the use of a second set of primers designed to amplify a larger region 
of exon 2 (termed Exon 2L). Sanger sequencing of these amplicons again supported the 
reference allele at both positions [Supplementary Figure 3]. Comparison of the Sanger 
sequencing data from both RNA and DNA suggests these mRNA alterations may be 
caused by RNA editing. Furthermore, clonal analysis of Sp140 exon 2 RT-PCR products 
revealed that both editing changes always occurred in cis on the same strand [Figure 4]. 
RNA editing is a process involving the post transcriptional modification of RNA transcript 
bases, which is enzymatically catalysed by deaminase enzymes of the APOBEC or ADAR 
families. As RNA editing is known to increase the complexity of expressed transcripts in 







Figure 2. Validation of RNA modification in Sp140. Sanger sequencing confirms 
c.166C>T (i.e. U) and c.180G>A variants in (a) forward and (b) reverse sequencing traces 
of Sp140 exon 2. Both variants appear to be heterozygous. Similarly, exon 7 variant 
c.478T>A was confirmed in (c) forward and (d) reverse sequencing traces. Altered sites 




















Figure 3. Validation of identified RNA modifications in Sp140 at the gDNA level. (a) 
Exon 7 is mutated at the genomic DNA level in 5TGM1 PCs. Sanger sequencing trace 
supports a prominent missense change to alternate nucleotide A (reference nucleotide is 
T) at position c.478. (b) Exon 2 of Sp140 is unmutated at the genomic level in 5TGM1 
PCs. Sanger sequencing reveals a clean sequencing trace that supports the reference 
nucleotides of C and G at positions c.166 and c.180, respectively. Sites of interest are 






















Figure 4. Clonal analysis demonstrates association of the two Sp140 exon 2 RNA 
editing changes. Comparative analysis of representative sequencing traces of cloned 
RT-PCR products from an edited Sp140 RNA molecule (clone 3) ((a) forward and (b) 
reverse sequence) versus an unedited Sp140 RNA molecule (clone 2) ((c) forward and 
(d) reverse sequence) illustrates that RNA editing of both c.166 and c.180 sites occur in 
cis on the same RNA molecule. Sites of interest are indicated by arrows, with position 
c.166 highlighted in yellow. (e) A total of 10 clones were sequenced, with data 
supporting cis RNA editing changes in Sp140 exon 2 with either tandem editing (6/10 
clones) or tandem non-editing (4/10 clones).  
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In view of these findings, we sought to explore whether RNA editing activity was a 
plasma cell specific phenomenon. In addition to 5TGM1, five other murine cell lines 
including NIH-3T3 (embryonic fibroblast), NS1 (B lymphocyte), BA/F3 (pro B cell), 
FDCP1 (myeloid progenitor) and RAW264.7 (macrophage) were investigated. 
Specifically, cDNA was generated from RNA isolated from each cell line and the Sp140 
exon 2 region was amplified by RT-PCR. Sanger sequencing analysis of PCR products 
revealed that both c.166 and c.180 sites were subject to varying levels of RNA editing 
across the different cell lines [Figure 5a]. With 5TGM1 cells used as an editing reference 
control, FDCP1 and NS1 cells exhibited prominent non-synonymous C>T (i.e. U) changes 
with ~57% and ~30% of c.166 edited, respectively. NIH-3T3, BA/F3 and RAW264.7 cells 
also showed editing changes, however, the occurrence of editing was at much lower 
frequency with ~12%, ~9% and ~9% of c.166 edited, respectively [Figure 5b] 
[Supplementary Table 3]. These findings suggest that site specific RNA editing alterations 
are not exclusive to cells of PC origin and are found in other murine cell lines and their 
respective different mouse strains including NIH/Swiss (NIH-3T3), BALB/c (NS1 and 
RAW264.7), C3H (BA/F3) and DBA/2 (FDCP1). While RNA editing of Sp140 was not 
unique to 5TGM1 PCs, the rates were highest with ~59% of c.166 edited. Moreover, 
SP140 has been identified to be recurrently mutated in patient derived MM PC studies and 
has been suggested to be a tumour suppressor due to recurrent inactivating nonsense 
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Figure 5. RNA editing of Sp140 occurs in multiple mouse cell lines (a) Sanger 
sequencing of the exon 2 region of interest revealed Sp140 was edited at varying levels in 
other non-PC cell lines. Position c.166 is highlighted in yellow (b) Calculation of the 
percentage of altered nucleotide at RNA editing sites c.166 and c.180. Sequencing counts 
revealed that FDCP1 and NS1 cells also exhibited prominent c.166C>T (i.e. U) change. 
	 158	
4.4.3 SP140 is not a target of RNA editing in human MM PCs 
Prior to investigating the occurrence of SP140 RNA editing in human MM cell lines, the 
conservation of Sp140/SP140 gene sequence between mouse and human was examined. 
Comparison of the Sp140/SP140 exon 2 region for sequence homology between mouse 
and human demonstrated that site c.166 from mouse was cross-species conserved, 
whereas, c.180 was not [Figure 6]. Gene sequences were derived from Ensembl genome 
browser (https://asia.ensembl.org), which also revealed that site c.166 is a catalogued 
deleterious missense C/T variant in humans (dbSNP rs755024352). As RNA editing at 
c.166 was identified to lead to a high impact STOP gain change in 5TGM1 PCs, we 
similarly screened a range of human MM cell lines for this alteration. 
 
 
Utilising the human MM PC line RNA sequencing data generated by Dr Jonathan 
J. Keats laboratory (The Translational Genomics Research Institute, Phoenix, Arizona; 
http://www.keatslab.org/data-repository), the transcript counts of SP140 was assessed in 
14 human MM plasma cell lines available in our laboratory including: JIM-1, KMS-11, 
KMS-18, LP-1, MM.1R, MM.1S, NCI-H929, OPM2, RPMI 8226, U266, JJN3, KMM-1, 
MOLP-8 and EJM. We found SP140 to be expressed at variable levels across all the MM 
cell lines [Supplementary Table 4], with 9 PC lines exhibiting moderate or high SP140 
expression. These were chosen for screening on the basis of the abundance of transcript 
available for screening, and protein that would be affected by RNA editing changes. These 
MM PC lines were curated into 2 groups, namely the “high expressing” group which 
included KMS-18, MM.1R, MM.1S, U266 and JJN3; and the “moderate expressing” group 
which included RPMI-8226, NCI-H929, MOLP-8 and EJM. 
 
	
Figure 6. Comparative analysis of mouse Sp140 and human SP140 gene sequences. 
Comparison of the Sp140/SP140 exon 2 region of interest between mouse and human 
genome revealed position c.166 to be conserved, while c.180 was not.  
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For each human MM cell line, RNA was extracted for cDNA synthesis followed by PCR 
amplification of SP140 exon 2. PCR products were purified and sequenced to screen for 
the identified variant affecting SP140. Sanger sequencing trace analysis revealed that the 
c.166 site was not edited in any of the human MM PC lines examined, with prominent C 
nucleotide calls in both “high expressing” and “moderate expressing” SP140 PC lines 
[Figure 7a, 7b]. Taken together, our Sanger sequencing data revealed that RNA editing is 
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Figure 7. RNA/cDNA sequence screening of SP140 in human MM cell lines. 
Sanger sequencing of exon 2 region revealed that SP140 is not a target of RNA 
editing, with traces supporting the reference C nucleotide in both SP140 (a) “high 
expressing”: KMS-18, MM.1R, MM.1S, U266, JJN3; and (b) “moderate expressing”: 
RPMI-8226, NCI-H929, MOLP-8 and EJM, human MM cell lines. Position c.322 is 
highlighted in yellow. 
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4.4.4 Molecular mechanisms inducing RNA editing of SP140  
While RNA editing of SP140 was not a feature in any human MM PC lines, identification 
of Sp140 as a target of editing in the mouse 5TGM1 cell line suggests a possible role of 
RNA editing as a mechanism of PC transformation in this preclinical model of MM. As we 
identified a C>T (i.e. U) change at c.166, we postulated that this was due to the action of a 
member of the Apobec family of enzymes. APOBECs are a class of cytidine deaminases 
known to catalyse C>U RNA editing changes, where currently APOBEC1, APOBEC3A 
and APOBEC3G are known to cause recoding changes28.  
 
RNAseq data showed that only Apobec1 and Apobec3 were expressed in the 
5TGM1 PC line. RT-qPCR analysis revealed that both Apobec1 and Apobec3 were 
expressed in all of the mouse cell lines that had previously been screened for Sp140 RNA 
editing levels. Notably, there was no correlation between the levels of gene expression of 
either Apobec and the frequency of RNA editing in these cell lines (R2 = 0.16 for 
Apobec1; and R2 = 0.11 for Apobec3) [Figure 8a, 8b].  
 
The Apobec family members contain a domain structure characteristic of cytidine 
deaminases34. Mouse Apobec1 contains one putative cytidine deamination domain (CDD) 
with a conserved active site (AS) that includes a H-X-E, motif followed 28 amino acids 
later by a P-C-X2-4-C motif. The His(H)-Cys(C)-Cys(C) residues of these motifs 
coordinate zinc binding and the Glu(E) residue acts as a proton shuttle during catalysis35. 
Point mutation of any of the conserved H, E, C and C amino acids of Apobec1 has been 
shown to abolish in vitro RNA editing activity36,37 and greatly reduced cytidine deaminase 
activity37. C-terminal truncated rabbit Apobec1 (66 amino acids long) also has no 
detectable RNA editing activity36. Smaller C-terminal truncated Apobec1 (181 amino acids 
long) also displayed no in vitro RNA editing activity, and point mutations in key lysine 
residues in this region (L185, L189) also greatly reduces editing activity38.  Although no 
RNA cytidine deamination activity has so far been ascribed to mouse Apobec3, critical 
residues/motifs important for its ssDNA deamination activity have been characterised. 
Mouse Apobec3 contains two putative CDDs each with a conserved AS that includes the 
H-X-E motif followed 23-28 amino acids later by a P-C-X2-4-C motif. According to Nair et 
al., the N-terminal domain appears to be the sole locus of deamination activity in mouse 
Apobec339. Replacing any of the conserved E, C and C amino acids from the N-terminal 
domain completely abolished any in vitro deamination activity39, an effect that was not 
observed following mutation of any of these amino acids in the C-terminal domain. By 
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contrast, the C-terminus of Apobec3 appeared to be necessary for the encapsidation into 
retrovirus particles39. Hakata and Landau had previously shown that mutation of the 
conserved Glu(E) of AS1, but not that in AS2, was sufficient to abolish in vitro deaminase 
activity40. Somewhat contradictory to the results of Nair et al., Hakata and Landau stated 
that mouse Apobec3 with mutations of both of the cysteines at either AS1 or AS2 also 
lacked deaminase activity, but no data was shown40. Similarly they stated that single 
mutation of either of the two cysteines of AS2 prevented deamination activity despite the 
presence of an intact AS1 catalytic domain, however, again not data was shown40. 
Together, these data suggest that mutation of the conserved P-C-X2-4-C motif within each 



























Figure 8. Correlation of Apobec enzyme expression with RNA editing of Sp140 exon 
2 in mouse cell lines. RT-qPCR revealed varying levels of (a) Apobec1 and (b) Apobec3 
expression in multiple mouse cell lines: 5TGM1, FDCP1, NS1, HIH-3T3, BA/F3 and 
RAW264.7. There was no correlation between the levels of expression of either Apobec 
with the percentage of altered nucleotide at RNA editing site c.166. Correlation 
coefficients R2 = 0.16 and R2 = 0.11, were calculated for Apobec 1 and Apobec3, 
respectively, illustrating a weak linear relationship. 
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Plasmid-based CRISPR-Cas9 gene editing was used to mutate Apobec1 in 5TGM1 
cells30. Two different single guide RNAs (sgRNAs) were used to target exon 6 (the largest 
coding exon) of Apobec1 with the intention of generating insertion/deletion mutations that 
would generate inactivating frameshift mutations. A total of 36 clonal 5TGM1 cell lines 
from each Apobec1-sgRNA transfection were screened for mutations. Only one Apobec1-
sgRNA2 5TGM1 clonal cell line was found to harbour two frameshift inducing mutations 
[Figure 9] [Supplementary Figure 5]. Both of the mutated alleles in Apobec1-sgRNA2-
clone#1 (Apobec1 KO cell line) were predicted to encode for severely C-terminal 
truncated proteins, lacking any of the conserved H-X-E and P-C-X2-4-C motifs that are 
required for cytidine deamination activity [Figure 10a, 10b] [Supplementary Figure 6]. 
RT-qPCR also showed a ~56% reduction of Apobec1 mRNA levels in the Apobec1 KO 
cell line compared to an empty vector clonal 5TGM1 cell line (EV11) [Figure 10c]. To 
assess the effect of Apobec1 mutation on resulting RNA editing of Sp140, cDNA was PCR 
amplified before purification and Sanger sequencing. Analysis of sequencing traces 
illustrated that the EV sample showed c.166C>U editing activity [Figure 11a]. The 
Apobec1 KO cell line also demonstrated unchanged levels of RNA recoding activity, 
suggesting that Apobec1 is not the enzyme responsible for the RNA editing of Sp140 in 
mouse [Figure 11b].  
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a	 	 	 	 	 	 		b 












 In addition to this, a transgene consisting of Sp140 exon 2 and it surrounding exon 
1 and 3 elements (termed the Sp140 Minigene) was constructed in the pLeGO Cer2 vector, 
to assess whether exogenous Sp140 RNA could be a template for RNA editing in 5TGM1 
cells. Sequencing analysis revealed no evidence of editing, with traces supporting 
reference C and G nucleotides at position c.166 and c.180, respectively. This demonstrates 
that further elements of the Sp140 gene beyond the immediate exon 2 region, such as the 
intronic sequences are required by the RNA editing enzyme responsible for the C>T 




Figure 9. Generation of Apobec1 frameshift mutant clone in 5TGM1. CRISPR-Cas9 
mediated gene editing of Apobec1 exon 6 reveals two frameshift mutations in Apobec1-
sgRNA2-clone#1 (a) forward and (b) reverse compared to empty vector (EV11) (c) 
forward and (d) reverse sequencing traces. (e) Mutation deconvolution illustrates the 
resulting 4 base pair frameshift deletions in the Apobec1-sgRNA2 5TGM1 clonal PC 










Figure 10. Predicted effects of frameshift mutations on Apobec1 protein formation, 
and its quantitation in knockout construct Apobec1-sgRNA2-clone#1.  
CRISPR-Cas9 mediated (a) mutant allele 1 and (b) mutant allele 2 in the Apobec1 KO 
cell line are predicted to result in severely truncated Apobec1 proteins. While translation 
of unmutated Apobec1 results in a 229 amino acid protein, both mutant alleles are 
predicted to encode 65 amino acid proteins with significant truncations of the C-
terminus, lacking motifs that are required for its deaminase activity. Green highlighted 
text illustrates the wildtype protein sequence, while yellow highlighted text illustrates 
the mutated C-terminal protein sequence. Cyan highlighted text shows the altered 
protein sequence exclusive to Mutant Allele 1. Full protein sequence can be found in 
Supplementary Figure 6 (c) Reduction of Apobec1 mRNA levels in Apobec1 KO cells. 
Apobec1 expression was measured in cell lines using quantitative real-time PCR, 
confirming a ~56% knockdown in the Apobec1 KO construct (Apobec1-sgRNA2-
clone#1) compared to the empty vector control (EV11).  Data were normalised to ActB 
(mean ±standard deviation of triplicates).  
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 Given the low targeting efficiency of this plasmid-based approach, an alternative 
lentiviral transduction methodology (with inducible sgRNA expression)32 was used to 
mutate Apobec3. Two different sgRNAs were designed to target exonic sequences just 
upstream of regions encoding the conserved P-C-X2-4-C motifs of each of the two active 
sites (AS) of mouse Apobec3 (one sense orientation sgRNA and one antisense orientation 
sgRNA at each AS). A total of 10 clonal cell lines were generated from each of the four 
Apobec3 sgRNAs and screened for putative inactivating insertion/deletion mutations. 13 
different clonal 5TGM1 cell lines were found to harbour homozygous or compound 
heterozygous frameshift mutations in exon 3 of Apobec3 [Figure 12a, 12b] 
[Supplementary Figure 7, 8]. All exon 3 mutations were predicted to encode for severely 
C-terminal truncated proteins that lack the second active site (AS2) and lack one or more 
of the cysteines within the P-C-X2-4-C motif of AS1 [Supplementary Figure 11, 12]. 
Similarly, homozygous or compound heterozygous frameshift mutations in exon 7 of 
Apobec3 were observed in a separate 13 independent clonal 5TGM1 cell lines [Figure 12c, 
12d] [Supplementary Figure 9, 10]. These exon 7 mutations were all predicted to encode 
C-terminally truncated Apobec3 proteins that lack one or more of the cysteines within the 
P-C-X2-4-C motif of AS2 [Supplementary Figure 13, 14]. Subsequently, we assessed 
whether the loss of Apobec3 function resulted in changes to the RNA editing of Sp140. 
cDNA of each clone was PCR amplified before purification and Sanger sequencing. 
a              b 
EV11              Apobec1 KO 
    
 
Figure 11. Apobec1 is not responsible for catalysing RNA editing changes in Sp140. 
Sanger sequencing of Sp140 region of interest reveals RNA editing in exon 2 is not due to 
the cytidine deaminase action of Apobec1. (a) Sequencing traces of empty vector (EV11) 
cells show both C and T nucleotides at c.166. (b) Sequencing traces from Apobec1 KO 
cells, also showed c.166 C>U RNA editing. Position c.166 is highlighted in yellow. 
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Analysis of sequencing traces illustrated that both Apobec3 AS1 and AS2 mutant clones 
showed unchanged levels of RNA editing activity at c.166C>U [Figure 13]. This suggests 
that neither Apobec1, nor Apobec3, are the enzymes responsible for the RNA editing of 
Sp140 observed in mouse. As such, the RNA editing of Sp140 is likely to be caused by 

















Figure 12. Generation of Apobec3 frameshift mutant 5TGM1 clones. An inducible 
CRISPR-Cas9 gene editing system was used to mutate two different active sites (AS) of 
Apobec3 (one sense orientation sgRNA and one antisense orientation sgRNA at each 
AS). 13 different clonal 5TGM1 cell lines were found to harbour homozygous or 
compound heterozygous frameshift mutations in exon 3 of Apobec3 using either (a) 
sense or (b) antisense sgRNAs. Sequencing traces illustrating mutations can be found in 
Supplementary Figure 7, 8. Similarly, homozygous or compound heterozygous 
frameshift mutations in exon 7 of Apobec3 were observed in a separate 13 independent 
clonal 5TGM1 cell lines using either (c) sense or (d) antisense sgRNAs. Sequencing 





























Figure 13. Apobec3 is not responsible for catalysing RNA editing changes in Sp140.  
Sanger sequencing of the Sp140 region of interest in mutant Apobec3 clones revealed 
unchanged RNA editing of exon 2, suggesting that this is not due to the cytidine 
deaminase action of Apobec3. Sequencing traces of Sp140 in AS1 (a) sense sgRNA and 
(b) antisense sgRNA-induced double frameshift clones shows RNA editing with both C 
and T nucleotides at c.166. Similarly, sequencing traces of Sp140 in AS2 (a) sense 
sgRNA and (b) antisense sgRNA-induced double frameshift clones also demonstrate 
c.166 C>U RNA editing. Sites of interest c.166 and c.180 are indicated by arrows. 
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4.5 Discussion 
Cancer, in its many forms, is due to the deregulation of biological processes following 
mutations that affect the normal program of DNA transcription to mRNA, and mRNA 
translation to protein. RNA editing is an unconventional event that adds to the diversity of 
expressed transcripts and protein repertoire of tumour cells. Recoding changes have been 
implicated in many malignancies such as hepatocellular carcinoma23, glioblastoma24, 
prostate cancer25, colorectal cancer26 and chronic myeloid leukaemia20. In a MM context, 
there has been one study that has investigated gene-specific RNA editing, finding that 
ADAR1 recoding of GLI1 promotes malignant regeneration22. Here, we explored the novel 
identification of RNA editing in mouse Sp140, inducing STOP gain (c.166) and 
synonymous change (c.180) edits, in the 5TGM1 MM PC line.  
 
Notably, recent NGS analyses of MM patient samples have shown that SP140 is 
recurrently mutated at the genetic level in ~3-12% of patients, with a suggested role as a 
tumour suppressor2,3,12. In chapter 2, our genetic analysis of paired MGUS/SMM to MM 
using whole exome sequencing found that SP140 was mutated in 30% of our patients. 
Therefore, alteration at position c.166 was notable as it induces a nonsense STOP gain 
codon change in the transcript. Notably, RNA editing in coding regions is a rare 
occurrence, with editing normally occurring within introns or 3’ UTRs28. An early 
truncation of Sp140 would result in inactivation and possible tumorigenic consequences. 
Although this is not a classical complete loss of function of a tumour suppressor gene, it 
has previously been shown that in a haploinsufficient phenotype (where one mutant and 
one wild type allele remains), a suboptimal level of gene product can result in lower level 
of function and oncogenesis41,42.  
 
It is curious that edited Sp140 transcripts are not subject to nonsense mediated 
mRNA decay in our samples43. While we initially found RNA editing changes in 5TGM1 
cells, they were not PC-specific, with varying levels of Sp140 editing also identified in 
other mouse cell lines. Studies show that RNA editing also occurs to some degree in 
normal cells, and thus recoding is not a cancer specific event, rather cancer associated 
editing may be more dependent on quantity of edited transcript, rather than site specific 
changes28. In addition, we also screened a range of human MM PC lines finding SP140 
exon 2 site c.166 to be conserved, however, it was not subject to any RNA editing. 
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To investigate the underlying mechanism responsible for the RNA editing 
phenotype in 5TGM1 cells, we explored known RNA editing enzyme Apobec1 that 
catalyses C>U changes. Verified C>U RNA changes catalysed by APOBECs are far less 
common than A>I changes by ADARs28. APOBEC family enzymes are principally known 
for their DNA editing activity, with APOBEC1 originally the only known RNA editor. 
However, knockout of Apobec1 did not result in a decrease in RNA editing phenotype at 
c.166 in 5TGM1 cells. While Apobec1 was not found to be responsible for the observed 
RNA editing, recent studies have demonstrated that APOBEC3A and APOBEC3G can 
also induce C>U changes under physiological conditions28,44,45. APOBEC3A shows highly 
site-specific activity, targeting coding region of genes and inducing missense or nonsense 
codon changes28. Notable, while there are 7 paralogous APOBEC3 genes (A3A-H) in 
humans, the mouse genome encodes one Apobec3 gene34,46,47. Generation of Apobec3 
double frameshift mutant clones did not result in a change of Sp140 RNA editing 
phenotype at c.166 in 5TGM1 cells. This indicates there may be other unknown enzymes 
capable of catalysing site specific C>U recoding changes. Interestingly, a recent study of 
APOBEC3A in Wilms Tumour (WT1) has identified tandem cis RNA editing changes 
with C>T (i.e. U) and G>A changes48. Similarly, we identified paired RNA editing 
changes of C>T (i.e. U) and G>A within 14 nucleotides in exon 2 of Sp140. As G>A is a 
non-classical editing change, it has been proposed that this type of dual editing change may 
be a tandem event, where the lost amine group from the first position (i.e. c.166) through 
C>U deamination, is shuttled to a linked nucleotide altering a G>A (G to 2,6-
diaminopurine that mimics A) at a second position (c.180)48.  
 
Intratumour heterogeneity is a common feature in many cancers, and has been 
shown to be characteristic of MM2,3,5,49-53. Therefore, it remains intriguing as to why 
tumour cells would require further diversity through RNA editing. The answer may be the 
dynamic nature of post transcriptional modification, which may confer survival advantages 
to the tumour cell. It may be that mutations which are advantageous to a cancer cell in 
most microenvironments are hardwired in the DNA, but those mutations which provide a 
competitive advantage, either in changing environments or certain disease stages, are 
regulated by RNA editing28.  
 
The existence of RNA editing in MM represents a novel mechanism inducing post 
transcriptional changes to mRNA, conferring increased variability in proteins and cell 
survival. This suggests that RNAseq expression studies of patient samples would also need 
to consider RNA recoding. Further, they should also consider the impact of the tumour 
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microenvironment and unnatural selective pressures, such as drug exposure, on cancer 
cells and their dynamic survival adaptability. The 5TGM1 cell line is frequently used as a 
preclinical model for in vitro testing, however, as we identified no corresponding RNA 
editing changes in human MM cell lines and patient samples, it is worth noting that this 
cell line may only model those patients showing SP140 post transcriptional modifications. 
As 5TGM1 cells harboured post transcriptional changes in 50% of their transcripts, these 
cells may mimic a subset of MM patients that are heterozygous at the DNA levels for 




































4.6 Supplementary  
4.6.1 Supplementary Figures 
 
Supplementary Table 1. Significantly mutated genes in MM patient studies. Large 
cohort patient sample studies (Chapman et al.5 n = 38, Lohr et al.3 n = 203, Bolli et al.2 n = 
67, Walker et al.4 n = 463) have identified 34 recurrent significantly mutated genes in MM, 
of which KRAS, NRAS, TP53, BRAF, DIS3 and FAM46C are believed to be drivers due to 




Supplementary Table 2. Genes that are significantly mutated in MM patients that 
show nucleotide variants in 5TGM1 RNAseq data and the predicted consequences on 
protein formation. Analysis of human MM genes with variants found in 5TGM1 
transcripts using the Ensembl Variant Effect Predictor tool revealed variants in 5 genes had 
potential impacts on their protein formation. Sp140 was identified to harbour high impact 




KRAS SP140 RASA2 PRDM1
NRAS IRF4 USP29 ACTG1
TP53 ROBO1 TRAF3 MAPK
BRAF FAT3 CYLD NF1
DIS3 EGR1 RB1 NFKBIA






Gene Chromosome Position Consequence Impact Exon CDS	Position Protein	Position Codon	(ref) Codon	(new) Amino	Acid	(ref) Amino	Acid	(new)
KRAS chr6 145246710 Synonymous	var LOW 3\3 96 32 TAT TAC Y	[Tyrosine	TYR] Y	[Tyrosine	TYR]
145246710 Synonymous	var LOW 2\6 96 32 TAT TAC Y	[Tyrosine	TYR] Y	[Tyrosine	TYR]
145246710 Synonymous	var LOW 2\5 96 32 TAT TAC Y	[Tyrosine	TYR] Y	[Tyrosine	TYR]
145246710 Synonymous	var/NMD	transcript	var LOW 2\4 96 32 TAT TAC Y	[Tyrosine	TYR] Y	[Tyrosine	TYR]
Trp53 chr3 69587616 Missense	var MODERATE 4\11 341 114 AAG ATG K	[Lysine	LYS] M	[Methionine	MET]
69587616 Missense	var MODERATE 4\11 341 114 AAG ATG K	[Lysine	LYS] M	[Methionine	MET]
69587616 Missense	var MODERATE 4\11 350 117 AAG ATG K	[Lysine	LYS] M	[Methionine	MET]
69587616 Missense	var MODERATE 4\11 350 117 AAG ATG K	[Lysine	LYS] M	[Methionine	MET]
BRAF chr6 39646740 Missense	var MODERATE 12\22 1267 423 GGC CGC G	[Glycine	GLY] R	[Arginine	ARG]
SP140 chr1 85609827 Stop	gained HIGH 2\17 166 56 CGA TGA R	[Arginine	ARG] *	[STOP]
85609841 Synonymous	var LOW 2\17 180 60 TCG TCA S	[Serine	SER] S	[Serine	SER]
85628219 Stop	lost HIGH 7\8 478 160 TAA AAA *	[STOP] K	[Lysine	LYS]
H2-Q7 chr17 35440154 Missense	var MODERATE 3\6 580 194 CAG GAG Q	[Glutamine	GLN] E	[Glutamic	Acid	GLU]
NF1 chr11 79475798 Missense	var MODERATE 35\57 4693 1565 TTC GTC F	[Phenylalanine	PHE] V	[Valine	VAL]
Missense	var MODERATE 36\58 4756 1586 TTC GTC F	[Phenylalanine	PHE] V	[Valine	VAL]
79547114 Synonymous	var LOW 41\57 6442 2078 GCG GCA A	[Alanine	ALA] A	[Alanine	ALA]
Synonymous	var LOW 42\58 6472 2099 GCG GCA A	[Alanine	ALA] A	[Alanine	ALA]
Synonymous	var LOW 2\18 249 83 GCG GCA A	[Alanine	ALA] A	[Alanine	ALA]
79547135 Missense	var MODERATE 41\57 6463 2085 TTC TTG F	[Phenylalanine	PHE] L	[Leucine	LEU]
Missense	var MODERATE 42\58 6493 2106 TTC TTG F	[Phenylalanine	PHE] L	[Leucine	LEU]
Missense	var MODERATE 2\18 270 90 TTC TTG F	[Phenylalanine	PHE] L	[Leucine	LEU]
Gene Chromosome Position Consequence Impact Exon CDS	Position Protein	Position Codon	(ref) Codon	(new) Amino	Acid	(ref) Amino	Acid	(new)
KRAS 6 145246710 Synonymous	var LOW 3\3 96 32 T T TAC Y	[Tyrosine	TYR] Y	[Tyrosi e	TYR]
145246710 Synonymous	var LOW 2\6 96 32 T T TAC Y	[Tyrosine	TYR] Y	[Tyrosi e	TYR]
145246710 Synonymous	var LOW 2\5 96 32 T T TAC Y	[Tyrosine	TYR] Y	[Tyrosi e	TYR]
145246710 Synonymous	var/NMD	t anscript	var LOW 2\4 96 32 T T TAC Y	[Tyrosine	TYR] Y	[Tyrosi e	TYR]
Trp53 3 6 587616 4\11 341 114 AAG ATG K	[L si e	LYS] M	[Methio ine	MET]
69587616 Missense	var MODERATE 4\11 341 114 AAG ATG K	[Lysine	LYS] M	[Methionine	MET]
69587616 Missense	var MODERATE 4 1 350 117 AAG ATG K	[Lysine	LYS] M	[Methionine	MET]
69587616 Missense	var MODERATE 4 1 35 117 AA ATG K	[Lysi 	LYS M	[Methionine	MET]
BRAF chr6 39646740 Missense	var MODERATE 12\22 1267 423 GGC CGC G	[Glycine	GLY] R	[Arginine	ARG]
SP140 chr1 85609827 Stop	gained HIGH 2\17 166 56 CGA TGA R	[Arginine	ARG] *	[STOP]
85609841 Synonymous	var LOW 2\17 180 60 CG TCA S	[Serine	SER] S Ser SER]
85628219 Stop	lost HIGH 7 8 478 160 AA AAA *	[STOP] K Lys LYS]
H2-Q7 chr17 35440154 Missense	var MODERATE 3 6 580 194 CA AG Q	[Glutamine	GLN] E	[Glutamic	Acid	GLU]
NF1 chr11 79475798 35 469 156 G C V	[Valine	VAL]
36 4756 158 G C V	[Valine	VAL]
79547114 Synonymous	var LOW 41\57 6442 2078 GCG GCA A	[Alanine	ALA] A	[Alan ALA
Synonymous	var LOW 42\58 6472 2099 GCG GCA A	[Alanine	ALA] A	[Alanine	ALA]
Synonymous	var LOW 2\18 249 83 GCG GCA A	[Alanine	ALA] A	[Alanine	ALA]
79547135 Missense	var MODERATE 41\57 6463 2085 TTC TTG F	[Phenylalanine	PHE] L	[Leucine	LEU]
Missense	var MODERATE 42\58 6493 2106 TTC TTG F	[Phenylalanine	PHE] L	[Leucine	LEU]




Supplementary Table 3. Differential site specific RNA editing occurring in mouse cell 
lines. Calculation of the percentage of altered nucleotide at RNA editing sites c.166 and 
c.180 in Sp140 exon 2 revealed FDCP1 and NS1 cell lines show much higher editing 




Supplementary Table 4. SP140 expression in human MM cell lines. Examination of 
RNAseq data from Keats laboratory for SP140 expression demonstrates varied levels of 
expression. Two groups were portioned based on “high” expressing (orange) and 







mm10	cell	line c.166	C c.166	C>T c.180	G c.180	G>A (%)	c.166	C>T (%)	c.180	G>A
5TGM1 368 532 392 371 59.11 48.62
FDCP1 387 509 341 340 56.81 49.93
NS1 612 258 606 168 29.66 21.71
NIH	3T3 773 101 829 80 11.56 8.80
BA/F3 975 98 830 143 9.13 14.70























Supplementary Figure 1. IGV sequence trace of Sp140 Exon 2. Exploring RNAseq 
reads of Sp140 exon 2 in the 5TGM1 cell line confirms ~heterozygous C>T changes at 
c.166 and G>A changes at c.180. 
	
Supplementary Figure 2. IGV sequence trace of Sp140 Exon 7. Exploring RNAseq 





























Supplementary Figure 3. Sequencing of identified RNA modifications in Sp140 at the 
gDNA level using Exon2L primer pair set. A secondary genomic primer pair (Exon 2L) 
was designed to amplify a larger region of Sp140 exon 2 in 5TGM1 PCs. We again found 
exon 2 of Sp140 to unmutated at the genomic level, demonstrating that this observation is 
not due to a specific primer set. Sanger sequencing revealed a clean sequencing trace that 
supports the reference nucleotides of C and G at positions c.166 and c.180, respectively. 



















Supplementary Figure 4. Exogenous Sp140 RNA construct (Minigene) is not edited 
in 5TGM1 cells. The Minigene consisting of Sp140 exon 2 and its surrounding elements 
of exon 1 and 3 was not sufficient as a template for RNA editing in 5TGM1 PCs. pLeGo 
Cer2 vector specific primers were used to amplify the Minigene region, and Sanger 
sequencing revealed a clean sequencing trace that supports the reference nucleotides of C 
and G at positions c.166 and c.180, respectively. This illustrates further Sp140 gene 
elements, such as intronic sequences, are needed for Apobec enzyme activity. Sites of 










Supplementary Figure 5. Apobec1 frameshift mutant clone in 5TGM1. (a) Full 
unmutated nucleotide sequence of Apobec1. Mutation deconvolution illustrates the 
frameshift-inducing 4bp deletions in the Apobec1-sgRNA2 5TGM1 clonal PC line 
(Apobec1-sgRNA2-clone#1) (b) mutant allele 1 and (c) mutant allele 2. Green highlighted 
text illustrates the start codon sites, while red highlighted text show the stop codon sites. 











Predicted Translation of Mutant Allele 1 (65 aa):  
MSSETGPVAVDPTLRRRIEPHEFEVFFDRSFGKRPVCCMRSTGVEGTVSGDTRAKTPATTLKSTS 
(c) 
Predicted Translation of Mutant Allele 2 (65 aa): 
MSSETGPVAVDPTLRRRIEPHEFEVFFDPRFGKRPVCCMRSTGVEGTVSGDTRAKTPATTLKSTS	
Supplementary Figure 6. Predicted effects of frameshift mutations on Apobec1 
protein formation. (a) Translation of unmutated Apobec1 results in a 229 amino acid 
protein. CRISPR-Cas9 mediated mutations in Apobec1 with (b) mutant allele 1 and (c) 
mutant allele 2 predicted to encode severely truncated protein. Mutated Apobec1 results in 
65 amino acid proteins with significant truncation of C-terminus, missing the motifs that 
are required for its cytidine deaminase activity. Green highlighted text illustrates the 
wildtype protein sequence, while yellow highlighted text illustrates the mutated C-
terminal protein sequence. Cyan highlighted text shows the altered protein sequence 























Supplementary Figure 7. Generation of Apobec3 AS1 sense sgRNA clones with two 
mutant alleles. Sequencing traces show induced CRISPR-Cas9 gene editing using sense 
sgRNA targeting AS1 of Apobec3 resulting in 8 different clonal 5TGM1 cell lines 














Supplementary Figure 8. Generation of Apobec3 AS1 antisense sgRNA clones with 
two mutant alleles. Sequencing traces show induced CRISPR-Cas9 gene editing using 
antisense sgRNA targeting AS1 of Apobec3 resulting in 5 different clonal 5TGM1 cell 


























Supplementary Figure 9. Generation of Apobec3 AS2 sense sgRNA clones with two 
mutant alleles. Sequencing traces show induced CRISPR-Cas9 gene editing using sense 
sgRNA targeting AS2 of Apobec3 resulting in 8 different clonal 5TGM1 cell lines 









Clone#6 allele 1 (larger PCR product)  
(contaminated slightly with smaller PCR product) 
 










Supplementary Figure 10. Generation of Apobec3 AS2 antisense sgRNA clones with 
two mutant alleles. Sequencing traces show induced CRISPR-Cas9 gene editing using 
antisense sgRNA targeting AS2 of Apobec3 resulting in 5 different clonal 5TGM1 cell 

























































































Supplementary Figure 11. Predicted effects of Apobec3 AS1 sense sgRNA double 
frameshift clones. All Apobec3 exon 3 mutant clones are predicted to encode for severely 
C-terminal truncated proteins that lack AS2 and lack one or more of the cysteines within 











































Supplementary Figure 12. Predicted effects of Apobec3 AS1 antisense sgRNA double 
frameshift clones. All Apobec3 exon 3 mutant clones are predicted to encode for severely 
C-terminal truncated proteins that lack AS2 and lack one or more of the cysteines within 


































































































































Supplementary Figure 13. Predicted effects of Apobec3 AS2 sense sgRNA double 
frameshift clones. All Apobec3 exon 7 mutant clones are predicted to encode for C-
terminally truncated proteins that lack one or more of the cysteines within the P-C-X2-4-C 
motif of AS2. Green highlighted text illustrates the wildtype protein sequence. 
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Supplementary	 Figure	 14.	 Predicted effects of Apobec3 AS2 antisense sgRNA 
double frameshift clones. All Apobec3 exon 7 mutant clones are predicted to encode for 
C-terminally truncated proteins that lack one or more of the cysteines within the P-C-X2-4-
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5.1 General Discussion 
Multiple myeloma (MM) is a blood cancer characterised by the aberrant proliferation of 
malignant plasma cells (PCs) in the bone marrow (BM). MM is a rare disease, accounting 
for 1.8% of all new cancer cases, and 2.1% of all cancer deaths per year1. Each year there 
are approximately 1800 and 31,000 newly diagnosed patient cases in Australia2 and the 
United States of America3, respectively. Despite the development of effective new 
therapies, which have led to improved outcomes, patients inevitably relapse and require 
further treatment. The mechanisms underlying MM initiation, therapeutic resistance and 
disease recurrence are complex and associated with intraclonal genetic heterogeneity4-7. 
 
The advent of Next Generation Sequencing (NGS) technologies has revolutionised 
our understanding of the genetic heterogeneity and key driver mutations in genes 
associated with MM disease development. The ‘Initial genome sequencing and analysis of 
multiple myeloma’ in 38 patients was carried out by Chapman and colleagues in 2011, 
identifying the first set of significantly mutated genes believed to be drivers of MM5. In 
addition to previously reported mutant genes, such as KRAS, NRAS and TP53, NGS 
identified new unexpected candidates such as DIS3 and FAM46C. Following this seminal 
study, 3 further large cohort studies of patients were carried out using patient samples of 
MM and its pre malignant stages of monoclonal gammopathy of undetermined significance 
(MGUS) or smouldering multiple myeloma (SMM)4,6,7. These studies demonstrated 
intraclonal heterogeneity as a hallmark of MM, where distinct PC populations carry 
differing mutations, with the rise and fall in dominance of clonal populations as disease 
progresses. The most recurrently mutated genes identified in these studies include KRAS, 
NRAS, BRAF, TP53, DIS3 and FAM46C, which are believed to be drivers of MM due to 
their recurrent nature4,6,7. Moreover, intraclonal heterogeneity has been observed at both 
the earliest stages of disease and also at MM, where the dynamics of progression are 
thought to be characterised by “Darwinian” evolution. In this model, the acquisition of 
driver mutations is suggested to confer an improved clonal fitness (i.e. selective advantage 
and dominance) allowing clones to survive and progress to MM. However, as these studies 
relied on the comparison of genetic changes between MGUS, SMM and MM samples 
isolated from different individuals, it remains unknown whether the genetic heterogeneity 
that was present at MM was also present at the asymptomatic MGUS and SMM stages.  
 
Intraclonal genetic heterogeneity is viewed as one of the main reasons for the 
disparate outcomes for MM patients. As different clonal populations within a tumour carry 
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differing combinations of mutations they exhibit diversified survival properties, therefore, 
treatment impacts the death or survival of clonal populations based on their clonal fitness. 
While standard treatment strategies kill off aggressive dominant clones with driver 
mutations, they leave indolent clones that resist the effects of treatment. Moreover, as 
treatment represents an unnatural selective pressure on indolent clones may cause them to 
mutate further and acquire driver mutations, facilitating an improved clonal fitness and 
subsequent dominance, leading to MM relapse. To date, few studies have investigated the 
changing clonal composition of MM in response to treatment using array and NGS 
techniques, finding substantial tumour heterogeneity with the acquisition of new mutations 
and resulting clonal tiding at relapse in response to therapy8-13. 
 
Our current knowledge of the genomic complexity in MM has been established on 
the examinations of unmatched samples isolated from different patients at MGUS, SMM, 
MM and PCL, and how genetic heterogeneity is observed to be related between stages4-7,14-
20. However, two very small studies have investigated the tumour evolution associated with 
the natural history of disease transformation from SMM to MM, using paired SMM-MM 
samples from the same patient (n = 4 in both studies)17,20. These studies found the majority 
of genetic changes required for MM were present from the asymptomatic stage of SMM. 
These initial studies have suggested that progression to MM does not involve many new 
mutations, where clonal progression is a key feature of transformation17. While these 
studies characterised the clonal heterogeneity present from the SMM stage, the subclonal 
evolution associated with disease progression was poorly understood. 
 
Due to the rare nature and difficulty in collecting paired samples from treatment 
naïve patients when first diagnosed with MGUS/SMM and then subsequently at MM, the 
studies presented in this thesis constitute the first genetic analysis of the changes associated 
with MM transformation. Based on the matched nature of our samples, we hypothesised 
that analyses of MM patients in a paired setting would reveal commonly mutated genes 
that represent key drivers of disease progression. To investigate this hypothesis, in Chapter 
2 we performed whole exome sequencing (WES) analysis of matched samples from 10 
patients, who progressed from MGUS to MM (n = 5) or SMM to MM (n = 5). Similar to 
previous NGS studies on large cohorts of unmatched MGUS-SMM-MM patient samples, 
we confirmed clonal heterogeneity is a common feature at diagnosis. However, in contrast, 
we identified that the driving events involved with disease progression are more subtle that 
previously reported. To this end, we found a changing spectrum of acquired mutations, not 
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total mutational load, to be associated with MGUS/SMM to MM progression. 
Interestingly, slightly higher somatic single nucleotide variant (SNV) and copy number 
variant (CNV) frequency were identified at the asymptomatic stages of MGUS/SMM 
compared to MM (SNVs: median 161 versus 152 per patient, respectively; CNVs: median 
70 versus 67.5 per patient, respectively). We found the RAS/MAPK pathway to be highly 
mutated in our study, with 40% of patients at MGUS/SMM and 70% of patients at MM 
harbouring mutations in KRAS and NRAS. These were identified to be mutually exclusive, 
consistent with previous observations that report the rare co-occurrence of mutations in 
these genes. Notably, we revealed that MGUS/SMM to MM progression is characterised 
by a prevailing model of tumour evolution defined by clonal stability, where the 
transformed PC subclones of MM were already present at the MGUS/SMM stage. 
Subclonality was evident at the earliest stages of disease, with the presence of between 5 to 
11 subclones at MGUS/SMM which progress to MM with subtle changes in the degree of 
emergence and/or extinction of child subclonal branches. These findings suggest that 
patients who progress in a short time frame are already sufficiently genetically complex at 
MGUS/SMM to be on the threshold of transformation to MM; a process that may be 
driven by PC-extrinsic selective pressures imparted by the tumour microenvironment. 
 
While Chapter 2 focused on the characterisation of the genetic architecture and 
subclonal evolution in PCs as a function of disease progression, Chapter 3 examined the 
changes in the transcriptomic and methylomic landscape associated with disease evolution. 
To date, little is known about the role of the transcriptomic changes associated with the 
progression to MM in a matched longitudinal setting. Current understanding of the MM 
transcriptome is derived from gene expression profiling (GEP) studies using array-based 
technologies, which provide a broad ranging insight into the transcriptomic landscape of 
MM at a single point. These insights have led to the generation of robust risk stratification 
models for the prognosis of patients, such as the UAMS-7021 and EMC-9222 gene 
signatures. However, these tools are not yet routinely utilised in the clinic, as further 
supporting evidence is required before they become commercially available for use in a 
clinical setting. The clinical precision of GEPs in MM prognostication is hampered by the 
presence of intraclonal heterogeneity throughout all stages of disease. As GEP provides a 
snapshot of expression patterns, it is only able to account for the dominant clones of a 
tumour, thus missing important information on subclonal changes such as possible driver 
genes and associated deregulated pathways in minor subclones. Interestingly, it has been 
shown that minor subclones that resist treatment are able to further mutate, gaining 
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selective fitness and malignant potential, leading to MM relapse10. With the advent of NGS 
technologies, such as RNA sequencing (RNAseq) and its progressive affordability, GEP 
may not represent the best methodology for detailed interrogation of the MM 
transcriptome. RNAseq is a highly sensitive technology, which is able to provide a deeper 
insight into the transcriptomic complexity of a cell as it assesses RNA transcripts with 
single base resolution in a high throughput manner23. Therefore, as RNAseq provides a 
quantitative measure of each RNA fragment from a cell, it can accurately detect both 
highly and lowly expressed genes, as would be found in a heterogeneous tumour.  
 
Gene expression is known to be regulated by epigenetic mechanisms such as DNA 
methylation. The rate of epigenetic change in cancers has been estimated to be orders of 
magnitude higher than that of genetic change, and could be a major determinant of clonal 
evolution24. Studies investigating the methylomic changes in MM have demonstrated that 
disease initiation is characterised by global hypomethylation25-28. Interestingly, however, 
analysis of disease progression has yielded conflicting results, with some studies 
identifying increased hypomethylation25,27,28, while another study showed decreasing 
hypomethylation due to progressive hypermethylation26. In Chapter 3, we investigated the 
transcriptomic and DNA methylation changes associated with the progression of 
MGUS/SMM to MM using RNAseq and whole genome bisulphite sequencing (WGBS), 
respectively. Interestingly, there was minimal variation in gene expression between the 
MGUS/SMM and MM stages. There were 250 genes approaching statistical significance in 
differential expression testing, with the top 10 genes including:  THEMIS2, BTBD19, HBB, 
ATP8A2, CELSR1, CD69, TWF2, SLC20A1, ALG1L and SLC23A3. Mutated genes of MM, 
found in WES analyses of the same patients described in Chapter 2, were expressed at low 
levels or not at all. In most cases, only the wild type allele of a gene harbouring 
heterozygous mutation was expressed. Analysis of the methylome using WGBS revealed 
the initiation and progression of MGUS, to SMM and MM, was associated with extreme 
hypomethylation. While an average of 77.5% of CpG sites were methylated in NPCs, an 
average of 43%, 45.6%, 41.7% of CpG sites methylated were methylated in MGUS, SMM 
and MM, respectively. Notably, compared to NPCs, there were 190,401 differentially 
methylated regions (DMRs) at MGUS/SMM, and 177,535 DMRs at MM. However, we 
found no DMRs between MGUS/SMM and MM. These findings indicate that PCs from 
the asymptomatic MGUS/SMM stages appear to be as genetically complex as the MM 
stage, with the majority of transcriptomic and methylomic changes occurring during the 
aberrant transition of NPCs to MGUS/SMM.  
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The initiating oncogenic events of MM are known to occur in a maturing B cell, 
when present within the germinal centre. The resultant PCs re-enter the BM, leading to the 
asymptomatic condition of MGUS. Common initiating events include IgH translocations 
and hyperdiploidy. Generation of highly specific Ig, through the somatic hypermutation 
process in the hypervariable region of the IgH locus is induced by the expression of 
activation-induced cytidine deaminase (AID). AID is a member of the APOBEC family of 
DNA/RNA editing enzymes. Genomic studies of patients have identified the enrichment of 
a mutational signature characterised by C>T transitions at CpG sites, which is 
hypothesised to be due to the aberrant activity of APOBEC enzymes4,29. Subsequently, a 
study has shown the association of the APOBEC mutational signature with the t(14;16) 
and t(14;20) translocation subgroups in MM that exhibit poor prognosis30. 
 
In Chapter 4, we investigated the phenomenon of RNA editing in SP140, a gene 
recurrently mutated in human MM patient studies4,6,9, in the 5TGM1 murine MM PC line. 
In addition to DNA, APOBECs also catalyse RNA editing, inducing C>U RNA changes, 
where currently APOBEC1, APOBEC3A and APOBEC3G are known to cause recoding 
changes31. Here, we identified a high impact C>T (ie. U) RNA editing change in exon 2 
(c.166) of Sp140, resulting in an early STOP codon, and hypothesize that Apobec enzymes 
are the likely candidates inducing this phenotype. In vitro studies revealed site specific 
RNA editing of Sp140 was present in the 5TGM1 cell line, with ~59% of exon 2 (c.166) 
edited. In addition, Sp140 RNA editing was not unique to murine PCs, but present in other 
mouse cell lines to a varying degree, with exon 2 (c.166) edited at a frequency of ~57%, 
~30%s, ~12%, ~9% and ~9% in FDCP1, NS1, NIH-3T3, BA/F3 and RAW264.7 cells, 
respectively. While the exon 2 region of interest was conserved between the mouse and 
human genome, Sanger sequencing revealed this site was not edited in a range of SP140 
expressing human MM PC lines. Moreover, in studies investigating the underlying 
mechanism of C>U RNA editing in 5TGM1 cells, we showed that Apobec1 and Apobec3 
were not responsible in this process. This suggests there may be other novel 
uncharacterised enzyme candidates present in 5TGM1 PCs, which can cause dynamic 
RNA editing changes. 
 
The 5TGM1 cell line and the 5TGM1-C57BL/KaLwRij model are commonly used 
in vitro and in vivo preclinical models of MM as they reproduce many of the features of 
human MM disease32-34. However, as recent genomic studies have demonstrated a marked 
genetic heterogeneity between patients, it would be valuable to ascertain which specific 
	 209	
clinical subtype(s) of MM are being represented by this mouse model, to better translate 
findings to the appropriate genetic subgroup(s) of MM patients. As we identified no 
corresponding RNA editing changes in human MM cell lines and patient samples, it is 
worth noting this in vitro model may replicate those MM patients with post transcriptional 
modifications resulting in STOP codons and truncated protein formation. Moreover, 
further large cohort studies of MM patients concurrently using WES and RNAseq will 
enable the potential to study RNA editing changes throughout MM, which may be 
widespread in disease. 
 
Intratumour heterogeneity is a common feature of MM4-7,17, therefore it remains 
intriguing why tumour cells would require further diversity through RNA editing. The 
answer may be the dynamic nature of post transcriptional modification, which may confer 
survival advantages to the tumour cell. It may be that mutations advantageous for a cancer 
cell in most microenvironments are hardwired in the DNA, but those advantageous only in 
changing environments or certain disease stages are regulated by RNA editing31. As such, 
future transcriptomic studies of patient samples should also consider RNA recoding and 
the impact of the tumour microenvironment and unnatural selective pressures, such as drug 
exposure, on cells and their dynamic survival adaptability.  
 
The studies presented in this thesis represent a unique examination the genomic 
complexity and tumour evolution associated with the progression of MGUS/SMM to MM 
in a longitudinal nature. Our data supports a clonal stability model of tumour progression 
in MM. While initial unmatched studies of patient samples illustrated “Darwinian 
evolution”, with the rise and fall in dominance of clonal populations based on selective 
advantages, our analysis of matched samples generally demonstrates clonal cooperation, 
not competition, of transformed clones from MGUS/SMM to MM. Similarly, we observed 
minimal variation in the transcriptomic and methylomic landscape associated with 
progression to MM. Taken together, these studies highlight that the genomic architecture 
of MGUS/SMM patients could be prognostic of transformation to MM. However, it 
remains unknown why patients harbouring transformed PC populations at MGUS/SMM 
are not symptomatic. It has been noted that that both intrinsic (genetic architecture) and 
extrinsic (immune cells and bone marrow microenvironment) factors may regulate tumour 
subclones and their subsequent symptomatic evolution35. The data in this thesis points to a 
more pronounced role of the tumour microenvironment in the development and 
progression of MM disease. Notably, it has previously been shown in a haematological 
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setting of myelodysplasia that changes in the microenvironment can create a 
“promalignant” niche which precedes the acquisition of any tumorigenic genetic 
aberrations, highlighting the concept of niche induced oncognesis36,37. The complex 
interactions of the tumour microenvironment with subclones can provide signals that may 
support tumour growth or restriction, which influences their transformation. Indeed in 
MM, a recent in vivo study has demonstrated microenvironment dependent disease 
progression; with xenograft of MGUS patient derived CD138+ bone marrow mononuclear 
cells into a genetically humanized MIS(KI)TRG6 mice model exhibiting progressive growth 
over an 8 - 12 week period38. Humanisation was achieved through a genetic knock-in of 6 
genes important for innate immune cell and MM cell development, including IL-6, CSF1, 
IL-3, CSF2, SIRPA and TPO38. This preclinical model further supports the notion that 
strong selective pressures are existent within the tumour microenvironment, which mediate 
clonal stability at asymptomatic disease, and subsequent progression to MM. Conversely, 
tumour subclones may modify the host-mediated growth control to influence their 
progression35. Furthermore, interaction of MM PCs with the microenvironment has been 
shown to influence dormancy of tumour cells, where dormant MM PCs are resistant to 
standard therapies and contribute to minimal residual disease (MRD), that can be 
reactivated at a later time point leading to disease progresion39. Supporting the importance 
of the microenvironment, is the observation that failure to control disease long-term in the 
MRD setting could reflect a damaged microenvironment40. The current standard of care at 
the asymptomatic stages involves monitoring patients, with no treatment options until they 
display evidence of progress towards symptomatic MM. To fully realise personalised 
medicine strategies that target “at risk patients” who would benefit from earlier therapeutic 
intervention, further large cohort longitudinal and spatial sequencing studies of both 
treatment-naïve and post-treatment patients are required to characterise the response of 










5.2 Towards A Cure for MM 
The marked intraclonal genetic/cytogenetic heterogeneity that characterises MM is thought 
to be the main obstacle to finding a unifying cure for patients. As MM presents as a 
heterogeneous disease with a heterogeneous clinical course, it can otherwise be considered 
not as a single disease entity, rather a collection of monoclonal gammopathies which all 
share similar clinical symptoms41. Current treatments are given based on mechanistic 
purposes such as proteasome inhibition, immune modulation (anti-inflammatory and 
antineoplastic) and induced cell death42, with the objective of managing MM as a chronic 
disease. NGS has significant potential to be implemented in the clinical assessment of risk 
stratification and mutation specific treatment strategies for patients; however, currently it is 
primarily used for research purposes only. As illustrated in Chapter 2, the main hurdle 
surrounding the use of NGS in the clinical setting for targeted treatment is not only the 
presence of intraclonal genetic heterogeneity, but also the occurrence of driver mutations 
within subclonal populations. As such, administration of selected drug would only 
eliminate a subpopulation of tumour cells, resulting in only a partial response. 
Alternatively, NGS could be used to screen and select only patients who would respond to 
established targeted therapies (in a combination therapy setting) against known drivers, 
such as vemurafenib for activating BRAF V600E mutations42,43. However, it should be 
noted that treatment targeted to mutated genes would only be effective if the mutant is 
expressed. A recent study by Rashid et al. has demonstrated that most mutated genes in 
MM are lowly expressed or not expressed at all44. This finding was confirmed in the 
studies described in Chapter 3, where our transcriptomic analysis revealed that genetic 
mutations that were acquired at MM in our cohort were only expressed at low levels or not 
at all. 
 
Currently, there are no approved target based treatment strategies for MM patients, 
however, recent clinical trials of the small molecule BCL-2 inhibitor, Venetoclax, as a 
monotherapy45 or in combination46, in the t(11;14) subgroup of MM has shown good 
efficacy and safety. The t(11;14) cytogenetic alteration is the most prevalent subgroup in 
MM (~15-20% patients)47, and PCs from these patients are known to overexpress the anti-
apoptotic factor BCL-2 which promotes tumour cell survival. Thus, drug administration 
facilitates activation of pro-apoptotic pathways to induce cell death of malignant PCs. In 
light of these findings, Venetoclax may be the first targeted treatment for a specific 
subgroup of genetically defined MM, thus beginning the personalised medicine revolution 
in MM48.  
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Notably however, as demonstrated in our longitudinal investigation of progressive 
patients, and in studies from Zhao et al20 and Walker et al17, most of the genetic 
complexity and subclonal architecture of MM is present at the asymptomatic stages of 
disease. This proposes the question as to whether MGUS should be considered the real 
“disease”, as it is the earliest stage of disease where subclonality and clonal heterogeneity 
originates, evolving under selective pressures to give rise to clonal evolution associated 
with development and progression to MM. As such, should patients be treated at the 
asymptomatic stages to eradicate subclones for the prevention of progression and possible 
cure in MM?49 Currently, this is not routine practice as MGUS and SMM are 
asymptomatic conditions therefore patients remain untreated. The standard of care involves 
a careful “watch and wait” strategy in which patients are monitored for signs of 
progression to MM. The risk-benefit ratio of early treatment needs to be considered, as 
therapeutic strategies are highly toxic to patients, such as current induction therapies using 
the proteasome inhibitor bortezomib that is known to cause peripheral neuropathy in ~55-
67% of patients50-53. Moreover, in the case of MGUS, only 20% of patients actually go on 
to develop MM, therefore it may be considered more beneficial to leave patients to only be 
monitored at this stage54.  
 
In the case of SMM however, there has been an urge for early treatment of patients 
before they progress to MM due to the armamentarium of new classes of effective drugs. 
SMM is an intriguing disease stage where two subsets of patients have been identified, one 
group exhibits indolent disease akin to MGUS, while another group displays a more 
aggressive disease course described as “early myeloma”49. In 2014, the International 
Myeloma Working Group reclassified these “early myeloma” SMM patients as being overt 
MM, through the addition of criteria assessing Myeloma Defining Events (MDEs) into the 
clinical classification system, which is designed to look beyond just end organ damage 
(from CRAB features) as a marker of MM onset55. Very recent data from NGS studies of 
high risk SMM presented at The American Society of Hematology Annual Meeting and 
Exposition 2017, have suggested that these patients are characterized by a higher 
mutational load (average 1.44 mutations/Mb compared to 0.73 mutations/Mb for low risk 
SMM patients)56, mutations in the MAPK and NFkB pathways56, and MYC-IgH structural 
variation, which predicts a rapid progression to MM in < 2 years57. Notably, this high 
mutational load is comparable to that of the median somatic mutation rate of MM, which is 
observed to be 1.6 mutations/Mb47. Indeed the first clinical trial (QuiRedex Phase III trial) 
investigating the early treatment of high risk SMM patients, using induction therapies 
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lenalidomide and dexamethasone, has shown significant survival advantage of patients 
treated early (vs. standard of care monitoring) with an increased median time to 
progression (TTP) (median not reached vs. 21 months) and overall survival (OS) (94% vs. 
80%)58. Notably, toxic effects were mainly restricted to moderate/mild side effects (grade 
2 or lower). Long term follow up of patients after 6 years, demonstrated continued 
significant benefit to high risk SMM patients treated early with a prolonged effect on TTP 
and OS59. Another recent clinical trial in intermediate and high risk SMM (CENTAURUS 
Phase II trial), investigating single agent activity of the new FDA approved treatment 
Daratumumab (Darzalex), a human anti-CD38 monoclonal antibody, has shown significant 
activity with approximately 50% of patients in both intermediate and long dosing 
schedules displaying a partial response (PR) or better and increased 12-month progression 
free survival (PFS) rates60.  
 
Although, it should be again noted that clonal heterogeneity adds an extra layer of 
complexity and not all patients fall into defined groups. Currently the diagnosis of 
MGUS/SMM is an incidental process when an individual visits the clinic for a routine 
blood test. Identification of asymptomatic disease is largely based on increased clonal 
immunoglobulin in the blood (i.e. paraproteinemia), using relatively insensitive assays 
such as serum protein electrophoresis35. As it has been shown mutational load increases 
towards MM, it may be suggested that future diagnostic methods could be based on 
mutational burden and specific cytogenetic/mutational events, allowing patients to be 
stratified to a course of clinical care that is specific for that subgroup. In this sense, it may 
also be recommended that NGS can be implemented to assess patients at regular intervals 
(along current guidelines of 3 – 6 months) to track mutational load, gene expression 
signatures and acquisition of known driver mutations61. However, serial bone marrow 
biopsies are an intrusive and painful procedure (with possible secondary complications 
such as bleeding or infection), and thus regular NGS assessment may not be a feasible 
option for all patients. This is especially true in MM, which is a disease affecting the 
elderly, with a median age of diagnosis of 65 years old62. Recent studies have investigated 
the merits of non-invasive measures such as simple blood tests that can measure cell free 
DNA (cfDNA) or circulating tumour cells (CTCs) as a marker of MM disease 
development. Initial studies performing NGS analysis of matched peripheral blood and 
BM biopsies, have demonstrated the ability of blood samples to successfully capture the 
clonal genetic mutations and heterogeneity of MM, similar to that detected in standard BM 
biopsy sample analysis alone63-67. A high concordance in the presence of clonal somatic 
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NS-SNVs (in MM driver genes) and CNV mutations was identified between liquid and 
BM biopsy samples. These findings suggests that quantitative disease monitoring of 
patients in the clinic at regular intervals may be a real possibility in the near future. As 
MM is a blood cancer, this has significant potential for clinical applicability compared to 
solid tumours due to: 1) the ability of tumour PCs to be repeatedly sampled, as the original 
tumour is not resected; and 2) the yield of enriched tumour PCs that can be captured for 
analysis (solid tumours yield ~1-10 cells per/mL of blood, whereas in MM, samples can 
yield 10-100x this)65. Moreover, blood biopsy has the ability to capture the spatial 
heterogeneity of MM, which otherwise would be impossible due to the practical challenges 
of sampling patients at multiple sites. Indeed recent NGS analysis of BM samples from 
newly diagnosed MM patients has illustrated that intraclonal heterogeneity with clonal 
selection may not be the only defining evolutionary feature associated with progression to 
MM, with the involvement of spatial heterogeneity and regional site seeding and 
outgrowth of advanced clones leading to progression68. Taken together, liquid biopsies 
may provide improved detection of the temporal and spatial nature of acquired mutations 
in MM patients, while also reducing the effects of bias due to single BM site sampling, 
which may not always reveal the full spectrum of genetic heterogeneity. 
 
As health technologies continue to mature, it is viewed that larger throughput sequencing 
studies of patients in a longitudinal, spatial and treatment response setting will be carried 
out in order to derive a comprehensive understanding of MM as a disease and its 














Using NGS techniques of WES, RNAseq and WGBS to analyse a rare collection of paired 
patient samples, the data presented in this thesis reveals a new understanding of the 
underlying genomic complexity and tumour evolution model involved in disease 
progression of MM. Here, it has been demonstrated that MGUS/SMM patients that 
progress, appear to be sufficiently genetically complex to be on the threshold of 
transformation to MM; a process that may be driven by PC extrinsic factors such as the 
tumour microenvironment. The existence of subclonality and clonal stability as a model of 
tumour evolution provides new considerations required for patients at diagnosis and the 
subsequent treatments that are employed. This work should underpin further longitudinal 
patient sample studies and the consideration of genomic and subclonal architecture with 
risk stratification. Ultimately, comprehensive knowledge of the underlying biology 
involved in MM gained from NGS studies will significantly influence our understanding of 
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